Cellular Imaging in Regenerative Medicine, Cancer and Osteoarthritis by Tiel, S.T. (Sandra) van
Sandra T. van Tiel
Cellular im
aging in regenerative m
edicine, cancer and osteoarthritis
63563-Sandra van Tiel-cover.indd   Alle pagina's 28-08-2020   15:12

Cellular Imaging in Regenerative 
Medicine, Cancer and Osteoarthritis
Sandra Theresia van Tiel
63563-Sandra van Tiel-proefschrift.indd   1 04-09-20   08:45
ISBN: 978-94-6332-677-3
 
Cover design: Patricia Mulder and Jeroen Frings
Design: Ferdinand van Nispen tot Pannerden
 Citroenvlinder DTP & Vormgeving, my-thesis.nl
Printed by: GVO Drukkers en vormgevers, Ede, The Netherlands
Copyright © 2020 Sandra van Tiel
 
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or 
transmitted in any form or by any means without prior permission of the author.
63563-Sandra van Tiel-proefschrift.indd   2 04-09-20   08:45
Cellular Imaging in Regenerative 
Medicine, Cancer and Osteoarthritis
Cellulaire beeldvorming in regeneratieve geneeskunde, kanker en artrose
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus
Prof.dr. R.C.M.E. Engels 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op 
vrijdag 16 oktober 2020 om 9.30 uur
door
Sandra Theresia van Tiel
geboren te Rotterdam. 
63563-Sandra van Tiel-proefschrift.indd   3 04-09-20   08:45
Promotiecommissie:
Promotor: prof. dr. ir. M. Hendriks - De Jong
Overige leden: prof. dr. G.J.V.M. van Osch
dr. ir. A.G. Denkova
prof. dr. M. Smits
Copromotor: dr. M.R. Bernsen
63563-Sandra van Tiel-proefschrift.indd   4 04-09-20   08:45
63563-Sandra van Tiel-proefschrift.indd   5 04-09-20   08:45
Table of contents
1. Introduction 9
2. Variations in labeling protocol influence incorporation, 
distribution and retention of iron oxide nanoparticles into 
human umbilical vein endothelial cells
27
3. Cell quantification: evolution of compartmentalization and 
distribution of iron-oxide particles and labeled cells
51
4. SPIO labeling of endothelial cells using ultrasound and 
targeted microbubbles at diagnostic pressures
75
5. In vivo stabilized SB3, an attractive GRPR antagonist, for  
pre- and intra-operative imaging for prostate cancer
101
6. Albutate-1, a novel long-circulating radiotracer targeting the 
somatostatin receptor subtype 2
125
7. Evaluation of a radiolabeled somatostatin analog for SPECT 
imaging of pro-inflammatory macrophages
143
63563-Sandra van Tiel-proefschrift.indd   6 04-09-20   08:45
8. Summary, discussion, concluding remarks 165
9. Nederlandse samenvatting 183
10. Dankwoord 193
11. PhD portfolio 199
12. Curriculum vitae 211
63563-Sandra van Tiel-proefschrift.indd   7 04-09-20   08:45
63563-Sandra van Tiel-proefschrift.indd   8 04-09-20   08:45
1
INTRODUCTION
63563-Sandra van Tiel-proefschrift.indd   9 04-09-20   08:45
Chapter 1
10
Introduction
Non-invasive imaging of cells in vivo plays a major role during diagnosis and 
therapy of various diseases. So, to understand the composition of a tissue or 
organ, or to visualize processes within a certain body area disease-related and 
labelled cells can be visualized. Such labels must first reach the cell, efficiently 
incorporate in the cell or attach to the cell and give a detectable signal (1) and 
next to that they should not affect the functionality of the cell (2). Cell labelling 
can be performed in a non-targeted manner; the label can be taken up in a 
cell, e.g. through endocytosis. Also targeted cell labelling is being applied; 
the label specifically binds a target, e.g. receptor or enzyme, on or in the cell. 
After labelling of the cells, they can be visualized using an imaging device. 
Depending on the imaging device the molecular, (patho)physiological and/
or anatomical changes of the cells/tissue/organ can be imaged using different 
methods: 
•  In case of the use of (super) paramagnetic labels magnetic resonance 
imaging (MRI) can be applied
•  When the labels are radioactive, single photon emission computed 
tomography (SPECT) and positron emission tomography (PET) might be 
used
•  With fluorescent/bioluminescent labels optical imaging (OI) is the 
technique of choice 
•  Bubbles filled with gas are used in ultrasound (US) imaging.
Within the focus of this thesis we will explain MRI, SPECT, CT and US 
technologies in more detail below. For detailed descriptions of these and other 
technologies the reader is referred to review papers (3, 4) and books (5-7) on 
this topic. 
In this thesis we describe cellular imaging in regenerative medicine where 
damaged or aged tissue needs to be substituted with healthy cells to regain 
a proper function of the tissue. We also address cancer cell imaging, it is of 
importance to detect tumour cells to establish the location and spread of the 
tumour to decide on/or to investigate options for therapy, and to detect any 
changes in tumour growth. Finally, we also focused on imaging of specifically 
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activated macrophages during inflammatory disease in a mouse model 
for osteoarthritis (OA). Different phenotypes of macrophages are present 
overtime during inflammatory disease processes such as in OA. Knowing which 
phenotype is present at a certain moment can help determining the stage of 
disease, but also give directions how to interfere in the disease development. 
So, for cellular imaging in regenerative medicine, cancer and inflammatory 
processes such as in osteoarthritis it is important to label the cells involved in 
the disease, so they can be non-invasively detected with an imaging device. 
This to be able to stage the disease and to be able to interfere in the disease 
development.
Imaging cells in regenerative medicine
Regenerative medicine deals with the restoration of damaged or ageing 
tissues. Stem cells have infinite cell division potential and can differentiate 
into other types of cells and have an important role in regenerative medicine 
research. Earlier, evaluations of the effectiveness of regenerative approaches 
were limited by the inability to monitor response to treatment over time, 
but nowadays we are able to incorporate a label into the cells by which the 
transplanted cells can be distinguished from their surrounding using imaging 
technologies (8-10). This way it is possible to determine their fate as well as 
their functional capabilities and the biological role they fulfill (11). We searched 
for the best iron labelling protocol for cells in vitro and in vivo, and we tried to 
quantify the iron labelled cells.
Cancer cell imaging for diagnosis and therapy
In preclinical tumour imaging studies nuclear imaging markers can be applied 
and are widely being used (12). Glucose metabolism is a key cellular function 
in cells, which is high in tumour cells, and can be imaged with a radioactive 
glucose derivative: 18F[F]-FDG (13, 14). Receptors on or in tumour cells can 
be imaged with the use of e.g. peptide receptor radionuclide imaging. In the 
paragraph on targeted radiolabelled peptides, their structure and receptor-
mediated uptake mechanisms are described. 
For the last 20 years peptide receptor radionuclide therapy (PRRT) has been 
used to treat patients suffering from neuroendocrine tumours (NETs). These 
NETs are rare cancers, they are often already metastasized at time of diagnosis 
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(15) and typically express high levels of somatostatin receptor subtype 2 
(SST2). This makes the somatostatin receptor an excellent target for diagnosis 
and treatment of the disease using high affinity radiolabelled peptide ligands 
with high affinity for the SST2. In the course of time different modifications to 
the original radiolabelled peptide have been made. For diagnosis and staging 
of the NETs [68Ga]Ga-DOTA-Tyr3-octreotate PET imaging is very often applied 
(16). With the same peptide sequence, it is also possible to treat the tumour 
cells, but instead of the radionuclide Gallium-68 a therapeutic radionuclide, 
such as Lutetium-177, will be applied. This represents a good example of a 
so-called theragnostic peptide. Upon receptor binding Lutetium-177 can 
eradicate tumour cells via beta decay. At Erasmus MC, NETS are being treated 
with [177Lu]Lu-DOTA-Tyr3-octreotate (17, 18). This treatment has a positive 
effect on life expectancy and improves quality of life (19). There is ongoing 
research conducted to even further improve this treatment by, for example, 
use of alpha-emitting radionuclides (20). Alpha emitters are increasingly 
applied because of their emission of high linear energy transfer particles with a 
relative short path length, causing double-strand breaks in DNA. Therefore, the 
cytotoxic property in cells is much greater for α-emitters than for β-emitters 
(21). Other improvements of PRRT can be achieved by combination therapies 
with e.g. chemotherapeutics to reach a synergistic effect or by adjustment 
of radiopeptide administration routes to be able to enhance uptake of 
radiopeptides in the tumour cells (22-24). The blood clearance of [177Lu]Lu-
DOTA-Tyr3-octreotate in humans is rapid (<10%ID in blood at 3 h post injection) 
(25) and may be decreased by using a radiopeptide combined with an albumin 
binding strategy. In this way the tracer circulation time will be prolonged, 
resulting in higher tumour uptake.
NETs express the SST2 receptor, but many other receptors can be used for 
imaging, staging and treatment of other types of cancers. In this thesis we 
also investigated the gastrin-releasing peptide receptor (GRPR) as target. 
GRPRs are e.g. expressed at high density on the cell membranes of prostatic 
intraepithelial neoplasia (PIN), primary prostate cancers and invasive prostatic 
carcinomas (26). For diagnosis, the GRPR antagonist Sarabesin 3 (SB3) has 
recently been developed (27). Pre-clinically, in mice, a high tumour receptor 
affinity was found together with good in vivo stability and excellent targeting 
efficacy. In clinical PET imaging studies [68Ga]Ga-SB3 was used with success as 
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well. The first clinical data showed encouraging results: in fifty percent of the 
patients the lesions were visualized (28, 29). During surgical excision of such 
tumours the surgeon may prefer to visualise the tumour pre-operatively with 
SPECT and also detect the tumour intra-operatively (30). This can be achieved 
when a radionuclide is coupled to the tracer which emits gamma photons, 
like Indium-111 (31). Here we investigated the potential of [111In]In-SB3 as 
a radiotracer for pre-operative SPECT/MRI and sub sequentially improved 
tumour targeting.
Macrophage imaging 
Macrophages are abundantly present immune cells characterized by 
phagocytic activity. When macrophages become activated, upon receiving 
signals from their microenvironment, they secrete cytokines that influence 
matrix remodelling and other cells in close proximity. Macrophages are then 
polarized towards different phenotypes (M1=pro-inflammatory, M2=anti-
inflammatory) expressing a characteristic repertoire of surface markers. M1 
macrophages constitute the first line of defence against intracellular pathogens 
and occur in an inflammatory environment. They are able to produce pro-
inflammatory cytokines (e.g. TNF-α, type I IFN) and several chemokines. 
M2 macrophages are particularly involved during parasitic, helminthic and 
fungal infections. They down regulate pro-inflammatory cytokines and induce 
production of anti-inflammatory mediators (32, 33). The original polarization 
can be reversed upon environmental changes (34). 
To emphasise the importance of in vivo macrophage visualisation, one 
should realize that macrophages play a role in many diseases. Activated 
macrophages are e.g. found in the brain of patients with schizophrenia (35, 
36) and pulmonary macrophages are associated with tissue fibrosis (37). In 
the vasculature macrophages contribute to the formation of atherosclerotic 
plaques (38, 39). Macrophages also play a role in inflammatory diseases such 
as inflammatory bowel disease (40) and rheumatoid arthritis (41). Depending 
on the type of activation, macrophages can facilitate or prevent disease. So, 
knowing which kind of macrophage is present during the development of a 
disease is important for interference in disease development. In collaboration 
with the Orthopaedics Department we focused on macrophage involvement 
in the development of osteoarthritis (OA). OA affects many persons worldwide 
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leading to major societal impact (42). The presence of inflammation in 
the joint is a cause or an exacerbating factor for OA, for which there is no 
effective treatment currently. The focus is now primarily on pain reduction, so 
knowledge on how to delay or stop inflammatory damage may be crucial for 
the development of more curative treatment strategies. A possible treatment 
could be the modulation of the functional state of the inflammatory cells. The 
aims of our study described in this thesis were 1) to determine how macrophage 
phenotypes and monocyte subsets vary with time after destabilization of the 
medial meniscus; 2) to investigate associations between monocyte subsets or 
macrophage phenotypes and OA features 3) in vivo macrophage visualisation 
during the course of OA (43). 
Labels for cell imaging
There are many types of imaging labels with different size, shape, composition 
and functionality (44), including liposomes, polymers, dextran coated particles, 
antibodies and peptides. When injected in the bloodstream these carriers 
travel throughout the body and can end up in extravascular spaces, followed 
by binding to and/or uptake in the targeted cells. The fact that carriers can 
bind and or be taken up by cells has enabled new ways of imaging of organs, 
tumours and other tissues in the body (45, 46). 
Non targeted iron oxide particles
The most commonly applied and easiest way to achieve spontaneous uptake 
of an imaging particle is by exposing the cells to the labelling agent in culture. 
This may require additional use of a transfection agent (47). The cells then 
actively incorporate the particles through endocytotic pathways; the particles 
generally end up in endosomal compartments (Fig. 1). The now cell-associated 
labelling agent serves as the signaling beacon by which transplanted cells can 
be identified in imaging studies (48-51). 
Particulate label types used in this thesis are two types of iron oxide particles: 
super paramagnetic iron oxide particles (SPIO) and micro particles of iron 
oxide (MPIO) which provide high detection sensitivity. SPIO particles have a 
particle diameter between 80 and 150nm, consisting of an iron oxide core of 4 
nm with a low-molecular-weight dextran coating (52-54). MPIO particles are 
composed of polystyrene–divinyl benzene polymer micro spheres containing 
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Figure 1 A Non targeted uptake of nanoparticles (brown dots) through endocytosis B MR image of 
single cells labelled in vitro with iron particles (black dots).
a magnetite core and are tagged with the fl uorescent dye Dragon green 
(480/520 nm). The iron oxide crystals have a strong magnetic moment, causing 
a disturbance of the local magnetic fi eld resulting in local signal loss in MR 
images. MPIO have an average size of 1630 nm and have been shown to be 
functionally inert and they create a larger and stronger eff ect in MRI than SPIO 
(55, 56). Both SPIO and MPIO are effi  ciently endocytosed by many cell types 
(Fig. 2) and are passed along to daughter cells during mitosis (57-59). 
CD31 targeted microbubbles
In cell imaging there is always the challenge to get enough label in the cell for 
effi  cient imaging during a longer period of time. In vitro one can increase the 
dose of the label, but in vivo this is much more diffi  cult to achieve. Therefore, 
targeting solutions are needed to achieve more effi  cient uptake. 
In this thesis we used gas-fi lled microbubbles to target (CD31 (60)) cells. 
These microbubbles are between 1 and 10 micrometres in diameter and 
often coated with lipids. They are excellent ultrasound scatters due to their 
high compressibility. High-frequency sound waves make the gas in the 
microbubble vibrate as a response to the pressure change (61). The oscillation 
of microbubbles has been shown to increase cell membrane- and capillary 
permeability (62). We used this capability to introduce iron nanoparticles into 
the cell.
Targeted radiolabelled peptides
Cells express receptor proteins on their plasma membranes. Receptors can 
have high affi  nity for regulatory peptides allowing cellular communication 
with the outer environment. If certain receptors are overexpressed during 
disease, they can be used for imaging and therapy applications. The radioactive 
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peptides attach to the receptors upon which they can be internalised or stay at 
the cell surface (Fig. 3) (63, 64). Radiolabelled peptides hold great promise for 
imaging and treatment of cancer cells, but also for imaging of other cells, e.g. 
macrophages.
Figure 2 Schematic drawing of receptor-mediated uptake of a radiolabelled peptide A Cell with 
receptors on cell surface B Radioactive tracer attached to receptor C Representative SPECT image of the 
chest of a mouse showing radioactive tumour cells (in red) after receptor-specifi c radiolabelled peptide 
injection. 
Radiolabelled peptides, also called tracers, can be used in diagnostic imaging 
of (tumour) cells or can be used in radionuclide therapy of tumours. This all 
depends on the radionuclide attached to the peptide. A radiolabelled peptide 
consists of diff erent components. One component is the peptide; this peptide 
is the part that binds to the receptor present in or on the surface of the cell. 
Another possible component is attached to the peptide and called a linker; 
this creates space between the chelator and the binding site to prevent loss 
of binding affi  nity. On the other site of the linker a third component can be 
coupled; a chelator containing the radionuclide (Fig. 4) (65).
Figure 3 General representation of a radiolabelled peptide consisting of a radionuclide in a chelator, 
a linker and a peptide, which recognises the receptor on the cell.
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Radionuclides
A radionuclide is a radioactive form of an element. Some of them exist in 
nature, while others are man-made. Radioactivity can be used for many 
different purposes, i.e. to study living organisms, to diagnose and treat 
diseases, to produce energy for heat and electric power and it can be used to 
sterilize medical instruments and food, etc. Half-life is the time required for half 
of the radioactive atoms present to decay. The radiation that is emitted by a 
radionuclide does this at its own specific rate (https://www.epa.gov/radiation/
radionuclideswww.epa.gov/radiation/radionuclides). The half-life can range 
from milliseconds to millions of years, but clinically a half-life between 20 
minutes and 10 days is most often used.
Two radionuclides have been applied in this thesis work. The first one is 
Indium-111, which is being applied for diagnostic imaging. It decays with a 
half-life of 67,9 h, emitting gamma-rays of 171 and 245 keV. Lutetium-177 
is the second one and is being used for radiotherapeutic applications; it 
decays with a half-life of 161 h, emitting β− particles with a maximum energy 
of 498 keV. Also, low energy γ-rays of 113 and 210 keV are emitted, making 
this radionuclide suitable for theragnostic applications. Other radionuclides 
applied in nuclear medicine are presented in Table 1 (66) (https://www.nndc.
bnl.gov/nudat2).
Table 1 Specifics and applications of some radionuclides frequently used in nuclear medicine. 
Radionuclide Half-life (h) Type of decay (%) Production mode Used for
Bismuth-213 0,76 α (2), β− (98) 225Ac/213Bi generator Therapy
Copper-64 12,7 β+ (19), β− (40), Ɛ (41) Cyclotron PET imaging
Copper-67 61,9 β− (100), ɣ Accelerator Therapy
Fluor-18 1,83 β+ (97), Ɛ (3) Cyclotron PET imaging
Gallium-68 1,13 β+ (89), Ɛ (11) 68Ge/68Ga generator PET imaging
Indium-111 67,9 Ɛ (100), Auger,ɣ Cyclotron SPECT imaging
Lutetium-177 161 β− (100), ɣ Reactor Therapy 
+ SPECT imaging
Technetium-99m 6,02 IT (99.99), ɣ (0,01) 99Mo/99mTc generator SPECT imaging
Yttrium-90 64,1 β− (100) 90Sr/90Y generator Therapy
Zirkonium-89 78,4 Ɛ (77), β+ (23) Cyclotron PET Imaging
Ɛ = electron capture, IT= isomeric transition
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Imaging modalities
The various medical in vivo imaging techniques each have their own 
advantages and disadvantages regarding their use in cellular imaging. Optical 
imaging techniques have been widely used in pre-clinical studies. The limited 
tissue penetration capability of light, however, to a large extent limits the use 
of these techniques to small laboratory animals (67). Studies aimed at clinical 
translatability, have therefore largely focused on US, MRI, PET or SPECT, where 
the latter three are not limited by signal penetration depths in tissue (68, 69). 
An overview of different imaging modalities used in preclinical research was 
recently given by de Jong et.al. (70), the modalities used in this thesis are 
explained below.
MRI
Magnetic resonance imaging (MRI) offers several advantages for in vivo cell 
tracking. Through the use of a strong homogenous magnetic field, gradients 
and radio waves, an image is generated. MRI has high temporal and spatial 
resolution, excellent tissue contrast and tissue penetration, does not apply 
ionizing radiation, is non-invasive for serial studies, and simultaneous 
acquisition of anatomical structure and physiological function can be obtained 
(71). In this high magnetic field, hydrogen atoms can be manipulated. Our 
body contains up to 70% of water, which provides an abundant amount of 
hydrogen atoms. The spin of hydrogen atoms is affected by the radiofrequency 
(RF) pulse. When the RF pulse is turned off, the hydrogen atoms can return to 
the original state. This entire process is known as “relaxation.” After positional 
measurement of the relaxation by receiver coils, the relaxations can be 
transformed into a MRI image (72). Contrast agents can enhance the relaxation 
rates (73). Longitudinal and transverse relaxation time (resp. T1 and T2) is being 
used to characterize different tissues. T1 is the time constant which determines 
the rate at which excited hydrogen atoms return to equilibrium. T2 is the time 
constant which measures the time taken for spinning hydrogen atoms to lose 
phase coherence among the nuclei spinning perpendicular to the main field. 
US
Ultrasound imaging, like MRI and CT, is used for diagnostic imaging, but also 
as a therapeutic tool. Sound frequencies of 1 MHz and higher are used and are 
also referred to as ultrasound. The human body consists of different structures, 
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which all scatter and reflect high-frequency sound waves differently resulting 
in intensity differences in an ultrasound image. Compared to MRI, SPECT, 
PET and CT imaging ultrasound imaging has some advantages such as price, 
convenience, and fast real-time imaging, but it has poor penetration through 
bone or air (74, 75). The sound waves can also be used for site-specific cell 
labelling. This can be achieved with the use of ultrasound contrast agents 
like microbubbles. The microbubbles change their size under influence of 
the generated waves. The vibration of the microbubbles that arises can 
change the structure of cell membrane and enhance its permeation. Through 
sonoporation reversible or non-reversible cell membrane pores are generated 
upon microbubble oscillations (76, 77).
SPECT
Single-photon emission computed tomography (SPECT) is a nuclear imaging 
technique just like positron emission tomography (PET). SPECT is widely 
used in (pre)clinical studies and is an advanced radionuclide molecular 
imaging technique that is able to evaluate biochemical changes and levels 
of molecular targets in vivo (78). It enables whole body imaging of molecular 
targets/processes with high sensitivity. Since biochemical changes often occur 
before anatomical changes in disease, SPECT has clear diagnostic strength 
(79). However SPECT has a key weakness, which is, showing poor anatomical 
information. This weakness may be eliminated through the combination 
of instruments with either CT or MRI, producing a single scanner capable of 
accurately identifying molecular events with precise correlation to anatomical 
findings (80, 81). 
SPECT can measure the biodistribution of extremely small (<10−10  molar) 
concentrations of radiolabelled biomolecules/nanoparticles  in vivo with, 
when using a pre-clinical system, sub-millimetre resolution and quantify the 
molecular kinetic processes in which they participate. Its capabilities include:
(i)  the ability to image radiolabelled biomolecules/nanoparticles
(ii)  compared to PET, SPECT has the ability to measure relatively slow kinetic 
processes due to the relatively long half-life of the commonly used 
radionuclides 
(iii)  the ability to probe two or more molecular pathways simultaneously by 
detecting radionuclides with different emission energies (82).
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In SPECT, collimator design is always a compromise between spatial resolution 
and sensitivity. Parallel hole collimators can be used in clinical SPECT imaging 
and in the preclinical setting (multi)pinhole collimators are used. Preclinical 
multi pinhole collimators are used to obtain a much better spatial resolution 
compared to conventional parallel-hole collimator (83). In comparison to a 
parallel-hole collimator, pinhole collimators provide a smaller field of view 
(FOV). These collimators are suited to image focal uptake or organs in the 
body or the whole body, because they generate magnified images. So, smaller 
pinhole diameter leads to an improvement the spatial resolution, but also 
a loss in sensitivity (84-86). A drawback of SPECT use is that the subject is 
exposed to radioactivity.
CT
In computed tomography (CT) images are obtained thanks to different levels 
of X-ray attenuation by tissues within the body (87). Pre-clinical devices are 
very fast and offer ultra-high-resolution scanning at low x-ray doses. A detector 
rotates around the animal or patient, acquiring volumetric data (88). When 
associated with other imaging modalities, CT can give an anatomical reference 
frame for the biochemical and physiological findings that are provided by 
other imaging instruments. A CT is also of importance with quantification of 
SPECT/PET data as it is used for accurate scatter and attenuation correction 
(89). One of the drawbacks of the use of a CT is that it has little soft tissue in 
small animals, so there is a need for contrast agents. Next to that the subject is 
exposed to radiation.
Aim and thesis outline
This thesis describes several methods for imaging of cells in regenerative 
medicine, cancer and osteoarthritis. The overall aim of the studies was to 
label cells involved in disease, so they can be detected non-invasively with an 
imaging device as a means to stage the disease and to potentially interfere in 
the disease development. In Chapter 1, a general introduction to molecular 
imaging is given. We describe the imaging devices used in molecular imaging 
and cell labelling strategies that can be employed. In regenerative medicine 
the aim is to substitute damaged or aged tissue with healthy cells to regain a 
proper function of the tissue. To be able to visualize this process with MRI, cells 
can be labelled with iron particles. In Chapter 2 the efficacy of iron particles 
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for cell labelling and MR imaging studies was investigated by studying the 
effect of variations in labelling protocols regarding incorporation, distribution 
and retention of iron oxide nanoparticles. By mimicking the effects of various 
distribution patterns through labelling of cells with small (SPIO) and larger 
(MPIO) iron particles we studied the effect of various inter- and intra-cellular 
distributions profiles on quantifiability of iron oxide-labelled cells, as described 
in Chapter 3. To label the cells with iron oxide particles different strategies 
can be followed. So, in Chapter 2 and 3 we added a transfection agent to 
enhance entrance of iron particles into the cells. The aim of our in vitro study 
described in Chapter 4 was to find the optimal parameters for non-invasive, 
microbubble-mediated SPIO labelling of endothelial cells to eventually enable 
iron particle endothelial cell labelling in the body. In Chapter 5 our research 
aimed to increase in vivo stability of an Indium-111 labelled radiopeptide 
targeting the gastrin-releasing peptide receptor (GRPR). In Chapter 6 we 
investigated how to further improve the biodistribution of another peptide, 
targeting somatostatin receptor subtype 2, by prolonging the tracer circulation 
time upon adding an albumin-binding domain to the radiopeptide structure. 
In Chapter 7 we investigated the value of the somatostatin receptor subtype 
2 as a novel imaging marker for pro-inflammatory macrophages also using the 
DMM osteoarthritic mouse model.
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Abstract
Various studies have shown that various cell types can be labeled with 
iron oxide particles and visualized by magnetic resonance imaging (MRI). 
However, reported protocols for cell labeling show a large variation in terms 
of labeling dose and incubation time. It is therefore not clear how different 
labeling protocols may influence labeling efficiency. Systematic assessment 
of the effects of various labeling protocols on labeling efficiency of human 
umbilical vein endothelial cells (HUVEC) using two different types of iron 
oxide nanoparticles, i.e. super paramagnetic iron oxide particles (SPIOs) and 
microparticles of iron oxide (MPIOs), demonstrated that probe concentration, 
incubation time and particle characteristics all influence the efficiency of label 
incorporation, label distribution, label retention and cell behavior. For SPIO 
the optimal labeling protocol consisted of a dose of 12.5 mg iron/2 ml/9.5 cm2 
and an incubation time of 24 h, resulting in an average iron load of 12.0 pg 
iron/per cell (uptake efficiency of 9.6%). At 4 h many SPIOs are seen sticking to 
the outside of the cell instead of being taken up by the cell. For MPIO optimal 
labeling was obtained with a dose of 50 mg iron/2 ml/9.5 cm2. Incubation time 
was of less importance since most of the particles were already incorporated 
within 4 h with a 100% labeling efficiency, resulting in an intracellular iron load 
of 626 pg/cell. MPIO were taken up more efficiently than SPIO and were also 
better tolerated. HUVEC could be exposed to and contain higher amounts of 
iron without causing significant cell death, even though MPIO had a much 
more pronounced effect on cell appearance. Using optimal labeling conditions 
as found for HUVEC on other cell lines, we observed that different cell types 
react differently to identical labeling conditions. Consequently, for each cell 
type separately an optimal protocol has to be established.
Keywords: cell imaging; MRI; iron oxide; SPIO; MPIO
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1 Introduction
Cell-based therapy approaches are currently receiving a lot of attention 
for regenerative medicine purposes (1). In order to assess the clinical value 
and safety of cell therapy approaches, it is necessary to track the fate of the 
transplanted cells in vivo. For in vivo cell tracking it is essential that the cells 
have incorporated a label in order to distinguish them from their surroundings 
in MR images (2–5). The easiest way to label a cell is to add the label to the 
culture medium. To improve uptake efficiency, a transfection agent can be 
used (5). In labeling of cells some aspects have to be considered:
(1) the efficiency of the labeling procedure;
(2) the effect of labeling on cell survival;
(3) the behavior of the label in the cell;
(4) the duration of label retention in the cell;
(5) preservation of cell function and surface marker expression.
For cell tracking by MRI different labels can be used (1,6,7). Iron-oxide 
nanoparticles are, however, the most commonly used labels, and were even 
shown to allow for detection of single cells in vivo (8). A vast amount of studies 
have been published dealing with labeling of various cell types with iron oxide 
nanoparticles (9–11). In these studies a large variety of labeling protocols 
have been described (12–14). While for every cell type tested efficient 
labeling and subsequent detection by MRI has been reported, it is not clear 
how different labeling protocols may influence labeling efficiency. Various 
studies have shown effects of particle coating, particle size, labeling dose and 
labeling time on labeling efficiency and the ability to detect labeled cells by 
MRI (15–18). The purpose of this study was to systematically investigate the 
effect of variations in dose and duration of labeling on label incorporation, 
distribution, retention and toxicity using two commonly applied types of 
iron oxide nanoparticles – the so-called SPIO (super paramagnetic iron oxide 
particles) and MPIO (micro particles of iron oxide) particles. Of these two, the 
most widely used are SPIO particles, which have a particle diameter between 
80 and 150 nm, consisting of an iron oxide core (Fe2O3 and Fe3O4 crystals) of 
4 nm with a low-molecular-weight dextran coating (19–23). MPIO particles 
are composed of polystyrene–divinyl benzene polymer micro spheres 
containing a magnetite core and are tagged with the fluorescent dye Dragon 
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green (480/520 nm). These particles are highly effective T2* contrast agents, 
and can also be imaged by fluorescence microscopy and used in fluorescent 
activated cell sorting (FACS) studies. MPIO have an average size of 1630 nm 
and have been shown to be functionally inert (24,25). Both SPIO and MPIO are 
efficiently endocytosed by many cell types and passed along to daughter cells 
during mitosis. Cell cycle analysis demonstrates that the labeling process does 
not have a negative impact on the cell cycle profile in comparison with non-
labeled cells (26,27).
2 Results
2.2. Labeling efficiency
2.1.1. Iron uptake
Labeling efficiency of human umbilical vein endothelial cells (HUVECs) is 
dependent on various labeling parameters: the dose of iron that the cells are 
exposed to, the incubation time used and the type of iron oxide nanoparticle 
used (Fig. 1A, B). Using an incubation time of 4 h and doses of 6.25 mg iron/ 
2 ml/9.5 cm2, less than 50% of the cells were labeled as assessed by Prussian 
blue staining. This was also the case for an incubation time of 24 h and a dose 
of 3.13 iron/2 ml/9.5 cm2. These conditions were therefore not used to measure 
the average iron content per cell. High concentrations at long incubation 
times were also not further analyzed since these conditions led to significant 
cell death (see further below).
For SPIO a maximal iron load of 1.82 mg per 100 000 cells was obtained, 
representing an average iron load of 18.2 pg per cell. A much higher iron 
load was achieved with MPIO particles. With MPIO a maximal iron load of 66.1 
mg per 100 000 cells was achieved, corresponding to an average iron load of 
661 pg per cell. Note that the conditions under which these maximal iron loads 
were achieved for the two different iron oxide formulations were not the same. 
In the case of SPIO, maximal incorporation was achieved when cells were 
exposed to 25 mg iron/2 ml/9.5 cm2 for 24 h. In the case of MPIO, maximal 
incorporation was achieved within 4 h of incubation using an iron oxide dose 
of 100 mg iron/2 ml/9.5 cm2. As displayed in Fig. 1(C–E), uptake of MPIO is 
much more efficient than uptake of SPIO. For MPIO the uptake efficiency 
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ranged from 60 to 100% in terms of the amount of iron taken up relative to the 
labeling dose. For SPIO uptake efficiency was maximally 9.6%.
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Figure 1 Labeling efficiency: Incorporation of iron (SPIO or MPIO) in the cell. A and B Amount of 
iron taken up by 100,000 cells as measured by ICP-OES. Closed bars represent the iron uptake within 
4 hrs. Dotted bars show the uptake within 24hrs and the striped bars represent an incubation time of 
48hrs. Note the difference in scale for SPIO A and MPIO B. C percentage of iron which is taken up by the 
cells relative to the labeling dose with incubation time 4hrs. D Similar to C with incubation time 24hrs. 
E Similar to C with incubation time 48hrs. * Doses listed are in mg of iron/2 ml/9.5cm2.
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2.1.2. Label distribution
Distribution of label within the cell population and within the cell is also 
dependent on the labeling protocol used. For MPIO, cell labeling efficiency in 
terms of the percentage of cells labeled as assessed by Prussian blue staining 
soon reached a plateau. As shown in Fig. 2(A), >85% of the cells were labeled 
at doses of 6.25 mg iron/2 ml/9.5 cm . For SPIO a minimum amount of 12.5 mg 
iron/2 ml/9.5 cm2 was needed to ensure that all cells were labeled. Differences 
in labeling efficiency between SPIO and MPIO were also found in terms of 
distribution of iron oxide complexes per cell. Following an incubation time 
of 4 h, iron oxide complexes were mostly attached to the outside of the cell, 
in case of SPIO, while for MPIO, most of the label was found within the cell 
(Fig. 2B). Differences seen in the location of MPIO particles depending on 
the incubation time used were also seen. Following 4 h of incubation, MPIO 
particles were spread throughout the cell as opposed to a more perinuclear 
clustering of the particles following incubation for 24 or 48 h (Fig. 2C). This 
latter observation probably reflects intracellular trafficking of the endosomes 
occurring after internalization of the cells, and most likely also occurs at later 
time points following a short incubation time.
2.1.3. Label retention
As shown above, the amount of label incorporated by HUVECs is strongly 
dependent on both the labeling dose and the incubation time used. This 
effect was most pronounced for SPIO. For instance at a dose of 12.5 mg iron/2 
ml/9.5 cm2 the average iron load increased from 7.5 to 12.0 mg iron/cell 
when incubation times were increased from 4 to 24 or 48 h. For MPIO, longer 
incubation times generally did not result in significantly higher intracellular 
iron loads. For instance, at a dose of 25 mg MPIO the average intracellular iron 
load was similar for incubation times of 4, 24 and 48 h. As can be appreciated 
from in Fig. 1, for SPIO comparable iron loads were obtained when cells were 
labeled with 50 mg for 4 h, or with 25 mg for 24 h, or with 12.5 mg for 48 h. 
To assess whether the potentially different kinetics of iron uptake under 
these conditions may result in differences in label retention we counted the 
percentage iron-positive cells over time, for cells labeled according to these 
three protocols. These experiments revealed that, 1 week post-labeling, more 
cells contained detectable amounts of iron oxide when a short incubation time 
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with a high dose of SPIO was used, compared with the use of a long incubation 
time with a lower dose of SPIO (26 vs 16%; p < 0.05; Fig. 3).
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Figure 2 Label distribution A Percentage of cells labeled using different labeling doses and an 
incubation time of 24 hrs. B Label distribution following labeling for 4hrs with 25 mg MPIO. Label 
(Dragon green) is seen attached to the outside of the cell and also distributed within the cell C Label 
distribution following labeling for 48hrs with 25 mg MPIO. Label (Dragon green) is seen clustered around 
the cell nucleus D-E. Corresponding light and fluorescence microscopy images of HUVEC labeled with 
25 mg MPIO for 24 hrs illustrating the high MPIO load inside cells. F Label distribution following labeling 
for 4 hrs with 50 mg SPIO. Label (blue=iron staining) is seen attached to the outside of the cell. G Label 
distribution following labeling for 24 hrs with 25 mg SPIO. Label (blue=iron staining) is seen clustered 
around the cell nucleus.
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For all samples, when iron-positive cells could be visualized by Prussian blue 
staining, sensitive imaging by MRI at the single cell level in vitro was possible as 
exemplified in Fig. 4.
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incubation time/labeling dose % labeled cells
4 hrs 50 ug iron/2ml/9.5cm2 25.6 ± 4.9
24 hrs 25 ug iron/2ml/9.5cm2 22.3 ± 6.5
48 hrs 12.5 ug iron/2ml/9.5cm2 16.1 ± 5.1*
A B
C
Figure 3 Label retention. HUVECs were labeled with three different labeling protocols that each 
resulted in an approximate iron load of approximately 1.25 mg iron per 100.000 cells A, i.e. 12.5 
mg for 48 hrs B, 25 mg for 24 hrs and 50 mg for 4 hrs C. The number of Prussian blue positive cells over 
time was determined. These results show that the label retention is better when incubated for 4hrs 
with 50 mg SPIO (C) than with a lower dose for a longer time (A and B). The percentage of Prussian blue 
positive cells 1 week after labeling is listed in the table. * Significantly different from 4 hrs and 24 hrs.
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2.2. Toxicity
2.2.1. Cell survival
Toxicity of the labeling procedure was dependent on both the labeling dose 
and the incubation times used. At incubation times of 24 and 48 h significant 
cell death of more than 50% of the cells was seen at doses of 50 and 25 mg, 
respectively, for SPIO and at doses of 100 and 50 mg, respectively, for MPIO. 
These conditions were therefore not used in other studies. For the other doses 
and incubation times tested, cell viability was between 80 and 100% (Fig. 5C). 
For both MPIO and SPIO higher doses were tolerated at shorter incubation 
times. At equal incubation times, MPIO was better tolerated than SPIO. For 
example, at incubation times of 24 h, a dose of SPIO 50 mg resulted in a loss of 
cell viability of 50% while for MPIO cell viability was 80% at this dose.
2.2.2. Cell morphology
At the highest doses tested for each of the incubation times that did not affect 
cell survival too severely (cell viability 80%), a change in morphology of the 
cells was observed. This change involved a more spindle-like appearance 
of the cells in culture. In FACS studies, clear changes in forward scatter and 
side scatter plots, corresponding to changes in cell size and cell granularity, 
respectively, were observed following labeling
(Fig. 5A and B). Both effects were more pronounced after labeling with MPIO 
than with SPIO. At the highest doses of MPIO tested cell sizes increased 4–7 
times in cell volume compared with unlabeled control cells. Cell volumes 
were calculated from the average measured length and the width of labeled 
and unlabeled cells and the assumed height of 0.5x the cell width using the 
formula to calculate the volume of an ellipsoid.
2.2.3. Cell function
Unlabeled (control) HUVECs show tube formation when seeded on matrigel 
(Fig. 6). This phenomenon is already apparent after 4 h. After 24 h the tubular 
network is much finer of structure. The effects of SPIO and MPIO labeling 
on tube forming capacity of HUVECS were tested at all doses that did not 
significantly affect cell survival. For all these conditions tested, HUVECs still 
displayed tube forming capacity (Fig. 6).
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2.2.4. Labeling efficiency in other cell types
Based on all findings, i.e. labeling efficiency in terms of percentage of cells 
labeled, label incorporation, label retention and retention of cell viability and 
cell function, we found the optimal labeling conditions for HUVECs to consist 
of a labeling dose of 12.5 mg/2 ml/9.5 cm2 and an incubation time of 24 h in 
the case of SPIO, and in the case of MPIO to consist of a labeling dose of 50 
mg/2 ml/9.5 cm2 and an incubation time of 4 h.
A B
C D
Figure 4 MR visibility of labeled cells. Representative images showing the high imaging sensitivity 
that can be reached for the various labeling conditions. A Composition of light microscopy images 
showing a small sample preparation (demarcated region of interest is approximately 1 mm by 1 mm) of 
(labeled) HUVECs in culture as used from MR imaging. B MR Image of a comparable region of interest 
of a sample containing unlabeled cells. C MR Image of a comparable region of interest of a sample 
containing cells labeled with SPIO at a dose of 12.5 mg/2ml/9.5 m2 for 24 hrs 5 days after labeling. 
D MR Image of a comparable region of interest of a sample containing cells labeled with MPIO at a dose 
of 25 mg/2ml/9.5 m2 for 4 hrs 5 days after labeling.
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Using these optimal labeling conditions for HUVEC, we also labeled human 
chondrocytes and murine myoblast cells (C2C12) with SPIO and MPIO particles. 
In both cell types, labeling efficiency with SPIO particles was similar to that 
observed in HUVEC. For MPIO, however, labeling efficiency was considerably 
less in these cell types. For C2C12, labeling of all cells was only achieved at doses 
of 12.5 mg iron/2 ml/9.5 cm2 and an incubation time of 24 h. Also different was 
the reaction of these cells to incorporation of MPIO. Following incorporation of 
MPIO, morphological changes as observed in HUVEC were far less pronounced 
in C2C12 cells (Fig. 7). Remarkably, labeling of chondrocytes with MPIO was 
highly inefficient. No incorporation of label occurred using an incubation time 
of 4 h. Using a dose of 100 mg iron/2 ml/9.5 cm2 MPIO and an incubation time 
of 24 h maximally 70% of the cells showed incorporation of MPIO particles.
3. Discussion
This study was set up to learn more about the effect labeling conditions have 
on the incorporation, distribution and retention of iron oxide nanoparticles. 
In the vast amount of studies dealing with labeling of cells with iron oxide 
nanoparticles, a large variation of labeling protocols is encountered; labeling 
doses varying from 1 to 2800 mg/ml and incubation times varying from 1 to 
72 h have been described (28–30). Generally, higher doses, longer incubation 
times, larger particle size and the use of lipofection techniques result in 
increased labeling efficiency (15,16,18). While in most of these studies labeling 
in the absence of major adverse effects is reported, it remains unclear what 
the influence of different labeling protocols is on label incorporation, label 
distribution and label retention.
As shown in this study, each of these aspects is strongly influenced by the 
exact labeling protocol used. In terms of intracellular iron load, the optimal 
labeling protocol for HUVEC using SPIO (Endorem) consisted of a labeling 
dose of 12.5 mg SPIO/2 ml/surface area of 9.5 cm2 and an incubation time 
of 24 h. With this protocol an average iron load of 12.0 pg iron/per cell was 
obtained. This corresponds to an uptake efficiency of 9.6%. If a significantly 
shorter labeling time is used (4 h) many SPIOs are seen sticking to the outside 
of the cell instead of being taken up by the cell. As reported by Metz et al., 
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Figure 5 Toxicity. A Forward scatter FACS plots showing increases in cell size with increasing MPIO 
incorporation. B Side scatter FACS plots showing increases in cell granularity with increasing MPIO 
incorporation. C Cell viability of cells labeled for 24 hrs with increasing doses of MPIO.
 
at some point a plateau of intracellular incorporation of ferumoxides will be 
achieved when doses and/or labeling times are being increased. They tested 
doses of up to 2000 mg/ml for labeling of human monocytes and did not 
find a major increase in intracellular iron content or susceptibility effect in MR 
images (16). In addition, large amounts of extracellular iron sticking to the cell 
have been reported to diminish the chondrogenic differentiation capacity of 
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MSC. High intracellular amounts of iron and/or exposure of MSCs to high iron 
concentrations also inhibited chondrogenic differentiation capacity of MSCs 
(31,32). Not only the labeling dose but also exposure time were factors in 
creating this adverse effect.
For MPIO optimal iron incorporation was obtained with a dose of 50 mg iron/2 
ml/9.5 cm2. For MPIO the labeling time was of lesser importance since most of 
the particles were already taken up within 4 h with a 100% labeling efficiency. 
Under these conditions, the resulting intracellular iron load is 626 pg/cell. 
This is significantly higher than reported in other studies using different cell 
types (9,25). In these studies murine hepatocytes were labeled with MPIOs and 
they generally contained iron levels of 100 pg. On occasion, some cells had 
levels as high as 400 pg. Macrophages labeled with 1.63 mm MPIOs had an 
average cellular iron uptake of 39.1 pg/cell, corresponding to approximately 
35 particles per cell.
Because of the high uptake efficiency of MPIO, a relatively low dose of 6.25 
mg iron results in the labeling of all cells. However, at this dose an incubation 
time of 24 h is needed. For a dose of 50 mg MPIO, an incubation time of 4 h 
suffices to label all cells and uptake of most of the iron particles. This shorter 
incubation time, however, results in a different intracellular distribution of 
the iron than longer incubation times. After a 4 h incubation period, MPIO 
particles are homogenously distributed over the cytoplasm. In contrast, after 
an incubation time of 24 or 48 h, the MPIO particles are found clustered around 
the cell nucleus. This latter observation is most likely due to intracellular cell 
trafficking of the endosomes that occurs in time after uptake of the particles. 
For HUVEC, increasing labeling doses and consequently increasing intracellular 
iron loads result in more pronounced changes of morphological features. 
The cells become more spindle-like, larger in size and more granulated. 
Such effects were not seen in murine monocytes/macrophages in a study 
by Valable et al. using similar assays (27). As shown in this paper, the labeling 
efficiency of SPIO is significantly less than for MPIO. Higher doses and longer 
incubation times are needed to achieve labeling of all the cells. Also, HUVEC 
displayed a higher tolerance for MPIO than for SPIO. This means that more iron 
can be brought inside the cell with MPIO in a short period of time. In terms 
of labeling dose and incubation time the SPIO labeling efficiency was much 
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more dependent on the exact labeling protocol used. The highest intracellular 
iron loads without major adverse eff ects were obtained with incubation times 
of 24 h and intermediate labeling doses. Alternatively, better retention of 
label was observed after short incubation times and high labeling doses. This 
latter observation may be explained by diff erences in endocytosis kinetics, 
as depicted in Fig. 8. Labeling with high doses and short incubation times 
may result in large intracellular vesicles with multiple iron-oxide complexes. 
Labeling with low doses and long incubation times may result in small 
intracellular vesicles with just one iron-oxide complex. Following cell division 
the vesicles will be divided over the daughter cells; however, the vesicles 
themselves will not divide. Through these dynamics, the high dose and short
A B
C D
E F
Figure 6 Cell function: tube forming capacity. Unlabeled and labeled HUVECS were seeded on 
matrigel and tube forming capacity was monitored after 4 hrs (A, C and E) and after 24 hrs (B, D and F). 
After 4 hrs initial tube formation is apparent for unlabeled cells A, SPIO labeled cells (12.5 mg SPIO for 
24hrs) and MPIO labeled cells (50 mg MPIO 4hrs). A fine tubular matrix is apparent after 24 hrs for each 
of the conditions (B: unlabeled; D: SPIO labeled; F: MPIO labeled).
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incubation time may result in more cells containing enough iron for detection 
after multiple cell divisions. For both MPIO and SPIO, no major effect on cell 
function in terms of tube forming capacity was observed, even at doses that 
did result in changes in morphological features and some cell death (< 20%).
For tracking of single cells by MR, labeling with MPIO appears to be most 
suitable. Only one iron particle is sufficient for detection (26). MPIO particles 
have higher relaxivity than SPIOs, based on equivalent iron content. The 
labeling protocol is easier for MPIO than for SPIO. No transfection agent is 
needed, medium with serum can be used and the labeling time is much 
shorter (4 h compared with 24 h for SPIO). MPIOs also contain a fluorescent tag, 
so they can be readily used in multi-modality imaging approaches combining 
MRI with optical imaging. However, MPIOs as used in this and other studies 
are not intended for clinical use but for experimental use only. SPIOs, however, 
exist in clinically approved formulations and have been used in clinical settings 
already (33–35). SPIOs are therefore better suited to clinical applications.
Using optimal labeling conditions as found for HUVEC for both SPIOs and 
MPIOs on other cell lines, we observed that different cell types react differently 
to identical labeling conditions. The mouse myoblast cell line C2C12 shows no 
change in cell size after administrating MPIO as opposed to HUVEC. Also, the 
high labeling efficiency found for MPIO in HUVEC was much less in C2C12 cells 
and labeling was absolutely absent in chondrocytes at an incubation time of 
4 h. Even at doses of 50–100 mg and incubation times of 24 h, chondrocytes 
showed limited uptake. In contrast, a 100% labeling efficiency could be 
obtained with SPIO in these cells (36). In studies by Arbab et al. (19,37), 
significant differences in cell apoptosis and label incorporation were also found 
between different cell types when identical labeling protocols were used.
4. Conclusion
HUVECs can be labeled efficiently both with SPIO and MPIO but dose 
and duration of exposure of cells to these particles strongly influence 
label incorporation, label distribution and label retention. Optimal label 
incorporation requires different protocols for SPIO and MPIO. Applying 
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optimized protocols for HUVECS to different cell lines shows that no standard 
labeling protocol is useful for all the cell types growing in vitro. Consequently, 
an optimal labeling protocol has to be determined for each cell type in 
combination with the specific particle separately.
5. Experimental procedures
5.1. Cell culture
For extensive assessment of the effects of labeling dose and duration primary 
culture HUVECs were used. HUVECs were grown in endothelial growth medium 
(EGM-2 bullet kit CC3156 with CC4176; Cambrex, Verviers, Belgium) in a six-
well plate (Corning Incorporated, New York, USA) with a surface growth area of
9.5 cm2. For assessment of the general applicability of our findings, optimal 
labeling protocols as found for HUVEC were used for labeling of a murine 
myoblast cell line, C2C12 and human chondrocytes. C2C12 cells were cultured 
in Dulbecco’s modified Eagle medium + 4500 mg/l D-glucose (Invitrogen, 
Breda, The Netherlands) + 1% (v/v) penicilline/streptomycine [10.000 U 
penicilline/ml + 10.000 mg streptomycine/ml (Cambrex, Verviers, Belgium)] 
+ 10% (v/v) fetal bovine serum (Cambrex, Verviers, Belgium). Chondrocytes 
were cultured in chondrocyte expansion medium as described previously (38).
5.2. SPIO labeling
Labeling of cells with SPIO was performed at 90% confluence using Endorem 
(Guerbet S.A., Paris, France) and lipofectamine 2000 (Invitrogen, Breda, The 
Netherlands) (21). A labeling stock solution of 215 mg Fe/ml was prepared as 
follows: 10 ml Endorem was added to 250 ml Opti-MEM (Invitrogen, Breda, 
The Netherlands) and 10 ml of lipofectamine was added to 250 ml Opti-MEM. 
After 5 min the two solutions were mixed together and the resulting suspension 
was incubated at room temperature for 20 min. After washing the cells with 
phosphate-buffered saline (PBS) (Invitrogen, Breda, The Netherlands), the 
culture medium was replaced by 2 ml Opti-MEM and the SPIO–lipofectamine 
suspension (0, 3.13, 6.25, 12.5, 25, 50 mg) was added drop-wise to the medium 
such that an equal distribution of SPIO–lipofectamine complexes was obtained 
in the well. The cells were then incubated for 4, 24 or 48 h at 37°C/ 5% CO2. Before 
further use of labeled cells, the monolayer cultures were rinsed three times with 
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PBS, and incubated with 10% fetal calf serum (Cambrex, Heerhugowaard, The 
Netherlands) for 1 h, to remove loose SPIO-lipofectamine complexes.
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Figure 7 Labeling of C2C12 cells with MPIO. A Forward scatter FACS plots showing no change in 
cell size following labeling with MPIO in C2C12 cells as opposed to the observation in HUVECs shown 
in Figure 4. B Side scatter FACS plots showing also increases in cell granularity of C2C12 cells with 
increasing MPIO incorporation. C Light microscopy image of C2C12 cells in culture after labeling with 
MPIO at a dose of 25 mg iron/2ml/9.5cm2 for 24 hrs. Note the large amount of MPIO still present outside 
the cells.
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5.3. MPIO labeling
Labeling of cells was performed using MPIO (Bangs laboratories, Fisher, IN, 
USA) at 90% confluence. Diff erent amounts of iron (0, 3.13,  6.25, 12.5, 25, 50 mg 
which correspond to 0, 2.79 x 106, 5.58 x 106, 1.12 x 107, 2.23 x 107 and 4.47 x 107
particles) were added drop-wise to the cells, which were grown in complete 
culture medium. For 4, 24 or 48 h the cells were incubated at 37°C/5% CO2. 
Before further use of labeled cells, the monolayer cultures were rinsed three 
times with PBS (Invitrogen, Breda, The Netherlands).
Figure 8 Endocytosis dynamics. Hypothesized diff erence in endocytosis dynamics using diff erent 
labeling protocols.
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5.4. Incorporation of iron
5.4.1. Inductively coupled plasma–optical emission spectrometry
Cell pellets of unlabeled and labeled cells were dried for 72 h at 60°C. 
Subsequently they were digested in 40 ml of a 3:1 mixture of ultra-pure 
perchloric acid (EM Science, Gibbstown, NJ, USA) and ultra-pure nitric acid 
(JT Baker, Deventer, The Netherlands) at 60°C for 6 h. The standard line with 
different dilutions of Endorem or MPIO underwent the same procedure as 
the cells. To the digested substance 4 ml MiliQ was added and the amount of 
iron was determined with a Perkin Elmer Optical Emission Optima 4300 DV 
Spectrometer at 259 nm. The experiments were performed three times with 
triplicate samples. Uptake efficiency was calculated as the amount of iron 
measured in the labeled cells divided by the total amount of iron added for 
labeling multiplied by 100%.
5.4.2. Fluorescence activated cell sorting
The MPIO were tagged with Dragon Green, which is fluorescent. To analyze the 
amount of MPIO taken up by the HUVEC and to assess the effects of MPIO on 
morphological characteristics of the cell and cell survival, a FACS (FacsCanto, 
Becton Dickinson, Alphen a/d Rijn, The Netherlands) analysis was performed. 
After incubation with MPIO all the cells were collected and resuspended in 
FACS buffer (0.25% BSA, 0.5 mM EDTA, 0.05% NaN3), and 1% v/v propidium 
iodide (all from Sigma-Aldrich, Zwijndrecht, The Netherlands) was added to 
determine the amount of dead cells in the suspension. The wavelength used 
was 488 nm. Cell size was estimated using the forward scatter parameter and 
the side scatter parameter was used to determine the cytoplasmic granularity.
5.5. Localization of iron complexes and label retention
For assessing the localization of the iron complexes within the cell, cytospin 
slides were prepared from labeled cells. A cell suspension of 2 x 105 cells/ml 
was made and 150 ml was loaded in each cuvette. The cells were centrifuged 
(7 min, 800 rpm; Shandon Inc.) onto the slide. After the slides were dried by 
air the cells were fixed in methanol absolute (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) and Prussian blue staining (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) was performed. The slides were covered with a cover slip and 
imaged with an Axiovert S100 microscope (Zeiss, Oberkochen, Germany).
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The cytospins were also used to study retention of the iron inside the cell over 
time. The total number of cells was counted and the number of cells stained 
with Prussian Blue (blue coloration of the iron) was counted in three randomly 
selected fields of view (objective 40 x ) per time point.
5.6. Cytotoxicity and viability assays
5.6.1. Distribution of iron and cell morphology: Prussian blue staining
To study the effect of SPIO labeling on cell morphology and label distribution 
using different labeling protocols, labeled cells were washed with PBS and 
photographed at a light microscope. The cells were then fixed with 4% 
formalin. After 10 min of fixation, the samples were washed again and stained 
for 20 min with a freshly prepared solution containing 0.12 M K4Fe(CN)6 and 
1 M HCl (Sigma-Aldrich, Zwijndrecht, The Netherlands). The cells were washed 
again and the cytoplasm was stained with 1% w/v pararosaniline solution. 
Samples were washed a final time and examined by light microscopy. The 
appearance of the cells and the place where the iron was taken up in the cells 
was qualitatively scored.
5.6.2. Cell functionality: Matrigel test
SPIO- and MPIO-labeled HUVEC were seeded on Matrigel to study the tube-
forming capacity of the labeled cells (Matrigel Basement Membrane Matrix, 
Becton Dickinson, Alphen aan den Rijn, The Netherlands). After 4 and 24 h the 
cells were screened with a light microscope and photographed.
5.6.3. Visualization by MRI
All data acquisition was performed on a GE (HD) 3 T clinical MRI scanner using 
unmodified gradients and specially designed reception coils, to provide the 
best signal-to-noise (SNR) performance for the desired field-of-view.
For in vitro imaging of labeled cells, cells were harvested by trypsinization 
and a cell suspension was prepared in appropriate culture medium at a cell 
concentration of 50 cells/10 ml. On the bottom of a four-well culture plate 
(VWR international NUNC176740; Amsterdam, the Netherlands), a grid 
with rectangles of about 1.5 mm2 was carved (Fig. 4). This grid served as 
location marker for subsequent MR imaging sessions. A 10 ml aliquot of the 
cell suspension was seeded into the well, within the surface area of a single 
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rectangle of the grid. The cells were allowed to sediment and adhere to the 
bottom of the well before additional medium was added. Directly before each 
MRI scan, the medium was replaced with fresh medium containing Gd-DTPA 
(Magnevist, Bayer Schering Pharma AG, Berlin, Germany) at a v/v ratio of 1:200 
to provide enhanced SNR and contrast-to-noise (CNR) ratios using T1-weighted 
protocols to decrease imaging time. The grid was filled with ultrasound gel, 
to provide contrast in MR images. Each sample was placed over a single-loop 
solenoid coil with an inner diameter of 1.0 cm (Flick Engineering Solutions, The 
Netherlands). The distance between the loop and the cell monolayer was 1.3 
mm, which was the thickness of the bottom of the plate. The scan protocol was 
limited to a three-plane localizer followed by a high-resolution 3DT1-weighted 
scan. The following scan parameters were used: 3D-SPGR sequence with TR/TE 
41.1/10.5 ms, and a flip angle (a) of 508 with a resolution of 38 x 38 mm x 100 
mm and a FOV of 2 x 2 cm and an imaging time of 13 min.
5.7. Data analysis and statistics
Data are expressed as mean ± SD from triplicate samples in two or three 
repeated experiments. Statistical analysis of differences between data sets was 
performed by ANOVA (Graphpad Prism 4.0, GraphPad Software, La Jolla, CA, 
USA) followed by a post hoc test (Newman-Keuls Multiple Comparison Test). A 
p-value of <0.05 was considered significant.
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Abstract
The purpose of the study was to show the feasibility of quantification in 
the case of cell death, cell migration and cell division by parametric MRI. 
We identify limitations for quantitative cell tracking owing to mixed parallel 
processes. Various intravoxel SPIO-labeled cell, super paramagnetic iron oxide 
particles (SPIO) and micron-sized paramagnetic iron oxide (MPIO) particle 
distributions were prepared by methods mimicking biologically relevant 
processes (compartmentalization, migration, division and cell death). R2* and 
R2 relaxometry measurements were performed at 3.0 T; iron concentration was 
measured by optical emission spectrometry. The effects of spatial distribution 
and compartmentalization of paramagnetic iron-oxide particles on relativity 
were analyzed. Assessment of R2' (R2*-R2) allowed differentiation between 
intracellular and extracellular SPIO only if no high-iron-content extracellular 
particles were present. Relaxivity was sensitive to variations in cell labelling. 
Samples of the same cell types embedded in the same suspension media at 
the same cell density produced different relaxivity values, depending on the 
preparation of the labeled cells. In the case of cell division, a unique relationship 
between relaxation rate and iron concentration was found, where the relaxivity 
proved to be independent of initial cell labeling. In case of cell mixing, the cell 
density could be derived from relaxation values, even if iron concentration was 
undetermined. We demonstrated that relaxometry does not allow labeled cell 
quantification when multiple physiological processes such as cell division and 
cell migration coexist. The measured transversal relaxation rates were sensitive 
to the labeling technique. However, under special circumstances, despite the 
numerous limiting factors, quantification of the number of labeled cells by 
relaxometry was feasible. 
Keywords: iron-oxide; cell labeling; relaxometry; MRI; cell fate; iron and cell 
quantification
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Introduction
Cell labeling with super paramagnetic iron oxide particles (SPIO) offers a 
promising method for in vivo human and animal model cell tracking by MRI. 
The low signal intensity (SI) on T2 or T2* weighted images reveals the presence 
of labeled cells (1–6). Depending on the location and the different mechanisms 
in tissue development, the labeled cells can be followed for as long as several 
weeks (7,8). Cell death, cell division, cell migration and iron re-uptake by 
surrounding cells or macrophages influence the detected signal intensity 
(9,10), and eventually may lead to misinterpretation of SI differences between 
labeled and nonlabeled regions. Longitudinal studies require assessment of 
these processes. However, detection of low-SI areas is an inadequate method.
The imaging setup parameters (such as coil and patient position), the 
artifacts (owing to motion and flow) and also technical imperfections (e.g. 
inhomogeneity in the coil sensitivity, transmit- ter and receiver decoupling 
problems) may compromise the reproducibility of SI values. These problems 
hamper quantification or reliable tracking during physiologically relevant 
processes.
Some studies have suggested R2 (1/T2) and R2* (1/T2*) parametric mapping to 
be a feasible and reproducible quantification method of SPIO or SPIO labeled 
cells per voxel (11–13). At sufficiently high imaging resolution, where the 
image distortions owing to the susceptibility inhomogeneities are negligible, 
the relaxation rates can be related to the imaged voxels (14,15).
Voxel-based relaxometry potentially allows assessment of iron concentration 
if a unique relationship can be established between relaxation rates and iron 
concentrations. As such, voxel-based relaxometry may establish a method of 
quantification for density of labeling particles and eventually for the number 
of labeled cells. Although many reports have demonstrated a linear (or at 
least monotonic) relationship between R2* or R2 values and iron concentration 
(3,16–18), there are other variables that may influence relaxation values, such 
as intravoxel distribution and compartmentalization of iron oxide particles 
(12,16,17). Additionally, the dependence of R2* or the R2-Fe concentration 
calibration curve on compartmentalization or on labeling particle size and 
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type has also been reported (16). The reliability of relaxometry measurements 
is further complicated by deviations from a mono exponential decay in signal 
intensity (11,16,19–23). 
We further assume that the effects of biologically relevant variations of spatial 
distribution and compartmentalization of iron oxide particles may additionally 
affect the relationship between relaxation rates and Fe concentration. 
Specifically in dividing cells, both cells and intracellular SPIO content are 
subject to various evolution pathways. Cells may divide, sharing their SPIO 
content to daughter cells (24), or simply may translocate to nonlabeled regions, 
resulting in a mixture of labeled and nonlabeled cells. Some cells may die and 
disintegrate, transferring their content to the extracellular space, while may be 
taken up by macrophages or other surrounding cells. As these pathways may 
be differently represented, their effects on the SPIO compartmentalization 
and spatial distribution may result in different R2 and R2* values at the same 
SPIO concentration (25). Under these circumstances, relaxometry may lead to 
a misinterpretation of iron concentrations and hence to false conclusions on 
how tissue develops.
In our study, we address the effects of these evolution pathways by 
investigating the resulting change in transversal relaxation times. For this 
purpose, suspensions of labeled and unlabeled cells were used as a model 
to mimic cell translocation effects. We studied the effect of cell division by 
monitoring the evolution of labeled cells. Aggregation effects were studied 
by suspensions of SPIO, MPIO and SPIO-complexes. To create different spatial 
distribution of labeling SPIOs, we varied cell labeling and extracellular SPIO 
content and used different cell densities.
Materials and Methods
Cell culture and cell labeling
As a model system for dividing cells, Brown Norway 175 (BN175) sarcoma cells 
were used. Cells were grown in advanced RPMI medium (Invitrogen, Breda, The 
Netherlands) with 1% (v/v) penicillin– streptomycin (10 000 U penicillin ml-1 + 
10 000 ug streptomycin ml-1; Cambrex, Verviers, Belgium) and 10% (v/v) fetal 
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bovine serum (Cambrex, Verviers, Belgium) in 175 cm2 flasks (Fisher Scientific 
B.V., Landsmeer, The Netherlands).
Labeling of cells with SPIO was performed at 80–90% confluence using 
Endorem (Guerbet S.A., Paris, France) and lipofectamine 2000 (Invitrogen, 
Breda, The Netherlands). A labeling stock solution of 215 ug Fe ml-1, for a 
175 cm2 flask, was prepared as follows: 25 ul Endorem was added to 625 ul 
Opti-MEM (Invitrogen, Breda, The Netherlands) and 25 ul of lipofectamine was 
added to 625 ul Opti-MEM. After 5 min the two solutions were mixed together 
and the resulting suspension was incubated at room temperature for 20 min. 
After washing the cells with phosphate-buffered saline (PBS; Invitrogen, Breda, 
The Netherlands), the culture medium was replaced by advanced RPMI medium 
with 1% (v/v) penicillin–streptomycin and 233 ug (1082 ul) of iron was added to 
the cells, which were then incubated for 24 h at 37oC–5% CO2. Before further use 
of labeled cells, the monolayer cultures were rinsed three times with PBS.
Phantom preparation
For the MR measurements, phantoms were prepared consisting of six 0.5 ml 
Eppendorf tubes as sample holders. The sample holders were placed in 3 cm 
diameter dishes filled with water to avoid the proximity of an air interface 
(Fig. 2a and b). The samples were prepared with 0.3% agar (Becton Dickinson, 
Alphen aan de Rijn, The Netherlands) in order to avoid sedimentation. The 
cells used for the samples were fixed with 4% formaldehyde (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) for 10 min at room temperature.
Incorporation of iron, localization of iron complexes and label retention
The used agar samples were dried for 72 h at 60 oC. Subsequently they were 
digested in 40 ul of a 3:1 mixture of ultra-pure perchloric acid (EM Science, 
Gibbstown, NJ, USA) and ultrapure nitric acid (JT Baker, Deventer, The 
Netherlands) at 60 oC for 6 h. To the digested substance 4 ml MiliQ was added 
and the amount of iron was determined with a Perkin Elmer Optical Emission 
Optima 4300 DV Spectrometer (Perkin Elmer Instruments, Norwalk, NC, 
USA) at 259 nm. The experiments were performed three times with triplicate 
samples. To assess the presence and distribution of the iron complexes, 
cytospin slides were prepared from labeled cells. After the slides were dried 
by air the cells were fixed in absolute methanol (Sigma-Aldrich, Zwijndrecht, 
63563-Sandra van Tiel-proefschrift.indd   55 04-09-20   08:45
Chapter 3
56
the Netherlands) and Prussian blue staining (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) was performed. The slides were covered with a cover slip and 
imaged with an Axiovert S100 microscope (Zeiss, Oberkochen, Germany). In 
order to eliminate extracellular presence of SPIO, samples for cytospin slides 
were taken from labeled cell stocks. After visual inspection with microscopy, 
stocks were further processed (washed) if extracellular SPIOs were detected 
or otherwise approved for sample preparation (Fig. 1).
MR imaging and post-processing
Imaging was performed on a GE Signa 3.0 T whole-body clinical scanner 
(General Electric Healthcare, Milwaukee, USA). For radio-frequency (RF) 
excitation, the built-in whole body coil was used, and signal detection was 
performed with receive-only custom-made single channel 5 cm surface loop 
coil. R2 Relaxometry was carried out with a single-slice (coronal plane) two-
dimensional (2D) spin-echo (SE) sequence at various echo times (12 echoes, 
echo time TE = 10–210 ms, repetition time TR = 1500 ms). The image matrix 
was 256 x 256, at a field-of-view (FOV) of 40 x 40 mm, with a slice thickness of 
0.7 mm (resolution 0.16 x 0.16 x 0.7 mm).
For R2* relaxometry, a three-dimensional (3D) RF-spoiled gradient recalled 
echo (SPGR) sequence was used at the same resolution as the R2 measurements 
(0.16 x 0.16 x 0.7 mm), with eight echoes TE = 4–25 ms, TR = 33 ms and a flip 
angle of 13o. Coronal (horizontal plane) images were used for evaluation.
The TE values for both measurements were chosen to sample the expected 
exponential decay curves for different SPIO concentrations. Signal-to-noise 
ratios were taken into account to provide a good fit. Imaging resolution was 
chosen to match in vivo protocols, where R2 and R2* measurements were also 
matched in order to achieve a voxel based comparison with the in vitro results.
Mono-exponential curve fitting was carried out on T2- and T2*-weighted images 
with MATLAB (Levenberg–Marquardt algorithm, the MathWorks, Natick, MA, 
USA). The voxel-based and selected-region-of-interest based curve fitting was 
performed. Figure 2(b) illustrates the quality of data and fit results for spin 
echo (R2) measurements, and Fig. 2(d) for gradient echo (R2*) measurements. A 
three-parameter exponential function was used:
63563-Sandra van Tiel-proefschrift.indd   56 04-09-20   08:45
3
Quantification of iron labeled cell 
57
SI = a . exp ( - b . TE) + c
where SI is the measured signal intensity and TE is echo time. The fitting 
parameters are a, b and c.
Figure 1 A Coronal plane image of Eppendorf tubes containing super paramagnetic iron oxide particles 
(SPIO)-labeled cell suspensions. Tubes are embedded in a water-agar phantom to reduce macroscopic 
magnetic field inhomogeneities. The image was acquired using a 2D SE sequence. Distortions are 
observable around sample 1. Samples exhibiting distortion also had very short T2* value and thus were 
excluded from evaluation. B The graph displays measured signal intensities in SE experiments (data) as 
a function of echo time (TE). Exponential fit is also displayed (red continuous line), illustrating curve fit 
accuracy and data quality. Data points were acquired from sample 3. This sample contained a mixture 
of SPIO-labeled and unlabeled cells (in total 3106 cells) in 0.3% agar. R2 of the fit: R2 > 0.99. C Coronal 
plane gradient echo (SPGR) image of the same sample as in (A). D Measured signal intensities in SPGR 
experiments as a function of TE are displayed. Curve fitting result is plotted (red line). R2 of the fit: R2 > 0.99.
Relaxivity values (r2 = dR2/dcFe and r2*= dR2*/dcFe) were determined by linear 
fitting to the relaxation rate vs iron concentration (cFe) curves. Cellular relaxivity 
was calculated similarly from relaxation rate vs cell density plots; relative 
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relaxivity was calculated from relative relaxation rate vs relative extracellular 
iron content plots.
The R2' relaxation rate, as a physical quantity characterizing the B0 
inhomogeneity was calculated as R2' = R2* – R2. Similarly, the relaxivity, 
characterizing the samples, was calculated as r2' = r2* – r2.
Figure 2 BN175 cells and labeling super paramagnetic iron oxide particles (SPIO) particles (image 
acquired at 400 x magnification), prepared for MRI measurements. The typical vesicular perinuclear 
distribution of SPIO can be observed as often reported following endocytosis. No excess SPIO are 
observable in the extracellular space. A Cytospin slide after labeling; B cytospin slide 48 h after labeling.
Distribution phantoms
1. Aggregation and compartmentalization of the labeling particles
In order to assess the effect of labeling particle aggregation, a dilution series of 
SPIO, SPIO–lipofectamin complexes (in the following referred to as SPIOc) and 
MPIO (1.1 pg iron per particle, average size 1.63 um, Bangs Laboratories Inc., 
Fishers, IN, USA) was prepared. Separate SPIO (33.6, 16.8, 8.4, 4.2, 2.1 and 1.05 
ug iron content) and MPIO (36.9, 18.4, 9.2, 4.6, 2.3 and 1.15 ug iron content) 
solution series in 0.3% agar were prepared. SPIOc samples were prepared 
from a stock SPIO–lipofectamin complex dilution solution of 0.215 ug Fe ul-1. 
Different amounts (7–224 ug Fe) were mixed with 200 ul 0.3% agar in a 500 ul 
Eppendorf tube.
To characterize the effect of compartmentalization of labeling particles, 
suspensions of SPIO particles and labeled cells were prepared, where the cell 
density was kept constant with increasing amount of SPIO in the extracellular 
space. An aliquot of 3 x106 cells was suspended in 200 ul 0.3% agar with various 
(0–2.7 ug) SPIO contents added.
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2. Cell migration: variations in labeled and unlabeled cell densities
The physical principle of cell migration was mimicked by the mixing of the 
suspensions of labeled and unlabeled cells. To characterize the effect of 
variations in the density of labeled cells, phantoms were created with a total of 
3 x 106 cells in 200 ul 0.3% agar. The ratios of labeled and unlabeled cells were 
1:1, 1:3, 1:7, 1:15, 1:31 and 1:63.
3. Intracellular variations: cell division and labeling efficiency
We generated sample series to assess the effect of heterogeneity, which may 
arise from uneven SPIO distribution to daughter cells or from variations in cell 
doubling times. Cells were harvested from an initially labeled stock at different 
time points after labeling. Cells were growing in cell culture, and their SPIO 
content was passed on to daughter cells; thus the level of cell labeling was 
subject to cell division.
After labeling the cells were replated and the next samples were taken at 24, 
48 and 72 h. The pelleted cells were resuspended in 200 ul 0.3% agar (Becton 
Dickinson, Alphen aan de Rijn, The Netherlands) in a 500 ul Eppendorf tube 
(Fisher Scientific B.V., Landsmeer, The Netherlands).
To study the effect of variations in cell labeling, two different protocols (High 
and Low in the following) were followed to generate batches of labeled cells. 
The protocols were only different in the step preceding incubation for 24 h(see 
the protocol details in the ‘Cell culture and cell labeling’ section.): the added 
iron content was 279 ug (= 1296 ul) for the ‘High’ protocol or 233 ug (=1082 
ul) for the ‘Low’ protocol. Both batches were used independently in the cell 
dilution series (mixing labeled and unlabeled cells) and in the cell division 
series.
Results
Free and incorporated labeling particles
The relaxivity showed a strong dependence on the type of the labeling 
particles. MPIOs exhibited the highest relaxivity r2*= 635 mM
-1 s-1, followed by 
SPIOc r2*= 226  mM
-1 s-1 and SPIO particles r2* = 170 mM
-1 s-1. Compared 
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Figure 3 R2* relaxation rate (1/s) plotted against iron concentration cFe (mM). Linear fit on data is 
shown. Relaxivity values (slope of linear fitted curve) are shown next to linear fits (in units: mM-1 s-1). Free 
super paramagnetic iron oxide particles (SPIO), SPIO complex (SPIOc) and MPIO dilution series exhibit 
different relaxivities (r2*); r2* is higher for particles of higher Fe content. Cells labeled with SPIOc exhibit 
higher r2* than SPIOc dilutions. Cell division series (initially labeled and harvested at increasing delay 
times) and cell dilution series (mixture of labeled and unlabeled cells) exhibit different r2*. Cell density is 
identical for all cell-containing samples.
 
Figure 4 R2’ relaxation rate (1/s) plotted against iron concentration cFe (mM). Relaxivity values are shown 
next to linear fits (in units: mM-1 s-1). Preparation of samples is identical to that in Fig. 3. R2’ differentiates 
between intra- and extracellular super paramagnetic iron oxide particles (SPIO). r2’ ≈ 0 for free SPIO and 
SPIOc. MPIO and cell dilutions have very close r2’ values. For cell division and cell dilution samples, r2’ 
values are different.
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Figure 5 A Relative relaxation rates R2, R2* and R2’ (relaxation values normalized by relaxation value 
of the sample with no extracellular super paramagnetic iron oxide particles, SPIO) are plotted against 
relative extracellular iron content (percentage of the total SPIO content that is in the extracellular space). 
The samples have identical intracellular iron content, extracellular SPIO is evenly distributed and the cell 
number is kept constant throughout all samples. Relative relaxivities are displayed (slope of linear fit). 
B R2 relaxation rate plotted against iron concentration for SPIOc dilution, cell dilution and cell division 
samples. The SPIO complexes have lower r2 relaxivity when incorporated in the cells.
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with the free suspensions, SPIOc particles exhibited dramatically increased 
relaxivity when incorporated into cells: r2* = 412 mM
-1 s-1 for the cell dilution 
series and r2*= 758 mM
-1 s-1 for the cell division series (Fig. 3).
Figure 4 shows the R2' relaxation rates for the different samples. Free SPIO 
and SPIOc dilutions exhibited zero r2' relaxivity. SPIOc particles incorporated 
in cells and MPIO particles yielded nonzero r2' relaxivity. The cell dilution 
and the MPIO dilution series resulted in very close R2' values when Fe 
concentrations were in the same range (0.1–0.3 mM, see fitted linear curves, 
Fig. 4). The estimated values of the iron content per particle for the MPIOs 
and for the labeled cells in cell dilution series were 1.1 and 1.4 pg respectively 
(based on optical emission spectrometry for labeled cells and manufacturer 
data for MPIO particles). Figure 5(a) depicts the relative changes in the R2, 
R2* and R2' values, where the density of labeled cells was kept constant with 
increasing concentration of extracellular SPIO complex. For the coexistence 
of extracellular and intracellular SPIO, the relative change in R2* value with 
increasing amount of extracellular SPIO was negligible. Although the total 
iron content was almost doubled at a fixed number of labeled cells, R2* 
remained constant within error. In contrast, R2 value showed sensitivity to 
total iron content (relative relaxivity was 0.92). R2' was less sensitive to the 
change in the extracellular SPIO concentration (relative relaxivity was - 0.29); 
it decreased with increasing extracellular iron content. Figure 5(b) shows 
the R2 relaxation rate dependence on iron concentration for three different 
compartmentalization models: dilution series of free SPIO complexes; dilution 
series of cells labeled with SPIO; and cell division series with SPIO labeled 
cells. The r2 relaxivity was enhanced for free SPIO complexes (r2 = 329 mM
-1 s-1) 
compared with incorporated SPIO complexes (r2 = 169 mM
-1 s-1 for cell division 
and r2 = 148 mM
-1 s-1 for cell dilution).
Distribution of intracellular SPIO complexes
The R2* and R2' values at the same iron concentrations (also the r2* and r2'values) 
were different for the cell dilution and for the cell division series (see Figs 3 and 
4.). Although the cell types, the labeling particles and the cell densities were 
identical for these series, the relaxivities were clearly different (r2*, 758 vs 412 
mM-1 s-1; r2', 586 vs 314 mM
-1 s-1).
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Figure 6 A R2’ relaxation rate plotted against iron concentration. The linear fit is displayed for both 
sample series; relaxivities are displayed next to linear fits (in mM-1  s-1 units). In sample ‘low’ the average 
cell iron content is 1.0 pg. In sample ‘high’ the average cell iron content is 1.4 pg. The r2’ relaxivity is 
more than double for sample series ‘low’: 642 mM-1 s-1 compared with 314 mM-1 s-1. B The R2’ relaxation 
rate plotted against labeled cell density. The cellular relaxivity values are very close 0.01091 l/s for the 
labeled series ‘high’ and 0.01031 l/s for the ‘low’ series.
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Figure 7 R2' relaxation rate plotted against iron concentration. The linear fit on all data points excluding 
the day 0 data points is displayed. Data points belonging to one cell division series are connected. 
Data points are labeled, referring to data series (high, H; low, L) and the day of harvesting after labeling 
(days 0, 1, 2 and 3). After one day (approximately one cell cycle), all data points converged to the same 
relaxation curve (linear fit). Deviation from this relaxation curve on day 0 was apparent and proved to 
be systematic.
The different labeling protocols (High and Low) resulted in different estimated 
values of average iron content per cell (based on optical emission spectrometry). 
The High labeling protocol resulted in 1.4 pg per cell iron content; the Low 
yielded 1.0 pg per cell. The cell dilution series of these batches resulted in 
different r2' relaxivities (Fig. 6a). The relaxivity was more than double (r2' = 642 
mM-1 s-1) in the case of the Low labeling protocol compared with the one of 
the High protocol (r2' = 314 mM
-1 s-1). Figure 6b exhibits R2' relaxation rates as a 
function of labeled cell density. Despite the large difference in the average iron 
content per cell (High and Low labeling protocols), relaxation values at the same 
cell densities were very close, the cellular relaxivities being r2' = 10.9 x 10
-3 ul s-1 
for the Low series and r2' = 10.3 x 10
-3 ul s-1 for the high series.
A comparison between labeled cell division series, where the labeling protocol 
was different, is depicted in Fig. 7. The series exhibit very close R2' relaxation 
rates in a wide range of iron concentrations after one division cycle. In the 
case of the cell division series, R2' showed no sensitivity to the differences in 
initial cell labeling. Both division series converged to the same linear curve 
established by linear fit to the data points. The deviation from the relaxation vs 
iron concentration curve at day 0 appeared in both batches.
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Discussion
Mono-exponential signal decay
Several theoretical works and experimental studies (20–23) report deviation 
from mono-exponential signal decay in the presence of magnetic particles. 
In the case of SPIO labeled cells, a very fast initial signal decay followed by 
a slower decay was expected, where the components originated from the 
extra- and the intracellular compartments (21). Furthermore, Jensen et al. (26) 
predict nonexponential behavior of the signal decay, where the deviation from 
exponential depends on the MR acquisition scheme, diffusion and the shape 
of magnetic disturbers. 
However, these predictions were not observed in our measurements. We found 
good agreement with mono-exponential signal decay in every investigated 
sample. This can be explained in part by the relatively large value of the 
minimum echo times (10 ms in spin-echo, 4 ms in gradient echo experiments), 
that prohibit the observation of the fast initial signal decay. 
Theoretical considerations
The theoretical works of Brown (27) and Yablonskiy and Haacke (28) describe 
relaxation rates in the presence of magnetic inhomogeneities. These models 
are valid under certain assumptions, most importantly the static dephasing 
and dilute disturbers regimes (hereafter SD). From the model it follows that 
the relaxation rate is proportional to the local magnetization dose (LMD), the 
product of the volume fraction of the magnetic compartments, f (in our case, 
SPIO labeled cells) and the internal magnetization of these compartments, M:
 R2' = γ 2π  
. f . M (1)
    9√3 
With one further assumption, that the internal magnetization of the labeled 
cells (M) is proportional to the number of incorporated SPIOs, this predicts the 
following: rearrangement of SPIO particles between cells leaves R2' unchanged, 
if cell number (NL), total number of SPIOs and total volume (V) are constant.
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 LMD = f . M =  v . NL   .   n . µ  =   µ    .   n . NL . m0     = µ  . cFe
   V          v        m0                V              m0 
 (2)
where v is the cell volume, n is the number of SPIOs in a cell, m is the magnetic 
moment of an SPIO, m0 is the mass of iron per SPIO particle and cFe is the iron 
concentration in the sample. Any spatial rearrangement of SPIO leaves the iron 
concentration constant, and also 'R2' if SD is valid.
The difference between cell dilution and cell division sample at a given SPIO 
concentration (Fig. 4) can be viewed as a simple rearrangement of SPIOs in 
labeled cells: in the cell dilution samples the SPIOs are concentrated in fewer 
cells. Also the ‘High’ labeled sample has fewer cells with higher load compared 
with the ‘Low’ labeled sample at an equal amount of SPIO particles (Fig. 6a). 
These rearrangements of labeling particles lead to different R2' values and r2' 
relaxivities. SD theory fails to describe this behavior. The following explains this 
result: SD increasingly underestimates R2' at higher volume fractions of labeled 
cells (16,20,29). A rough estimate of the volume fraction range of the magnetic 
disturbers is 0.3–5% in our cell suspension samples. With the assumption 
of even distribution of SPIOs to daughter cells, the cell division samples 
represent a higher volume fraction of magnetic disturbers (here: labeled cells) 
compared with cell dilution samples; therefore the elevation of R2' values from 
SD prediction is higher. Similar to this, the ‘Low’ labeled samples have higher 
volume fractions compared with ‘High’ labeled samples at the same SPIO 
content, resulting in higher elevation of R2' values.
The SPIO and cell dilution samples exhibit minor deviation from the linear 
relaxivity–concentration curve (Fig. 3): the relaxivities decrease at lower 
concentrations. Also, an extrapolation to lower concentration from the data 
points leads to negative relaxation rates at zero iron concentration. Based 
on our results and the SD theory, one can predict that the different samples 
exhibit the same relaxivity when dilute; this relaxivity value is described by 
the SD theory. With increasing concentrations (as the theoretical prediction 
underestimates the relaxivity values), the relaxation rates of the samples 
deviate from the mutual, theoretically predicted value and exhibit higher 
relaxivity. As our results demonstrate, this relaxivity is dependent on spatial 
distribution of SPIOs.
63563-Sandra van Tiel-proefschrift.indd   66 04-09-20   08:45
3
Quantification of iron labeled cell 
67
Another possible explanation of the differences in relaxivities (Fig. 4) may be 
that the magnetization of the labeled cells is not proportional to the number of 
incorporated SPIOs (a hypothesized saturation effect). In this case, the samples 
where SPIOs are concentrated in fewer cells would lead to lower cellular 
magnetization and LMD value, and thus lower R2', according to SD model. 
However, this hypothesis would contradict the previous findings reported by 
Bowen et al. [(16), table 3], where the LMD and iron content of SPIO labeled 
cells were found proportional.
According to SD theory predictions, the relaxation rate is proportional to the 
internal magnetization of the magnetic disturbers relative to the magnetization 
of the surrounding medium R2' ≈(M - M0). The R2' values of the labeled cell 
suspensions are reduced by the presence of SPIOs in the suspension medium. 
This prediction is in good agreement with our findings (Fig. 5a). Irrespective to 
the validity of SD, it can be assumed that R2' is a monotonic function of M - M0.
The behavior of R2' relaxation illustrated in Fig. 6(a and b) is surprising, 
especially in comparison with the SD predictions. SD regime assumption with 
the further assumption that the intracellular magnetization is proportional 
to the SPIO content per cell predicts that R2' is determined by the iron 
concentration. The findings illustrated by Fig. 6 contradict this prediction. 
It can be hypothesized that at increasing volume fraction of the magnetic 
disturbers (moving away from the dilute SD regime), the cellular magnetization 
plays a lesser role and the number of disturbers (volume fraction) becomes 
more important.
Extra-cellular/intra-cellular differentiation
Numerous studies have suggested that the r2* and r2 relaxivities depend on 
compartmentalization of iron particles. The r2' relaxivity is negligible for free, 
equally distributed SPIO. As was previously suggested (12), R2' values can be 
used to determine labeled cell number per voxel. R2' is a valid measure of the 
number of labeled cells, assuming a simple scenario for cell death, where 
SPIO is transferred from the intracellular space to the extracellular space and 
evenly distributed. Our results confirm this assumption. However, they also 
suggest that extracellular iron may give a nonzero contribution to R2'. In case 
of extreme iron deposits (see MPIO on Fig. 3), extracellular iron produces 
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relaxivity values close to the relaxivity of samples with labeled cells. When 
the highly aggregated extracellular iron coexist with the labeled cells in the 
imaging voxels, the R2' based cell quantification method fails.
Cell death
Large clusters of EC SPIO may also be produced during cell death. When dead 
cells do not disintegrate entirely, or the EC matrix prevents even distribution of 
released labeling particles (e.g. in the presence of a collagen matrix), particles 
of high iron content may be present in the EC space. Consequently R2' will not 
indicate changes in cell viability (30).
In the case of the aforementioned simplistic scenario (where dead cells spread 
their contents to EC evenly), though, theoretically, one can find an indication 
of cell death: the R2' value will decrease (owing to decreasing concentration of 
labeled cells, see Fig. 4, and owing to increasing concentration of extracellular 
iron, see Fig. 5a). On the other hand, R2 will increase if SPIO is transferred 
from the intracellular to the extracellular space (12). Figure 5(b) shows that 
the relaxivity for free SPIO is higher than that for SPIO incorporated in cells. 
Furthermore, R2 is sensitive to solute concentration, and the IC space is usually 
more concentrated. R2 will increase if cell content is transferred from the 
IC to the EC space (31–33). Therefore, the decrease in the R2' value and the 
simultaneous increase in the R2 value may well indicate on- going cell death in 
the labeled cell region.
Cell migration/mixing
Translocation of cells potentially leads to a mix of labeled and unlabeled cells. 
R2' and R2* prove to be reliable measures. Both show a linear dependence on 
iron concentration. If it is assumed that there is no other source for iron deposits 
resulting from other sources, e.g. from red blood cells, it is possible to quantify 
the number of labeled cells. However, a careful calibration is necessary. As 
Fig. 6(a) indicates, the variations in iron content per cell can lead to different 
relaxivities. The iron concentration cannot be determined unambiguously by 
relaxometry. However, with a priori knowledge of the iron content per cell the 
cell density can be derived from the R2' relaxation rate (see Fig. 6b).
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Cell division
The problem with quantifying the number of labeled cells in the case of cell 
division (passing SPIO content to daughter cells) was indicated in previous 
studies (24). Even in a simplified model of a cluster of dividing labeled cells, 
where cell density is kept constant, increasing heterogeneity is expected. 
Variations in cell doubling time and uneven distribution of SPIO to daughter 
cells lead to inhomogeneities in the spatial distribution of SPIOs. However, 
our results on cell division samples reveal a unique curve of the relaxation 
rate vs iron concentration (Fig. 7). Despite the differences in the initial iron 
content per cell, the samples could be characterized by the same relaxivity. 
We can conclude that in a volume where the cells are labeled and dividing, 
and also the cell density is constant (e.g. constant intracellular volume ratio 
and cell size can be assumed), the iron content can be determined. This iron 
content may serve as a basis for estimation of the number of labeled cells in 
the corresponding volume.
Mixed processes
Cell death, cell migration (or translocation), cell division, extracellular SPIO 
accumulation or dispersion can be modelled in vitro and a calibration on 
relaxivity can be established. We have demonstrated here that mixing, division 
and cellular load variations can exhibit different relaxivities. Unless there is only 
one, well-defined process going on in the volume of interest, neither the iron 
concentration nor the density of labeled cells can be determined by relaxation 
rate measurements only. Based on theoretical grounds, this finding would 
make cell quantification impossible for many in vivo situations. However, 
one can argue that, at sufficiently high imaging resolution, the coexistence 
of the different pathways in a single voxel is not probable. This biologically 
homogeneous compartment size could be determined for the investigated 
tissue type and assumed physiological processes, thus the imaging resolution 
could be chosen correspondingly. In this scenario, with the further assumption 
that the processes can be identified on a voxel level, we can conclude that iron 
quantification can be carried out by relaxometry.
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Conclusion
Our results suggest that in vitro relaxivity calibrations can be applied to in vivo 
measurements only under special circumstances. We can conclude that the 
cell-to-cell variations play an important role in transversal relaxation rates. We 
demonstrated that samples of labeled cells of the same type at the same cell 
density at a given iron concentration can exhibit different R2* and R2' relaxation 
rates, depending on the cell-to-cell variations in the labeling particle content. 
Unless there is only one, well-defined, dominant process in the investigated 
volume, iron content cannot be determined by relaxation measurement. 
During cell mixing, cell densities can be derived from relaxation values, even 
if iron concentration remains ambiguous. When cell division is the dominant 
process, despite labeling variations, iron content and also cell densities can 
be determined from re- laxation rates. Cell death can be identified by the 
simultaneous increase in R2 and decrease in R2'.
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Abstract
In vivo cell tracking of therapeutic, tumor, and endothelial cells is an emerging 
field and a promising technique for imaging cardiovascular disease and cancer 
development. Site-specific labeling of endothelial cells with the MRI contrast 
agent superparamagnetic iron oxide (SPIO) in the absence of toxic agents 
is challenging. Therefore, the aim of this in vitro study was to find optimal 
parameters for efficient and safe SPIO-labeling of endothelial cells using 
ultrasound-activated CD31-targeted microbubbles for future MRI tracking. 
Ultrasound at a frequency of 1 MHz (10,000 cycles, repetition rate of 20 Hz) 
was used for varying applied peak negative pressures (10 – 160 kPa, i.e. low 
mechanical index (MI) of 0.01 – 0.16), treatment durations (0 – 30 s), time of 
SPIO addition (-5 min – 15 min with respect to the start of the ultrasound), 
and incubation time after SPIO addition (5 min – 3 h). Iron specific Prussian 
Blue staining in combination with calcein-AM based cell viability assays were 
applied to define the most efficient and safe conditions for SPIO-labeling. 
Optimal SPIO labeling was observed when the ultrasound parameters were 
40  kPa peak negative pressure (MI 0.04), applied for 30 s just before SPIO 
addition (0 min). Compared to the control, this resulted in an approximate 12 
times increase of SPIO uptake in endothelial cells in vitro with 85% cell viability. 
Therefore, ultrasound-activated targeted ultrasound contrast agents show 
great potential for effective and safe labeling of endothelial cells with SPIO.
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Introduction
In vivo cell tracking is a very promising technique to visualize cells of interest 
inside the body. It allows tracking of motile therapeutic cells like immune cells, 
stem cells, and endothelial progenitor cells to sites of inflammation, cancer, or 
ischemia [1-5]. Additionally, this technique can be used to track tumor cells [6], 
tumor vasculature [7, 8], or endothelial cells in tissue engineered valves [9] and 
vascular grafts [10]. 
After labeling the cells of interest with an imaging probe, they can be 
tracked by an imaging modality. Magnetic resonance imaging (MRI) is 
interesting for cell tracking because it is precise, harmless, and thus well 
suited for longitudinal studies. Moreover, single cell tracking is possible by 
MRI. However, in vivo cell labeling with an MRI contrast agent is challenging 
[6, 11-16]. For cell labeling, the T2 and T2*-shortening MRI contrast agent 
superparamagnetic iron oxide nanoparticles (SPIO) of 80–180 nm in size 
[17] are often used [18, 19]. They are relatively safe compounds [19-22], 
but most of in vitro cell labeling techniques for SPIO are not applicable in 
vivo, because of the high toxicity and broad systemic effects of transfection 
agents [23]. Therefore, there has been growing interest in safe, site-specific 
cell labeling techniques. One potential method involves using ultrasound 
contrast agent, which are comprised of microbubbles. The microbubbles 
have a low diffusible gas core (for example C4F10), vary in diameter from 
1–10 μm, and are encapsulated by a coating material (for example 
phospholipids). When ultrasound is applied, the microbubbles oscillate due 
to sequential compression and expansion caused by pressure variations in 
the surrounding medium. The oscillation of microbubbles has been shown 
to deliver therapeutic materials into cells and interstitial tissue [24-27]. Up 
till now there is no consensus on the mechanism of the enhanced uptake. 
One of the uptake routes is a phenomenon called sonoporation, when 
reversible or non-reversible cell membrane pores are generated upon 
microbubble oscillations or violent collapse. Other uptake routes include 
enhanced endocytosis and opening of cell-cell contacts [25, 26, 28]. It has 
been reported that the efficacy of cellular uptake of therapeutic agents can 
be improved up to 7.7-fold in vitro [29] and up to fivefold in vivo [30] by using 
targeted microbubbles (tMB) instead of non-targeted microbubbles (non-
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tMB). The tMB have a ligand added in their coating by which the tMB can 
adhere to disease-specific cell membrane biomarkers [31, 32].
It was previously shown that 45–60 nm SPIO (Resovist) could be delivered in 
vivo into the swine brain using SonoVue lipid-coated non-tMB and ultrasound 
(28-kHz ultrasound with 100-ms burst length and repetition rate of 1 Hz at 0.6 
– 1 MPa (mechanical index (MI) 4.8 – 6.0) applied for 5 min; MRI performed 3 h 
after treatment) [33]). Brain tumor delivery of SPIO (mean diameter 6 – 10 nm 
[34] or 35.7 ± 9.2 nm [35]) loaded in the lipid-coating of in-house produced 
non-tMB was shown in vivo in rats using ultrasound (0.4 MHz with 1,000 cycles 
and repetition rate of 1 Hz at 325 kPa (MI 0.5) applied for 90 s; MRI performed 
40 min after treatment [34] or 1 MHz with 5,000 cycles and repetition rate 
of 1 Hz at 300 kPa (MI 0.3) applied for 4 min; MRI performed 1 and 3 h after 
treatment [35]). Delivery of 120 – 180 nm SPIO (Feridex) was also shown in the 
aortic arch by SonoVue and ultrasound treatment (8.5 MHz ultrasound at an MI 
of 1.2 applied for 20 min; MRI performed 1 h after treatment) [36]. These studies 
demonstrate the possibility of SPIO-loaded MB or co-administrated SPIO with 
MB for labeling extravascular tissues and subsequent MRI imaging of the 
SPIO, but do not cover cell labeling. Successful SPIO (Revovist) mesenchymal 
stem cell labeling using SonoVue and ultrasound (1 MHz, 50% duty cycle, 1.0 
W/cm2 acoustic power applied for 60 s) has been reported in vitro [37]. SPIO 
(12 nm mean diameter) loaded in the polymer coating of in-house produced 
non-tMB were used to successfully label tumor cells in vitro using ultrasound 
(1 MHz, 20 cycles per burst, repetition rate of 10 kHz, 0.1 – 0.75 W/cm2 acoustic 
power applied for 40 s) [38]. However, MB are blood pool agents. Endothelial 
cells, which form the inner lining of vessels, are therefore the main target of 
intravascular administered MB [39, 40]. Exceptions are tumors that invade 
into the vasculature, as reported for hepatocellular cancer (i.e. a primary liver 
tumor) [41] and colorectal cancer [42]. On the other hand, tMB were shown 
to target ovarian cancer cells preclinically by an alternative administration 
route, namely intraperitoneal injection [43]. Additionally, tMB are preferable 
instead of non-tMB since they can be specifically targeted to the cells of 
interest and upon binding are close to the endothelium, which is a perquisite 
for the MB-mediated drug delivery effectiveness [26]. The in vivo study by Gao 
et al. demonstrated arterial wall uptake of SPIO particles using non-tMB and 
ultrasound [36], but only under one acoustic setting (8.5 MHz ultrasound at 
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1.2 MI, i.e. 3.5 MPa acoustic pressure), which induced considerable arterial 
wall damage. To the best of our knowledge, no in-depth studies have been 
performed to characterize the parameters (e.g., the acoustic settings, the SPIO 
addition time and incubation time) that strongly influence the efficacy and 
safety of SPIO-labeling of endothelial cells using tMB at low MI (<0.2). 
The aim of our in vitro study was to find optimal parameters for 
non-invasive, tMB-mediated, SPIO-labeling of endothelial cells for the future 
application of MRI tracking of tumor vasculature and tissue engineered 
vasculature structures. We used lipid-coated tMB targeted against CD31 
(i.e. platelet/endothelial cell adhesion molecule-1 (PECAM1)), a biomarker 
constitutively expressed on endothelial cell membranes [44], as proof of 
concept. Iron specific Prussian Blue staining in combination with calcein-AM 
based cell viability assays were applied to define the most efficient and safe 
conditions for SPIO-labeling of endothelial cells in vitro. We investigated a fixed 
ultrasound driving frequency of 1 MHz and a series of low diagnostic acoustical 
pressures (<200 kPa; MI<0.2) and treatment duration times (0 – 30 s). In our 
study we used 1 MHz as the ultrasound frequency because it is commonly 
used for microbubble-mediated drug delivery studies and is close to the 
resonance frequency of microbubbles [26]. Although the exact link between 
the type of microbubble behavior and drug uptake is not yet known [26], it 
was reported that endocytosis was stimulated at longer (2,000 – 10,000 cycles) 
acoustic cycles [45-47]. SPIO are typically 80 – 150 nm [17] nanoparticles which 
may require uptake by endocytosis, as this has been shown to be the main 
uptake mechanism for therapeutics larger than ~17 nm in radius [46]. This is 
the reason why we chose to study 10,000 acoustic cycles.
Materials and Methods
Endothelial cells
Human umbilical vein endothelial cells (HUVECs) (Lonza, Verviers, Belgium) 
were cultured in EGM-2 (Lonza) medium in T75 flasks (BD, Breda, the 
Netherlands) in a humidified incubator at 37°C with 5% CO2. Cells were 
detached with 0.25% Trypsin in EDTA (Lonza) and replated on one side of the 
acoustically transparent OptiCellTM (NUNC, Wiesbaden, Germany) chambers. 
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HUVECs were cultured as described before [48], for two days until 70% 
confluence to resemble neovasculature endothelial cells.
Targeted microbubbles
Biotinylated lipid-coated microbubbles (mean diameter 2.5 µm) consisting 
of a coating of DSPC (84.8 mol %; P 6517; Sigma-Aldrich, Zwijndrecht, the 
Netherlands), PEG-40 stearate (8.2 mol %; P 3440; Sigma-Aldrich), DSPE-
PEG(2000) (5.9 mol %; 880125 P; Avanti Polar Lipids, Alabaster, AL, USA), 
and DSPE- PEG(2000)-biotin (1.1 mol %; 880129 C; Avanti Polar Lipids) with 
a perfluorobutane (C4F10) gas core (F2 Chemicals, Preson, UK) were made by 
sonication as previously described [49, 50]. Biotinylated anti-human CD31-
antibody (BAM3567; R&D Systems, Europe, Abingdon, United Kingdom) was 
conjugated to the microbubbles via avidin-biotin bridging as previously 
described [50, 51]. Specificity of binding of these CD31-targted microbubbles 
was previously reported by us [48].
Cell treatment
The concentration of tMB was evaluated by Coulter Counter (Multisizer 3, 
Beckman Coulter, Mijdrecht, the Netherlands) measurements (n = 3) using a 
20-µm aperture tube allowing quantification of particle diameters between 
0.4 and 12 µm using a linear spacing between the 256 channels. Ten million 
tMB were added to an OptiCellTM chamber with cells plated on the bottom (cell 
to bubble ratio of 1:3), which was turned upside down to let microbubbles 
adhere to the cells by flotation. After 5 min incubation at 37°C, the chamber was 
reverted for the experiment so the bound tMB were on top of the endothelial 
cells as shown in Fig 1A. SPIO nanoparticles (Endorem™, Gerber S.A., Paris, 
France) were added at four time-points: 5  min before, immediately before 
(0 min), 5 min after, and 15 min after insonification as illustrated in Fig 1B, at a 
final concentration of 22.4 µg Fe/ml. Each OptiCellTM chamber was divided into 
six acoustically non-overlapping areas (25 × 30 mm each; see Fig 1C), which 
covered the beam area (6.5 mm for -6dB beam width) at the focus of the 1.0 
MHz transducer (V303; Panametrics-NDTTM, Olympus NDT, Waltham, MA, 
USA), as verified in advance with a calibrated 0.2 mm PVDF needle hydrophone 
(Precision Acoustics Ltd, Dorchester, UK). The OptiCell chamber was placed 
into a 37 °C water bath and connected to a 2D micropositioner (Fig 1 D). The 1 
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MHz focused transducer was configured at a 45° angle below the sample and 
the acoustic focus was aligned with the center of each subsection.
During the experiment, the position of the OptiCell chamber was manipulated 
so that the center of each subsection was insonified in sequence at a 
predefined pressure (10 to 160  kPa peak negative pressure (PNP), Fig 1C). A 
prolonged burst of 10,000 cycles with a repetition rate of 20 Hz was applied 
generated by an arbitrary waveform generator (33220A, Agilent, Palo Alto, 
CA, USA) and amplified using a broadband amplifier (ENI A-500, Electronics & 
Innovation, Rochester, NY, USA). The first subsection, without the application 
of ultrasound, was used as the control. The effect of the different total 
insonification time was determined (1 s, 10 s, and 30 s) at 40, 80, and 160 kPa 
PNP when SPIO were added 5 min prior to insonfication. To investigate the 
effect of the incubation time with SPIO, the OptiCells were incubated at 37°C 
for 5 min, 1 h, and 3 h after insonification when SPIO were added 5 min prior 
to insonification. The effect of SPIO addition time (-5, 0, 5, and 15 min with 
Figure 1 Experimental setup. A Schematic representation of the tMB adhering to HUVECs during 
treatment. B Timing diagram of the experiment. The time of insonification (0  min) was used as the 
reference time. Targeted microbubbles (tMB) were added 5 min before the ultrasound was applied; SPIO 
was added 5 min before (i.e. -5 min), just before (i.e. 0 min), 5 min after, and 15 min after insonification. 
Cells were fixated 60 min after SPIO addition. C Scheme of insonification of subsections of the OptiCellTM 
chamber (to scale). The acoustic pressure is given in PNP. D The treatment setup.
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respect to the start of insonification) was determined at 10, 20, 40, 80, and 
160 kPa PNP. To check the effect of insonification of HUVECs on SPIO uptake 
in the absence of tMBs, the OptiCells were insonified at 40, 80, and 160  kPa 
PNP for 30 s, while SPIO was added 5 min prior to insonification (n = 2). All 
other experiments were repeated three times. From these three datasets the 
average and standard deviation are plotted.
SPIO labeling
After the treatment described above (see also Fig  1B), cells were rinsed 
three times with phosphate-buffer saline (PBS; Invitrogen, Groningen, the 
Netherlands) to remove non-internalized SPIO. Then, cells were fixated with 
4% formaldehyde (Sigma-Aldrich, Zwijndrecht, the Netherlands) for 10 min. 
After fixation, the cells were washed three times with PBS and then incubated 
with Prussian Blue solution for 30 min (aqueous solution of 10% hydrochloric 
acid (Sigma-Aldrich) and 5% potassium ferrocyanide (Sigma-Aldrich)) to 
assess the SPIO-labeling [52]. Next, the cells were washed three times 
with PBS and the nuclei were stained with 0.1% nuclear fast red solution 
(Sigma-Aldrich). Thereafter the OptiCells were dried for 48 h and 
microscopically examined using a microscope (Olympus, Zoeterwoude, the 
Netherlands) equipped with 20× Plan (NA 0.4) objective (Olympus) and a 
color camera (Axiocam MRc, Carl Zeiss, Germany). SPIO uptake was assessed 
by manually counting Prussian Blue positive cells among ~500 cells (acquired 
in 5 fields of view) located within a circle of 6 mm diameter around the center 
point of each insonified area. A cell was counted as SPIO positive when it 
contained one or more Prussian Blue stained iron particles.
Cell viability assay
For each SPIO uptake measurement, cell viability was determined in triplicate 
by calcein-AM and propidium iodide (PI) assays in parallel. Cells were treated 
with SPIO, tMB and ultrasound as described before (see also Fig 1). Within 3 
to 4 min after the US treatment of all subsections of the Opticells, HUVECs 
were incubated at 37 °C, 5% CO2. Thirty min before assessing the cell viability, 
calcein-AM was added to the OptiCell chamber (C3100MP; Invitrogen; 
0.25 μM final concentration from a 1 mM stock prepared in DMSO (Sigma-
Aldrich)) and incubated for 30  min under the same conditions. Thereafter 
PI (P4864, Sigma-Aldrich, 25 μg/ml final concentration) and Hoechst 
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33342 (Invitrogen; 5 μg/ml final concentration) were added to the Opticell 
chamber. Microscopic examination was performed directly after the PI and 
Hoechst addition with a fluorescent microscope (Olympus) equipped with 
the same setup as applied for SPIO labeling measurements, only that a 5× 
LMPlanFl (NA 0.13) objective (Olympus) was used here. For each condition 
five different fields of view were acquired (~2900 cells) within the 6 mm circle 
around the center of the insonified area. Different filter sets (U-MWU2, 330 
– 385/420 nm; U-MWIB2, 460 – 490/510 nm; U-MWG2, 510 – 550/570 nm, 
Olympus) were applied for detecting all cells (stained with Hoechst), viable 
cells (stained with calcein-AM), and dead cells (stained with PI) respectively. 
All images were automatically analyzed in ImageJ [53]. The Find Maxima 
function in ImageJ was used to define the exact number of cells. To find 
an appropriate tolerance for the Find Maxima function in every image, the 
number of local maxima was defined for tolerance parameters of 0 to 200 
in steps of two. We analyzed the differences in number of maxima between 
the steps. When the difference became smaller than 20, this point was 
considered as the correct tolerance and the corresponding number of cells 
as correct number of cells. This approach was validated by selective manual 
counting of number of cells (n=10). The difference between manual and 
automatic counting was 2.1±0.4%. As shown in S1 Fig, the % of viable cells 
determined from the calcein-AM staining (live cells) was the same as the cell 
viability determined from the PI staining (dead cells). The cell viability data 
was therefore presented as the % of viable cells determined from the calcein-
AM staining.
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Results
Microbubble dynamics
During all studied ultrasound bursts, we observed displacement and 
disappearance of tMB. This was most pronounced for the 30 s insonification 
period, as shown in Fig 2. During insonification, tMB also clustered (Figs 2B-D). 
After the 30 s insonification period, no tMB were observed in the field of view 
(Fig 2E), suggesting they had been destroyed.
Figure 2 Optical recording of tMB on HUVECs during ultrasound treatment. A before treatment. 
B-E tMB displacement, clustering, and destroyment during 30 s insonification (1MHz, 80 kPa PNP, 10,000 
cycles, repetition rate of 20 Hz, 30 s insonification treatment, SPIO added at -5 min with respect to the 
start of insonification).
Insonification duration
In the absence of ultrasound, less than 2% of cells intracellularly incorporated 
SPIO naturally (Fig 3A). The efficacy of SPIO uptake by HUVECs and the 
corresponding cell viability as a function of the acoustic PNP and the total 
insonification duration (1, 10, or 30 s) at low MI (<0.16) are shown in Fig 3. 
The total ultrasound exposure time was a key factor for SPIO uptake efficacy. 
This was demonstrated by the amount of SPIO positive cells not exceeding 
4% for 1 s and 6% for 10 s of insonification, but with 30 s of insonification the 
amount of SPIO positive cells increased to more than 10%. Additionally, the 
PNP also influenced SPIO uptake significantly. With 30 s of insonification, the 
proportion of SPIO positive cells significantly increased with the PNP (i.e., from 
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~10% at 40 kPa to ~16% at 160 kPa). At the same time, cell viability (Fig 3B) 
decreased with both the increasing acoustical pressure and the insonification 
time. For example at 80 kPa PNP, the cell viability decreased from ~70% for 10 
s of insonification to ~60% for 30 s of insonification. For a treatment time of 
30 s, the cell viability dropped by nearly two-fold from 40 kPa to 160 kPa PNP. 
In general, the cell viability remained high for up to 40 kPa PNP. Specifically, 
insonification for 30 s demonstrated the best SPIO uptake and was selected 
for further experiments. We did not investigate a longer insonification time 
because after 30 s all tMB were destroyed (see Fig 2E). 
Figure 3 The influence of ultrasound insonification time on intracellular SPIO uptake efficiency. A 
SPIO positive cells. B Cell viability. HUVECs were treated with tMB and no ultrasound (- US) or ultrasound 
at varying PNP (40, 80, or 160 kPa) for 1, 10, or 30 s; SPIO added 5 min before insonification (-5 min); 1 h 
of incubation after SPIO addition.
SPIO incubation time
The influence of the SPIO incubation time (5 min, 1 h or 3 h) after the treatment 
with ultrasound and tMB on SPIO uptake and cell viability is illustrated in Fig 
4. In general, SPIO uptake increased prominently with the incubation time, for 
example for 180  kPa PNP SPIO uptake increased from below ~4% to ~22%. 
The largest ratio between control and treated uptake was at 1 h of incubation 
for all PNPs. Cell viability (Fig 4B) remained high (>75%) at 40 kPa PNP for all 
incubation times. It decreased with the pressure (80 – 160 kPa PNP) for both 
1 h and 3 h of incubation time. A longer incubation time did not lower cell 
viability, as cell viability was slightly higher after 3 h of incubation than after 1 
h of incubation. Based on the results from this experiment, 1 h of incubation 
with SPIO was selected for further investigations.
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Figure 4 The influence of SPIO incubation time on intracellular SPIO uptake efficiency. A SPIO 
positive cells. B Cell viability. HUVECs were treated with tMB and no ultrasound (- US) or ultrasound at 
varying PNP (40, 80, or 160 kPa) for 30 s. SPIO were added 5 min before insonification (-5 min). Incubation 
time after SPIO addition was varied from 5 min to 1 h and 3 h.
SPIO addition time
In Fig 5 the percentage of SPIO positive cells and cell viability are plotted for 
four different times between insonification and SPIO addition for different 
acoustic PNP. Similar to the previous observations, no ultrasound application 
resulted in less than 2% of SPIO positive cells. In addition, ultrasound 
application without tMBs present showed no significant difference in SPIO 
uptake in comparison to the control without ultrasound application for all 
studied PNP when the SPIO were added 5 min prior to insonification. For both 
additions of SPIO at 5 min prior (-5 min) and just before (0 min) the ultrasound 
application, we obtained a relatively large percentage of SPIO positive cells 
Figure 5 The influence of SPIO addition time on intracellular SPIO uptake efficiency. A SPIO positive 
cells. B Cell viability. HUVECs were treated with tMB and no ultrasound (- US) or ultrasound at varying 
PNP (10, 20, 40, 80, or 160 kPa) for 30 s; SPIO were added 5 min before insonification (-5 min), just before 
insonification (0 min), 5 min after or 15 min after insonification; 1 h of incubation after SPIO addition.
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(~>10%) for acoustic pressures above 20 kPa PNP. Moreover, the percentage of 
SPIO positive cells increased up to ~12-15% with higher PNP for SPIO addition 
before the insonification. In contrast, SPIO addition at 5 and 15 min after 
ultrasound application resulted in much lower SPIO uptake (<8%). Similarly, 
the cell viability remained above 50% for all settings.
SPIO cell labeling
In the absence of ultrasound, intracellularly incorporated SPIO were detected 
as small iron particle aggregates distributed in the cytoplasm (Figs  6A, 6B). 
Figure 6 SPIO cell labeling. Prussian Blue staining of SPIO uptake in (A, B) the control (i.e. no ultrasound, 
1 h after incubation) and in (C–F) the ultrasound and tMB treated HUVECs at different treatment 
conditions. C,D,E: 80  kPa PNP, SPIO added at -5  min, 30 s insonification, 1 h incubation after SPIO 
addition; F: 160 kPa PNP, SPIO added at 15 min, 30 s insonification, 1 h incubation after SPIO addition. B 
and D are zoomed in from A and C as illustrated by the dashed rectangles. In B and D, one example of a 
SPIO aggregate is indicated by an arrow. 
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Ultrasound and tMB treated cells demonstrated much higher SPIO uptake as 
shown in Figs  6C–G. Iron particles were detected as aggregates of different 
sizes in the cytoplasm (Figs  6C, 6D). Other typical individual examples of 
intracellular SPIO distribution patterns after ultrasound and tMB treatment are 
shown in Figs 6E-F. These staining patterns included distribution of aggregates 
varying in size and blue intensity throughout the cytoplasm (Fig 6E) and one 
large aggregate mainly located near the nucleus (Fig 6F) having a higher blue 
intensity in comparison to the aggregates in Fig 6E. The intensity differences of 
the blue stain suggest different concentrations of SPIO particles.
Discussion
Tracking of endothelial cells is important for cancer and cardiovascular disease. 
There are several ways of SPIO cell labeling in vitro [22, 54]. Most of these 
techniques require different transfection agents, which cannot be used in vivo 
due to the associated high toxicity and systemic effects. We therefore studied 
a technique, based on ultrasound-activated ultrasound contrast agents that 
will be compatible for in vivo use. The SPIO uptake was dependent on multiple 
factors, including the ultrasound settings, the time of SPIO addition, and the 
incubation time of SPIO with cells after the ultrasound treatment. Optimal 
labeling at 1 MHz ultrasound frequency was observed when the ultrasound 
parameters were 40 kPa peak negative pressure (MI 0.04), 10,000 cycles and 
repetition rate of 20 Hz, applied for 30 s when SPIO were added at 0 min. 
Compared to the control, this resulted in an approximate 12 times increase of 
SPIO uptake with 85% cell viability.
Microbubble dynamics
We found an increasing trend of both SPIO positive cells and cell death with 
the acoustic PNP increase. Note that we studied acoustic pressures up to 160 
kPa PNP, a regime in which the amplitude of radial lipid-coated microbubble 
oscillations increases with pressure [55, 56]. A previous study by Vos et al. [57] 
has reported that highly non-spherical microbubble vibrations can be induced 
at pressures as low as 140 kPa PNP for lipid-coated microbubbles at resonance. 
In this regime, the acoustic streaming generated by oscillating microbubbles 
and the produced shear stresses [58-61] can be one of the mechanisms for 
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enhanced permeability of the cell membrane [26]. As was expected, the total 
duration of insonification also showed an effect on the SPIO uptake (Fig 3A). It 
has been reported that at 1 MHz frequency at a low mechanical index (MI < 0.1), 
a lipid-coated microbubble can repeatedly oscillate for thousands of cycles; 
while at higher MI microbubbles are destroyed within about 100 µs (i.e. 100 
cycles) irrespective of pulse length [62]. We indeed observed microbubbles still 
present up to 30 s at 80 kPa PNP (MI=0.08) (Fig 2). The improved uptake with 
prolonged insonification may be related with the persistent effect produced 
by microstreaming generated by microbubble vibrations as formulated earlier. 
Moreover, we noticed displacement of tMB with subsequent microbubble 
clustering and merging driven by secondary radiation force over the prolonged 
burst, as illustrated by Fig 2. These findings are in line with our previous study 
where tMB bound to endothelial cells also displaced, clustered, and merged 
by insonification at 1 MHz, albeit for a single burst of up to 50,000 cycles [63]. 
Detachment of bound lipid-coated tMB has been reported to be due to the 
attractive secondary Bjerknes force between two tMB [64, 65]. Aggregation of 
detached tMB forming bigger microbubble clusters may have influenced their 
oscillation dynamics as larger microbubbles have a lower resonance frequency 
than individual small microbubbles [66]. At a low driving frequency (for 
example 1 MHz as applied in this study), microbubble clusters are expected 
to have a higher amplitude of oscillation as they will be closer to resonance, 
which could have contributed to the enhanced SPIO uptake.
SPIO uptake 
In our study, HUVECs showed ~1% natural uptake after 1 h of incubation, and 
this value increased to ~5% after 3 h (Fig 4A). Although the natural uptake of 
SPIO by HUVECs was previously reported by van Tiel et al. [67], this percentage 
of labeled cells is not sufficient for cell tracking. Treatment of HUVECs with 
ultrasound and tMB led to a dramatic increase of ~10-fold in SPIO uptake after 
1 h incubation (Fig 4A). On the other hand, cell viability decreased between 
5 min and 1 h incubation time (Fig 4B), suggesting that instantaneous cell 
death (i.e. irreversible sonoporation due to large pores) is less prominent than 
induced cell death. Induced cell death could occur via the apoptotic pathway, 
a process that takes time [68, 69], that can be activated by ultrasound and 
microbubbles as previously reported by others [70-72]. We also observed 
that the SPIO labeling efficiency was influenced by the SPIO addition time in 
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respect to the time of treatment with tMB and ultrasound (Fig 5). We observed 
the highest efficacy when SPIO were added with the tMB (0 min) for acoustic 
PNPs up to 80 kPa. When SPIO were added 5 or 15 min after treatment, SPIO 
uptake was lower, but still significantly higher (more than fivefold at 5 min) than 
natural uptake. This may suggest stimulated endocytosis as uptake mechanism 
rather than sonoporation, since resealing of pores created by ultrasound 
activated microbubbles has been reported on a relatively short time scale of 
up to a minute [28, 73]. On the other hand, our results may also suggest that 
both uptake by stimulated endocytosis and pore formation occurred when 
SPIO were added 5 min before or just before (0 min) treatment (Fig 5A). This is 
supported by four earlier ultrasound contrast agent studies [46, 47, 74, 75] as 
they reported uptake by both pore formation and endocytosis using similar (1 
MHz [46, 47, 74, 75]) and different (0.3 MHz [74]) acoustic settings. Meijering et 
al. [46] and De Cock et al. [47] also addressed the influence of particle size on 
the uptake route: for dextrans larger than ~17 nm in radius, the primary uptake 
route was endocytosis instead of pore formation. On the other hand, pores 
of 1 nm in size [76] to > 100 µm2 in area [28] have been observed. However, 
induced pores >100 µm2 do not tend to reseal [28] which likely leads to cell 
death. This could explain why higher acoustic pressures (i.e., ≥ 80 kPa) in our 
study corresponded to increased cell death. Pores < 100 µm2 can still reseal, 
according to a recent study [28]. The SPIO colloid with low molecular weight 
dextran coating in EndoremTM, as used in our study, are 120 – 180 nm in size 
[77] so they could enter cells via resealable pores. The reason why Meijering et 
al. [46] observed dextran particles larger than ~17 nm mainly to be taken up by 
endocytosis, could be the different type of microbubble used (SonoVue versus 
tMB in our study) and/or the type of cells studied (bovine aortic endothelial 
cells versus HUVECs in our study). 
The amount of SPIO positive cells was almost two times higher when SPIO were 
added 5 min instead of 15 min after insonification. This suggests a relatively 
short temporal window when the therapeutic agent can be actively taken 
up after microbubble insonification, especially when compared to the study 
by Yudina et al. who reported a temporal window of 24 h [78]. The difference 
could be due to the therapeutic compound (small 600 Da molecule Sytox 
Green versus the 120 – 180 nm SPIO in our study), the type of microbubble 
(SonoVue versus tMB in our study), the acoustic settings (ultrasound frequency 
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of 1.5 MHz, 440 kPa PNP, 300 cycles at 1 kHz repetition rate for 30 s versus 1 
MHz, ≤160 kPa PNP, 10,000 cycles at 20 Hz for 30 s in our study) and/or the type 
of cells studied (C6 rat glioma cells versus HUVECs in our study). Recently, the 
temporal window was reported to be cell type-dependent by the same group 
[79]. For HUVECs, the temporal was found to be 1 h for the small molecule 
SYTOX green.
In our study, we defined a cell as SPIO positive when we detected one or more 
SPIO particles within the cell. It is unlikely that the SPIO particles we detected 
were extracellular because the cells were washed three times. We observed 
different labeling patterns, namely differences in the intensity and the 
intracellular distribution of the SPIO particles, although we did not quantify 
this degree of uptake. Some cells took up small spots (submicron) of SPIO as 
dense granules ~2 nm in diameter, while others had large SPIO aggregates in 
the cytoplasm. This variation in uptake patterns may also suggest uptake by 
pore formation and endocytosis as SPIO homogeneously distributed in the 
cytoplasm may suggest pore formation while small aggregates may indicate 
endocytic uptake. This is supported by different uptake patterns previously 
reported for dextrans with aggregates verified to be co-localized with 
endocytic vesicles [46, 47].
As ultrasound contrast agent-mediated SPIO-labeling of endothelial cells is 
likely faster clinically approved for labeling tumor vasculature, we decided 
to mimic the tumor vasculature’s compromised endothelial monolayer with 
poorly connected and sprouting endothelial cells [80] by culturing the HUVECs 
till 70% confluence. Our findings of effective tMB-mediated SPIO-labeling may 
therefore not be applicable to a monolayer of HUVECs, i.e. 100% confluence, 
applicable to vascular grafts. Different ultrasound pressures may be needed 
for effective tMB-mediated SPIO-labeling HUVECs in a monolayer as cells in 
a monolayer are more likely in the senescent cell cycle phase (G0) and have 
a more organized cytoskeleton. With respect to sensitivity to ultrasound 
treatment, cells in the mitotis(M)-phase [81, 82] and synthesis(S)-phase [82] 
have been reported most sensitive whereas cells in the senescent cell cycle 
phase were least sensitive. By contrast, another study showed the opposite: 
cells in the M and S-phases were more resistant to ultrasound treatment [83]. 
However, these ultrasound sensitivity studies were performed without the 
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presence of MB and on cancer/epithelial cells. These studies may therefore not 
translate to our study and it needs further investigation whether the amount 
of cell confluence influences the response to tMB-treatment.
It was previously shown [38] that microbubbles with SPIO incorporated in 
their coating in combination with ultrasound could lead to an about three 
fold increase of SPIO labeling of tumor cells in vitro, without compromising 
cell viability. A polymer coated microbubble was used, which has been 
shown to behave differently than a lipid coated microbubble when exposed 
to ultrasound. Polymer microbubbles have a stiff coating, which can respond 
to ultrasound exposure under a high MI (>1) by cracking and releasing the 
encapsulated gas. On the contrary, lipid coated microbubbles will oscillate 
at low MI and can also fuse [26]. They can therefore have a more prolonged 
interaction with cells than polymer microbubbles. This could explain why we 
found a ~12 fold increase in SPIO labeling compared to the control treatment.
Clinical implications
From the in vivo perspective, using tMB instead of non-tMB is preferable for 
endothelial cell labeling and drug delivery since tMB can be specifically 
targeted to diseased endothelial cells [84]. In addition, when ultrasound is 
applied to bound tMB, the vibrations of the ultrasound-activated tMB will have 
a direct effect on the cell membrane. This may be the reason why tMB have 
been shown to be up to ~5 times more effective in stimulating cellular uptake of 
therapeutics in vivo [30]. CD31 used as target in this proof of concept study was 
chosen as model ligand because it is constitutively expressed on endothelial 
cell membranes. It can therefore be used to label endothelial cells with SPIO in 
tissue-engineered valves or vascular grafts in vitro. However, CD31 cannot be 
used in vivo as it is expressed throughout the entire vasculature tree [85]. For 
targeting tMB to tumor vasculature, αvβ3 or vascular endothelial growth factor 
receptor 2 (VEGFR2) can be used [84]. SPIO uptake by ultrasound-activated 
tMB in vivo is expected as we recently reported that tMB bound to αvβ3 can 
stimulate endothelial cell drug uptake in vivo [50]. VEGFR2 is another biomarker 
of interest for tMB. BR55, a tMB against VEGFR2, has recently successfully been 
used in clinical trials for prostate, breast, and ovarian cancer [86, 87]. Our future 
studies will focus on in vivo SPIO labeling as well as in vivo MRI tracking of the 
labeled endothelial cells. For the in vivo studies, our in vitro acoustic settings 
will need to be extrapolated taking into account that ultrasound is attenuated 
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by tissue (0.5 dB/cm/MHz [88]) and the microbubble vibration is damped in 
blood [89]. In our in vitro study we incubated the HUVECs for 1 h with the SPIO. 
As the elimination half-life of Endorem™ (Feridex® in the USA) is 2.4 ± 0.2 h in 
humans and the SPIO are administered as a drip infusion over ~30 min [77, 
90], it may be expected that the SPIO will circulate long enough in vivo to also 
achieve the 1 h incubation period. It was shown before that single cell tracking 
is possible by MRI using iron oxide as the label [13, 14, 16]. The micron-sized 
paramagnetic iron oxide (MPIO) particles used in one of these studies [13] are 
ten times bigger (1.6 µm) than SPIO. As it was revealed before [67] that the iron 
content of cells labeled with SPIO is less (~10 folds) than with MPIO, more cells 
may have to be labeled by SPIO to be detectable by MRI in vivo.
Conclusion
Our study shows that ultrasound-activated tMB are a promising technique 
to non-invasively enhance SPIO uptake by endothelial cells. From the current 
in vitro study, we derived optimal ultrasound parameters for SPIO delivery to 
HUVECs, that is, 40 kPa at 1 MHz (MI 0.04), 10,000 cycles and repetition rate of 
20 Hz, applied for 30 s when SPIO were added at 0 min. This setting increased 
SPIO uptake up to 12 times compared to the control with 85% cell viability. 
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Supporting Information
S1 Figure Cell viability determined from calcein-AM versus PI staining. Insonification for 30 s for 
SPIO added at -5, 0, 5, or 15 min in respect to the start of insonification and incubated for 1 h. The 
acoustic PNP in A was 10 kPa, while this was 20 kPa in B, 40 kPa in C, 80 kPa in D, and 160 kPa in E.
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Abstract
Purpose
The gastrin releasing peptide receptor (GRPR), overexpressed on various tumor 
types, is an attractive target for receptor-mediated imaging & therapy. Another 
interesting approach would be the use of GRPR radioligands for pre-operative 
imaging and subsequent radio-guided surgery, with the goal to improve 
surgical outcome. GRPR radioligands were successfully implemented in clinical 
studies, especially Sarabesin 3 (SB3) is an appealing GRPR antagonist with high 
receptor affinity. Gallium-68 (68Ga) labelled SB3 has good in vivo stability, after 
labeling with Indium-111 (111In) however, the molecule shows poor in vivo 
stability, which negatively impacts tumor targeting capacity. A novel approach 
to increase in vivo stability of radiopeptides is by co-administration of the 
neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA). We studied in 
vivo stability and biodistribution of [111In]SB3 without/with (-/+) PA in mice. 
Furthermore, SPECT/MRI on a novel, state-of-the-art platform was performed.
Procedures
GRPR-affinity of SB3 was determined on PC295 xenograft sections using [125I]
Tyr4-bombesin with tracer only or with increasing concentrations of SB3. For 
in vivo stability, mice were injected with 200/2000 pmol [111In]SB3 -/+ 300 µg 
PA. Blood was collected and analyzed. Biodistribution and SPECT/MRI studies 
were performed at 1, 4 and 24 h post injection (p.i.) of 2.5 MBq/200 pmol or 25 
MBq/200 pmol [111In]SB3 -/+ 300 µg PA in PC-3-xenografted mice.
Results
SB3 showed high affinity for GRPR (IC50: 3.5 nM). Co-administration of 
PA resulted in twice higher intact peptide in vivo versus [111In]SB3 alone. 
Biodistribution studies at 1, 4 and 24 h pi. show higher tumor uptake values 
with PA co-administration (19.7±3.5 vs 10.2±1.5, 17.6±5.1 vs 8.3±1.1, 6.5±3.3 
vs 3.1±1.9 %ID/g tissue (P<0.0001)). Tumor imaging with SPECT/MRI clearly 
improved after co-injection of PA.
Conclusions
Co-administration of PA increased in vivo tumor targeting capacity of [111In]
SB3, making this an attractive combination for GRPR-targeted tumor imaging.
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Introduction
The gastrin releasing peptide receptor (GRPR) is a G-protein coupled receptor 
overexpressed in a number of cancer types such as prostate cancer, breast 
cancer and gastrointestinal cancer, thereby representing an attractive molecule 
for tumor targeting [1, 2]. Multiple GRPR radioligands have been synthesized 
during the past decade, mainly for the purpose of receptor-mediated nuclear 
imaging and therapy [3, 4]. These studies, at the preclinical as well as clinical 
level, have expanded our knowledge on GRPR radioligands and have proven 
that targeting of GRPR for nuclear imaging and/or therapy can be beneficial in 
patient care [5-8]. Moreover, research has demonstrated that GRPR antagonists 
are usually superior to agonists for tumor targeting, in addition to exhibiting 
less adverse events [9, 10].
Sarabesin 3 (SB3) is a recently developed GRPR antagonist that has excellent 
receptor affinity and good in vivo stability when labeled with the positron-
emitting radionuclide gallium-68 (68Ga; t1/2: 68 minutes). Preclinical as well as 
clinical PET imaging studies using [68Ga]SB3 have been performed with great 
success [11, 12]. A novel and interesting approach would be the use of SB3 
for pre-operative imaging and intra-operative radio-guided tumor detection 
of GRPR-expressing tumors, especially for the detection of GRPR-expressing 
metastases and non-palpable tumors.
Radio-guided tumor detection is based on the intra-operative localization 
of malignant lesions using handheld detection probes following injection of 
a radiopharmaceutical (Fig. 1). Combining this intra-operative method with 
information from pre-operative nuclear imaging by single photon emission 
computed tomography (SPECT) or positron emission tomography (PET), 
together with computed tomography (CT) or magnetic resonance imaging 
(MRI), allows for accurate surgical guidance, ultimately improving surgical 
outcome while minimizing surgical invasiveness [13].
Currently, radio-guided surgery is successfully applied clinically for 
lymphoscintigraphy in melanoma and breast cancer patients, radio-guided 
occult lesion localization and radio-guided seed localization of non-palpable 
tumors, as well as minimal invasive parathyroid surgery for removal of 
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parathyroid adenomas [14-18]. Multiple radiopharmaceuticals and 
administration methods are applied for radio-guided surgery amongst which 
the application of systemically administered radiopharmaceuticals directed 
against targets that are overexpressed on tumor cells. Examples include 
ongoing preclinical and (pilot) patient studies evaluating the potential benefits 
of radio-guided surgery for the detection of neuroendocrine tumor and 
prostate cancer lesions using somatostatin receptor-targeting and prostate-
specific membrane antigen-targeting radiotracers [19-24].
Ideally, for radio-guided surgery, SB3 has to be radiolabeled with a gamma 
emitter that has a half-life enabling detection of radioactivity prior to surgery 
and during the full surgical procedure. For this purpose SB3 was therefore 
labeled with the clinically well-established γ-emitter indium-111 (111In; t1/2: 2.8 
days). This [111In]SB3 can be used for SPECT/MRI, which offers the opportunity 
to combine sensitive functional imaging by SPECT with high-resolution 
anatomical/functional imaging by MRI. Compared to commonly used CT, 
MRI has a number of advantages such as improved soft tissue contrast and 
the added value of multiparametric imaging, which may lead to better tumor 
localization.
[111In]SB3 has poor in vivo stability, ultimately resulting in low tumor uptake 
[25]. An explanation for the poor in vivo stability is degradation of the peptide 
by naturally occurring enzymes in vivo, such as the neutral endopeptidase 
(NEP), which cleaves peptides at the amino side of hydrophobic residues 
[26, 27]. To increase the in vivo stability of radiopeptides multiple solutions 
are available, including structural modifications of a peptide or the novel 
approach of inhibition of enzymes responsible for enzymatic degradation. 
Since structural modifications are time-consuming, and may have a negative 
impact on the binding affinity or biodistribution profile of the peptide, 
the latter solution is very attractive. Co-administration of the NEP inhibitor 
phosphoramidon (PA) enhanced the in vivo stability and thereby the tumor 
targeting capacity of multiple radiotracers [5, 26, 28-30]. The aim of our study 
is to evaluate whether we can also improve tumor targeting of [111In]SB3 by 
co-administration of PA to potentially use the radiotracer for pre-operative 
SPECT/MRI and ultimately for intra-operative radio-guided tumor detection 
of GRPR-expressing tumors and/or metastases as well. For this we compared 
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the in vivo stability and the biodistribution of [111In]SB3 without/with (-/+) PA, 
the latter by performing both biodistribution and SPECT/MRI studies in mice 
bearing GRPR-expressing PC-3 tumor xenografts.
Materials and Methods
Radiolabeling
SB3 (Fig. 2) was radiolabeled with 111In (Covidien) as previously described [31]. 
Small volume reactions were performed in conical vials. Sodium acetate was 
used to control pH, resulting in a final pH value of 4-4.5 and quenchers (ascorbic- 
and gentisic acid 3.5 mM and methionine 10 mM as final concentration) were 
added to prevent radiolysis. A mixture of 1 nmol SB3 and 125 MBq equivalent 
111InCl3 and quenchers in a final volume of 140 µL were heated for 15 min at 80°C. 
To complex non-incorporated 111In, after cooling down to room temperature, 
5 µL of 4 mM DTPA was added. To obtain a molar activity of 12.5 MBq/nmol, after 
the labelling 9 nmoles of SB3 was added. The incorporation was determined 
by instant thin layer chromatography (ITLC) silica gel using sodium citrate 
(0.1 M, pH 5) as solvent [32] and radiochemical purity (RPC) was measured 
by a HPLC system (Breeze, Waters), containing a 2690 quaternary pump, and 
radioactivity was monitored with a NaI detector, digital multichannel analyzer 
and dedicated software (MetorX B.V). A Symmetry C18 column (5 µm x 4.6 mm 
x 250 mm, Waters) was used with a gradient profile of: 0–5 min 100% A, 5-5.01 
min 60% B, 5.01–20 min 80% B, 20–20.01 min 100% B, 20.01–25 min 100% B, 
25.01–30 min (flow 1 mL/min), where A was 0.1% trifluoroacetic acid (TFA) in 
H2O and B was LC-MS grade methanol. No further purification was required.
A molar activity of 12.5 MBq/nmol and 125 MBq/nmol was used for the 
biodistribution and SPECT/MRI studies, respectively. For the in vivo stability 
studies both molar activities were used. To determine the affinity of SB3 for the 
human GRPR in a competition-binding assay, Tyr4-Bombesin (Sigma-Aldrich) 
was radiolabeled with iodine-125 (125I) based on the Iodo Beads® (Pierce) 
method, adapted with 5 min pre-incubation before addition of the peptide, 
as previously described [33, 34]. In short, 100 µL of PBS 50 mM Pi pH 7.5, 
sodium iodide solution (10-20 MBq Na125I in 0.01 M NaOH) and pre-rinsed Iodo 
Beads® were pre-incubated for 5 min, and Iodo Beads® were removed. Then, 
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Figure 1 The concept of radio-guided surgery: A Radiopharmaceuticals directed at tumor cells 
are administered to the patient followed by accumulation of radioactivity in these cells over time. 
B Subsequently, full body nuclear imaging is performed, e.g. SPECT/MRI, to localize the tumor 
pre-operatively. C Using this information the patient is operated for removal of the tumor. Intra-
operatively a handheld device is used to detect radioactivity derived from the tumor cells to guide the 
surgeon towards the tumor.
Figure 2 Structure of SB3.
total volume was added to 70 nmol of peptide in PBS, and the mixture was 
allowed to react for 5 min at room temperature. To exclude non-labeled iodine, 
a purification was performed by solid phase extraction using a J.T. Baker C18 
cartridge followed by HPLC purification [34].
Internalization studies
Internalization with [111In]SB3 was performed in PC-3 cells, a commonly used 
human derived androgen independent GRPR-expressing PC cell line (AACR). 
The cells were seeded in six-well plates at a density of 0.6x106 cells per well and 
cultured overnight. On the day of the experiment cells were washed twice with 
37°C PBS. Fresh internalization medium, RPMI + Glutamax with 20mM HEPES 
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and 1% Bovine Serum Albumin fraction V pH 7.4, 10-9 M [111In]SB3 was added. 
The cells were incubated at 37°C in triplicates for 60 minutes, incubation was 
stopped by removal of the medium and rinsing with cold PBS twice. Thereafter, 
the cells were incubated for 10 minutes with acid wash buffer (50 mM Glycin-
HCl/100 mM NaCl, pH 2.8). The supernatant was collected (membrane fraction), 
the cells were rinsed with acid wash buffer and collected in the same tube. 
Cells were lysed with 0.1 M NaOH and collected in another tube (internalized 
cell fraction). The amount of activity in the membrane- and cell fraction was 
measured on an automatic gamma counter.
Animal model
Healthy or xenografted Balb c nu/nu male mice (Janvier) were used in this 
study. To obtain xenografted mice, animals were injected subcutaneously 
in the right shoulder with PC-3, 3×106 cells in Matrigel (total volume: 150 
μL, solution: 66% RPMI, 33% Matrigel) per animal. Prior to tumor cell 
inoculation the PC-3 cells were cultured in RPMI medium supplemented with 
10% fetal bovine serum, 5,000 IU/mL penicillin and 5,000 µg/mL streptomycin 
at 37 °C in a humidified atmosphere containing 5% CO2. PC295 is an 
androgen-dependent patient derived cell line with high GRPR-expression. 
Xenografts were generated by subcutaneous implantation of the PC295 
human prostate tumor as previously described and were stored at -80°C until 
further use [35]. All culture supplies were purchased at Gibco.
Competition binding assay
For the competition binding assay, fresh frozen PC295 xenograft tissue 
slices (10 µm) were incubated in triplicate with 80 µL 5 × 10-10 M [125I]Tyr4-
Bombesin, with tracer only or with an increasing concentration (10-12 to 
10-6 M) of unlabeled SB3 for 1 h and exposed to super resolution phosphor 
screens (PerkinElmer) for 48 h. The phosphor screens were read using the 
Cyclone (PerkinElmer) and quantified using OptiQuant software. Binding of 
unblocked [125I]Tyr4-bombesin to the tissue slices was set at 100% and the 
percentage of binding relative to the unblocked tissue sample was calculated 
for the blocked tissue sections. These values were used to determine the IC50 
value of unlabeled SB3.
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Stability studies
To determine the stability of [111In]SB3 -/+ PA in vivo, healthy mice (n = 3 per 
group) were intravenously injected with 200 pmol/25 MBq or 2000 pmol/25 
MBq [111In]SB3 (volume: 100 µL), co-injected with either 300 µg/100 µL PA 
(Peptides International Inc) in 0.5% ethanol or 100 µL saline solution. Five 
minutes after injection of [111In]SB3 -/+PA, blood (0.5 – 1 mL) was collected 
by cardiac puncture, while animals were under isoflurane/O2 anesthesia, 
and transferred to blood-collection tubes containing 90 USP units of lithium 
heparin (spray coated), HPLC grade ethanol was added in a 1:1 (v/v) ratio, and 
the tubes were placed on ice. Blood samples were centrifuged 5 minutes at 
1250 G, and supernatant was collected. Next the collected supernatant was 
centrifuged again for 5 minutes at 12500 G. The secondary supernatant was 
collected and diluted with MilliQ down to <25% ethanol before injection 
on HPLC. The samples were analyzed by HPLC (Alliance, Waters) including 
a Symmetry C18 column (5 µm × 4.6 mm × 250 mm). Elution was performed 
in a 1 mL/min flow, completed in 30 min, with the gradient: 0–5 min 100% 
A, 5–5.01min 40% A 60% B, 5.01–20 min 20% A 80% B, 20–20.01min 100% 
B, 20.01–25min 100% B, 25.01–30 min 100% A, where A was 0.1% TFA in H2O 
and B was methanol. In one animal the sample volume was too low for further 
analysis, this animal was therefore excluded.
Biodistribution studies
Tumor-bearing mice received an intravenous injection of 200 pmol/2.5 MBq 
[111In]SB3, co-injected with either 300 µg/100 µL PA in 0.5% ethanol or 100 µL 
saline solution (n = 4 animals per group for each time point). In previous in 
vivo studies 200 pmol appeared to be the optimal peptide amount (regarding 
uptake in tumor and pancreas, data not shown). To determine specificity of 
tumor and organ uptake blocking experiments were performed; an additional 
group of animals (n = 3) was pre-injected with an excess (20 nmol) of unlabeled 
SB3 followed by injection of the radiotracer -/+ PA. At 3 different time points 
p.i. (1 h, 4 h and 24 h) animals were euthanized and blood, organs and 
tumors were collected, weighed and measured in a γ-counter (1480 WIZARD 
automatic γ-counter, Perkin Elmer). For γ-counter measurements an isotope 
specific energy window, a counting time of 60 sec and a counting error ≤ 5% 
was used. Results were expressed as the percentage of the injected dose per 
gram tissue (%ID/g tissue). Animals that had ≥ 7% ID in the tail were excluded.
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SPECT/MRI
For SPECT/MRI, PC-3-xenografted mice were intravenously injected with 25 
MBq/200 pmol [111In]SB3, co-injected with either 300 µg/100 µL PA in 0.5% 
ethanol or 100 µL saline solution. Subsequently, imaging was performed 1 
h, 4 h and 24 h p.i. of the radiotracer, while animals were anesthetized using 
isoflurane/O2, body temperature was maintained using warm air flow and 
respiratory rate was monitored. Whole body SPECT images were acquired 
using the novel and state-of-the-art 4-head multipinhole system (NanoScan 
SPECT/MRI, Mediso Medical Imaging) in 30 min (28 projections, 29 s/projection 
and 7 cm axial field of view). Images were reconstructed using OSEM with 6 
iterations and 4 subsets on a 120 × 120 matrix with 0.25 × 0.25 × 0.25 mm 
isotropic voxels. MR based attenuation correction was applied to all images. 
T2 MR images were acquired using a spin echo sequence (TR/TE=4500/52 ms) 
with a 35 mm diameter solenoid coil. Other scan parameters were: field of 
view: 70 mm, matrix: 256 × 128 and slice thickness: 1 mm with 0.1 mm spacing 
between slices. An ROI of the tumor was drawn by an experienced technician 
on the T2-weighted MR image to measure the intensity in the SPECT image.
Statistics
All statistical evaluations were performed with Graphpad Prism software (v 
5.01). The IC50 value was calculated using a log (inhibitor) vs response model. 
To compare in vivo stability -/+ PA, radioactivity uptake in the tumor -/+ PA 
and radioactivity uptake in the tumor without and with an excess of unlabeled 
peptide an unpaired t-test was used. P values <0.05 were considered 
statistically significant. Tumor to organ uptake ratios were calculated per 
animal and expressed as mean and standard deviation per group.
63563-Sandra van Tiel-proefschrift.indd   110 04-09-20   08:45
5
Stabilized Sarabesin-3 for prostate imaging
111
Results
Radiolabeling
The RCP and radiometal incorporation were both >90%.
Internalization studies
In internalization experiments with [111In]SB3 in PC-3 cells, the membrane 
faction contained almost 4 times more radioactivity compared to the cell 
faction.
Competition binding assay
Quantified binding of [125I]Tyr4-bombesin to PC259 tissue sections without and 
with increasing concentrations of unlabeled SB3 resulted in an IC50 value of 3.5 
nM (95% CI: 1.9 nM to 6.4 nM) (Fig. 3). 
Figure 3 Competitive binding assay using [125I]Tyr4-bombesin blocked with increasing concentrations 
of unlabeled SB3. 95% CI is shown in green.
Stability studies
In vivo stability of [111In]SB3 -/+ PA was analyzed in blood samples, collected 5 
min p.i. In the animals receiving 200 pmol [111In]SB3 37.3±2.5 % of the remaining 
circulating activity consisted of intact radiotracer, while this value significantly 
increased (P<0.0001) to 86.7±1.5 % when [111In]SB3 was co-injected with PA 
(Fig. 4 A+B). When a 10× higher peptide amount was administered, these 
values were 42.0±0.2 % vs 87.9±1.1 % (P<0.0001) of the radiotracer still being 
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intact in the blood, respectively (Fig. 4 C+D), indicating a clear increase of 
stability even with 2000 pmol peptide.
Biodistribution studies
The results of the biodistribution studies are displayed in Fig. 5. A maximum 
tumor uptake of 10.2±1.5 %ID/g tissue was reached using 2.5 MBq/200 pmol 
[111In]SB3 1 h p.i. in contrast to 19.7±3.5 % ID/g tissue after injection of [111In]
SB3 + PA. At all studied time points, there was significantly higher (P<0.0001) 
tumor uptake when PA was co-administered with [111In]SB3. Next to tumor 
uptake, high radiotracer uptake was also observed in the GRPR-expressing 
pancreas and in the kidneys, the latter as a result of renal excretion and partial 
reabsorption of the radiopeptide. The increased in vivo stability of [111In]SB3 + 
PA also resulted in an increase in pancreatic uptake (4.1±2.3 vs 10.1±4.3 %ID/g 
tissue 1 h p.i. -/+ PA, respectively), while renal uptake remained similar (3.9±1.4 
vs 4.5±1.4 %ID/g tissue 1 h p.i. -/+ PA, respectively). At 4 h and 24 h p.i. the 
same pattern was observed. A similar tumor to pancreas radioactivity ratio 
was found for [111In]SB3 +/- PA (3.4±2.5 vs 2.2±0.8, 1 h p.i. -/+ PA, respectively). 
The tumor to kidney ratio was more favorable however when the radiotracer 
was combined with PA (2.8±1.0 vs 4.8±2.2, 1 h p.i. -/+ PA respectively). Also, 
radiotracer uptake in the pancreas and the tumor was receptor-specific as 
can be concluded from the significantly decreased (P≤0.001) uptake when an 
excess of unlabeled SB3 was co-administered.
SPECT/MRI
In line with the biodistribution studies, SPECT/MR imaging performed 1 h, 4 h 
and 24 h p.i. of 25 MBq/200 pmol [111In]SB3 +/- PA resulted in clearly improved 
tumor visualization when the radiotracer was combined with PA, at all imaging 
time points (Fig. 6 A). ROI analysis showed an increase of 70% in signal 
intensity (1424 vs 2434 kBq/mL) 1 h p.i. of [111In]SB3 only and [111In]SB3 + PA, 
respectively. Intensity curves and the biodistribution time activity curves were 
normalized to 100% at 1 h for the + PA group. The normalized curves obtained 
from SPECT/MR images and biodistribution studies showed a well-comparable 
pattern for the tumor radioactivity (Fig. 6 B).
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Figure 4 In vivo stability of [111In]SB3. HPLC analysis of extracted radioactivity from blood 5 min p.i. of 
a low peptide amount (200 pmol/25 MBq) either a in the absence of PA or b in the presence of PA, and 
5 min p.i. with a high peptide amount (2000 pmol/25 MBq) either c in the absence or c in the presence 
of PA. - = peak is missing.
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Figure 5 Blood, organ and tumor uptake of [111In]SB3 a administered without PA and b with PA. Tumor 
to kidney and tumor to pancreas ratios are displayed in the insets of graphs of a and b.
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Figure 6 a SPECT/MRI 25 MBq/200 pmol [111In]SB3 without (top panel) and with (bottom panel) co-
administration of PA. The arrows indicate the tumor. b Time activity curve of radioactivity uptake in 
PC-3 xenografts obtained by ex vivo biodistribution (200 pmol/2.5 MBq/mouse) and by ROI analysis on 
SPECT/MRI (200 pmol/25 MBq/mouse).
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Discussion
The GRPR is overexpressed at high incidence and high density on various 
tumors, including prostate cancer, making it an appealing molecule for tumor 
targeting [2]. Over time multiple and promising GRPR targeting radiotracers 
have been developed, mostly for nuclear imaging and therapeutic purposes. 
Another interesting approach would be the application of GRPR radioligands 
for radio-guided surgery since handheld probes and cameras can be used to 
detect radioactive decay intra-operatively. For GRPR-targeting to be successful, 
the radiotracer applied should have good in vivo stability, good receptor 
affinity and favorable pharmacokinetic properties. 
In this study we evaluated whether co-administration of the NEP inhibitor 
PA with [111In]SB3, a radiolabeled GRPR antagonist, leading to in vivo 
stabilization of the radioligand, would improve the application use of the 
radiopharmaceutical for pre-operative SPECT/MRI, and the future use of 
peri-operative scintigraphy and radio-guided surgery. Currently MRI is the 
most powerful imaging tool for prostate cancer, among other factors because 
of its high soft-tissue contrast and high resolution [36, 37]. Combining MRI with 
sensitive and specific targeted nuclear imaging by SPECT potentially improves 
tumor detection.
Thereto, we performed in vivo stability studies, biodistribution studies and 
SPECT/MR imaging in healthy mice and mice subcutaneously xenografted with 
the GRPR-expressing prostate cancer cell line PC-3. Prior to this we confirmed 
a considerable higher membrane binding compared to internalized fraction 
of [111In]SB3 as expected for a receptor antagonist. Also we determined the 
receptor affinity of the unlabeled compound on tissue slices of xenografts 
generated from the human prostate tumor PC295, confirming previous 
reported affinities of unlabeled SB3 and natIn labeled SB3 in the low nanomolar 
range [25]. This data showed that SB3 had excellent affinity for the GRPR, 
confirming previous findings [11].
In vivo stability studies 5 min p.i. of [111In]SB3 -/+ PA in healthy mice, 
showed twice as much intact radiopeptide in the blood when PA was 
co-administered, similar to what has been reported for other radiopeptides [5, 
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28, 29]. The large amount of unlabeled compound might hamper formation 
and detection of radiometabolites, so caution is advised when comparing the 
results of the low and high peptide amounts. However, even when using a 
high amount of peptide a clear effect of PA was still observed.
The metabolic susceptibility of peptides can be influenced by a multitude of 
characteristics. Next to the peptide structure, also charge and configuration 
can play a role. The most well-known approach to protect peptides against 
degradation is modify the peptide, e.g. by stabilizing peptide bonds. It was 
found that specific changes of the C-terminal structure of peptide gastrin 
releasing peptide analogues resulted in receptor antagonists with improved 
potency and stability [38]. Previously it has been reported that charge, peptide 
chain length, choice of linker, etc can all, have large effects on metabolic 
stability and pharmacokinetics of GRP ligands [39, 40]. 
Concerning the biodistribution studies, stabilization of [111In]SB3 by inhibition 
of NEP, resulted in higher tumor uptake. Next to higher tumor uptake, high 
uptake of the radiotracer was also observed in the pancreas. Even though 
the radiopeptide uptake in the pancreas increased when [111In]SB3 was co-
administered with PA, the tumor to pancreas ratio remained unaffected. 
Nevertheless, this high uptake in the pancreas should be kept in mind when 
the radiotracer would be used for radio-guided surgery of lesions close to 
the pancreas. In this case the surgeon should carefully evaluate whether the 
signal measured by a gamma detection probe and/or a handheld gamma 
camera is derived from tumor lesions or neighboring healthy tissue. However, 
as can be seen from the biodistribution data, radioactivity washout from the 
pancreas was relatively fast, while tumor radioactivity uptake declined at 
a lower rate. This was also observed in previously published studies [11, 41-
43]. So, determining the time window with optimal tumor/pancreas ratio is 
required for optimal pre-operative and intra-operative tumor detection. In this 
respect, the uptake in the kidneys and the bladder due to renal excretion of 
the radiotracer should also be taken into account.
An interesting next step would be to modify the peptide to create a molecule 
that can serve both as radioactivity- and fluorescence-carrier. Even though 
radio-guided surgery is profitable, it has limitations. So, the use of radiotracers 
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allows for gross tumor localization by detection of γ-photons outside of the 
body, but this method is not suited for accurate tumor delineation during 
surgery [44]. On the other hand, fluorescence imaging is limited by the 
penetration depth of fluorescent light, which can only be detected when 
at close distance. However, fluorescence imaging does allow exact tumor 
delineation and can provide real-time intra-operative visualization [44]. 
Combining the strengths of radio-guided and fluorescence guided surgery 
can therefore be of benefit.
SPECT/MR imaging resulted in successful identification of tumor lesions on 
scans and, as expected, higher radioactivity uptake was visualized when [111In]
SB3 was co-administered with PA. Time activity curves obtained with ex vivo 
biodistribution studies and ROI analysis on SPECT/MR images demonstrated 
similar patterns, indicating the SPECT/MRI platform to correctly depict the 
pharmacokinetics of the radiotracer. 
With respect to the commercially available NEP inhibitor PA, to date preclinical 
studies evaluating its potential in potentiating the use of radiotracers have not 
indicated any adverse events [5, 28]. For application in patients NEP inhibitors 
that are already approved for clinical use such as Sacubitril and Racecadotril 
might be applied [45].
Furthermore, depending on the cancer type for which [111In]SB3 + PA will be 
used for tumor detection pre- and intra-operatively, the application should 
be compared to that using other radiotracers under investigation or applied 
for similar purposes, e.g. lymphoscintigraphy for sentinel lymph node biopsy 
in breast cancer patients and PSMA radio-guided surgery in prostate cancer 
patients [21, 46]. 
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Conclusions
Co-administration of [111In]SB3 with the NEP inhibitor PA, led to a significant 
increase of in vivo stability of [111In]SB3. So, SPECT/MRI using [111In]SB3 + PA 
resulted in excellent visualization of tumors in our preclinical model, indicating 
its potency for (pre-operative) imaging and future radio-guided surgery 
applications.
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Abstract
Background
Macrophages are crucial in the development and progression of various 
diseases. To monitor their role, various proteins expressed by macrophages 
may be used as imaging target. In this preclinical study we investigate the value 
of the somatostatin receptor subtype 2 (SSTR2) as a novel imaging marker for 
pro-inflammatory macrophages, using an experimental osteoarthritis (OA) 
mouse model.
Methods
SSTR2 gene expression levels in pro-inflammatory macrophages and human 
synovium was determined by qPCR. Tracer binding was determined in 
macrophages and human osteoarthritic synovium after in vitro stimulation 
with IFNγ and TNFα. Presence of pro-inflammatory macrophages in OA mice 
was determined by anti-CD64+ staining. Accumulation of the tracer in OA 
knees was determined by µSPECT.
Results
Human macrophages and synovial tissue stimulated with IFNγ+TNFα had 
significantly upregulated SSTR2 gene expression and showed increased 
uptake of SSTR2-targeting tracer. Shortly after OA induction an increase in 
the presence of pro-inflammatory macrophages was seen as assessed by 
immunohitochemsitry. Similar findings were obtained with SPECT, with peak 
uptake of the SSTR2-targeting tracer immediately after surgery followed by a 
gradual decrease during the course of the next 8 weeks. 
Conclusions
Pro-inflammatory macrophages have elevated SSTR2 expression which makes 
it possible to image an inflammatory process in the knee with a radiolabeled 
somatostatin analog for SPECT.
Keywords: macrophage, inflammation, somatostatin receptor subtype 2, 
imaging, osteoarthritis
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Introduction
Macrophages play a crucial role in the development and progression of 
various diseases, for example osteoarthritis (OA) (1, 2), atherosclerotic plaque 
(3, 4), type 2 diabetes (5, 6), rheumatoid arthritis (7, 8) and schizophrenia (9, 
10). Knowing the role of macrophages during disease development and 
progression opens possibilities for therapeutic interference . Macrophages 
varied roles can exacerbate and/or resolve diseases. To detect the presence of 
macrophage during disease processes, a specific target for imaging is needed. 
Depending on the activation state, macrophages express various proteins that 
may be used as imaging target such as the folate receptor β (11), mannose 
receptor (also known as CD206) (12) and translocator protein (TSPO) (13). 
These have been proposed as targets for a subtype of macrophages referred to 
as anti-inflammatory macrophages (14, 15). 
Previous studies suggested that the somatostatin receptor subtype 2 (SSTR2) 
is also a marker for macrophages (16, 17). More recently, it was shown that 
inflammation-related uptake of an SSTR2-targeting tracer was elevated in 
atherosclerotic plaques and it was confirmed that the tracer had macrophage 
specificity (18-20). Somatostatin is a peptide hormone which induces inhibitory 
effects on two key cellular processes, secretion and cell proliferation. It can 
bind to five distinct receptors subtypes named SSTR1, SSTR2, SSTR3, SSTR4 and 
SSTR5. These somatostatin receptors belong to the G-protein coupled receptor 
family. SSTR2 are highly expressed in human tumors, and are also present in 
pancreas, spleen, cerebrum, kidney, jejunum, colon, and liver (21, 22). Upon 
differentiation of human monocytes into pro-inflammatory macrophages, 
SSTR2 mRNA was found to be upregulated (23) in activated macrophages 
making it an interesting molecular target for these cells.   
The aim of this preclinical study was to evaluate the potential of SSTR2 as 
a novel marker to monitor pro-inflammatory macrophages. We therefore 
determined gene expression levels of SSTR2 in unstimulated and IFNγ+TNFα 
stimulated human macrophages, and evaluated SSTR2 protein expression 
via binding of a SSTR2-binding tracer. We further used osteoarthritis (OA) 
as disease model to investigate a SSTR2-targeting tracer for macrophage 
imaging in an osteoarthritic joint. During development of OA, macrophages 
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are attracted to the synovial lining (24, 25) and are pivotal in promoting the 
production of inflammatory and degradative mediators in the OA synovium, 
maintaining an inflammatory state in the joint. Human synovial explants were 
used to perform tracer binding tests in pro-inflammatory circumstances. In 
this study we evaluated targeting of SSTR2 as a tool for longitudinal imaging of 
pro-inflammatory macrophages in an experimental mouse model of OA.
Materials and Methods
Ethics approval 
All animal experiments were performed in accordance with the ARRIVE 
guidelines for reporting on Animal Research (26), the Dutch law on animal 
experimentation, and were approved on March 12th 2014 by the committee 
on animal experimentation of the Erasmus MC, with protocol number EMC 
3246. We chose male mice because sex hormones play a critical role in the 
progression of OA in the murine DMM surgical model, with males having more 
severe OA than females (27). Mice were housed at the Experimental Animal 
Facility of the Erasmus MC with a 12-h light–dark regimen, in individually 
ventilated cages including extensive cage enrichment. The mice received 
acidified tap water and standard chow ad libitum. 
Synovial tissue was obtained with implicit consent from the patients, meaning 
that they had the right to refuse. The protocol was approved by the medical 
ethical committee of the Erasmus MC on November 12th 2004 with protocol 
number MEC-2004-322. 
Somatostatin receptor subtype 2 expression 
To verify the expression of SSTR2 on monocyte-derived macrophages, primary 
human monocytes were isolated from five buffy coats of male donor blood 
samples (58±8Y; Sanquin Blood bank, Amsterdam, the Netherlands) by Ficoll 
density gradient separation (GE Healthcare, Little Chalfont, UK) and CD14+ 
magneticactivated- cell sorting (MACS; Miltenyi, Bergisch Gladbach, Germany), 
as previously described (15). To acquire pro-inflammatory macrophages in vitro 
(15, 28), the monocytes were stimulated 1h after plating with 10 ng/mL IFN-γ 
(PeproTech, New Jersey, USA) and 10 ng/mL TNF-α (PeproTech, New Jersey, 
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USA) in X-VIVOTM 15 medium (Lonza, Verviers, Belgium) supplemented with 
20% heat-inactivated fetal calf serum (FCS; Lonza, Verviers, Belgium), 50  µg/
mL gentamicin (Gibco, Carlsbad, USA) and 1.5 µg/mL amphotericin B (Gibco, 
Carlsbad, USA), from now on referred to as M(IFNγ+TNFα). The macrophages 
were stimulated 3 days at 37°C and 5% CO2. Media and stimuli were refreshed 
24h prior to harvest. 
To determine the expression of SSTR2 in human synovial tissue, synovium 
was obtained as waste material from OA patients (n=4, 60±13Y) undergoing 
total knee replacement surgery. Fat tissue was macroscopically removed and 
the synovium was cut into pieces of approximately 40 mg wet weight and 
cultured in Dulbecco’s Modified Eagle Medium, low glucose (DMEM; Gibco, 
Carlsbad, USA), supplemented with 1% Insulin-Transferrin-Selenium (ITS+ 
Premix, Corning, New York, USA), 50 µg/mL gentamicin (Gibco, Carlsbad, USA), 
1.5 µg/mL amphotericin B (Fungizone; Gibco, Carlsbad, USA) and 25  µg/mL 
L-ascorbic acid 2-phosphate (Sigma-Aldrich, St. Louis, USA). To simulate acute 
inflammation, half of the number of the explants was stimulated with 10 ng/
mL IFNγ + 10 ng/mL TNFα. After 24h of stimulation, the synovial explants were 
harvested and stored at -80°C until gene expression analysis.
Messenger RNA (mRNA) was isolated from the macrophages using the RNeasy 
Micro Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. 
For the synovial explants, the tissue was first frozen in liquid nitrogen followed 
by pulverization using a Mikro-Dismembrator (B. Braun Biotech International 
GmbH, Melsungen, Germany) at 3000 rpm. The tissue was then homogenized 
with Trizol (Gibco, Carlsbad, USA) and 20% chloroform (Sigma-Aldrich, St. Louis, 
USA). Complementary DNA (cDNA) was synthesized using the RevertAidTM 
First Strand cDNA Synthesis Kit (Fermentas GmbH, Leon-Rot, Germany) 
according to manufacturer’s instructions. Expression of SSTR2 was evaluated 
using a TaqMan SSTR2 Gene Expression Assay (Hs00990356_m1; Thermo 
Fisher Scientific). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Fw: 
CAACGGATTTGGTCGTATTGGG; Rev: TGCCATGGGTGGAATCATATTGG; Probe: 
GGCGCCCCAACCAGCC) was used as a housekeeping gene. 
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Radiolabeled tracers
Two SSTR2 agonists, DOTA-Tyr3-octreotate, further referred to as DOTA-TATE 
(BioSynthema, Saint Louis, USA) and DTPA-octreotide (Mallinckrodt Medical, 
Petten, The Netherlands), and the SSTR2 antagonist DOTA-JR11 (kindly 
provided by Dr. Helmut Maecke) were used. The tracers were radiolabeled with 
Indium-111 (Covidien, Zaltbommel, The Netherlands) as previously described 
(29, 30). Molar activity was 200-300 MBq/nmol. Radiochemical yield was >99% 
and radiochemical purity was >90% for each tracer.
Binding of SSTR2 tracer 
The binding of the radiotracer to SSTR2 present on macrophages was 
established in vitro. Human monocytes were seeded in 6-well plates at a 
density of 5x105 cells/cm2, and subsequently cultured for 3 days with IFNγ 
and TNFα, as described in the previous paragraph. After 3 days of stimulation, 
the macrophages were washed with PBS (Gibco, Carlsbad, USA) and were 
incubated with 4x10-9 M [111In]In-DOTA-TATE. To determine specific binding the 
cells were also incubated with 4x10-9 M [111In]In-DOTA-TATE plus 10-6 M DOTA-
TATE for 1 h at 37˚C. Cellular uptake of the tracer was stopped by removing the 
supernatant and washing twice with cold PBS. The cells were lysed with 0.1 M 
NaOH and the amount of radioactivity present in the samples was counted in a 
gamma counter (1480 WIZARD automatic gamma counter, PerkinElmer, Turku, 
Finland). 
In vitro autoradiography was performed on human OA synovium cryosections 
(10  µm). The sections were incubated for 1  hour with 80  µL  10−9  M  [111In]In-
DOTA-JR11 with or without excess (10−6 M) unlabeled DOTA-TATE to determine 
non-specific binding. After incubation, the excess radiotracer was removed 
and the sections were exposed to super resolution phosphor screens (Packard 
Instruments Co., Meriden, USA) for 7 days. Binding of the radiotracers to SSTR2 
containing areas in the sections was quantified using Optiquant (Packard 
Instruments Co., Groningen, The Netherlands) and expressed as density light 
units/mm2 (DLU/mm2). Sections of human H69 tumour, an SSTR2-positive 
xenograft, were used as positive control. All sections were stained with 
hematoxylin and eosin to determine the localisation of cell dense areas where 
the macrophages can be found. 
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Osteoarthritis induction 
Experimental OA was induced, during light time of the day/night cycle, by 
destabilization of the medial meniscus (DMM) (31). The right knees of 40 male 
C57BL/6 mice of 12-14 weeks old (Harlan Laboratories/Envigo, Cambridgeshire, 
UK) underwent dissection of the medial meniscotibial ligament (MMTL). As 
control, the contralateral knee underwent a sham procedure, which entailed 
no transection of the MMTL.
Immunohistochemical analysis
At 1, 3, 7, 14, 28, and 56 days after OA induction both DMM and control knees 
were excised and fixed for 10 days in 4% formaldehyde (BoomLab, Meppel, 
The Netherlands). After decalcification the knees were dehydrated, embedded 
in paraffin and completely sectioned in the coronal plane. For the CD64 
histochemical (IHC) staining, a CD64 antibody (Sino-Biological, 50086-R001, 5 
ug/ml) was incubated on the slides for 60 min, and subsequently incubated 
with link and label (Concentrated MultiLink® and Concentrated AP Label; 
BioGenex, Fremont, California, USA); New Fuchsine was used as substrate (32). 
The extent of positive CD64 staining in the sections was scored by bright-field 
microscopy and ranked. Ranking means that all knees were arranged from 
least intensely stained to most intensely stained using bright field microscopy. 
The staining intensity of the markers was ranked amongst all time points. 
To confirm that OA was induced after 8 weeks, three consecutive 
thionin-stained sections of the medial femoral condyle and medial tibial 
plateau were evaluated. The structural cartilage damage was scored by the 
OARSI scoring system by Glasson et al. (1, 33). The score of the quadrants of 
three consecutive sections was summed and used for analysis. Histological 
images were acquired with a NanoZoomer 2.0-HT slide scanner (Hamamatsu, 
Hamamatsu City, Japan).
In vivo imaging 
To evaluate the influx of pro-inflammatory macrophages during OA 
development, OA was induced in mice (n=6) as described above. Because 
macrophage polarization is a dynamic process, we wanted to scan the knee 
as soon as possible after tracer injection. The mice were imaged 2 hours 
after i.v. injection of radiolabeled tracer (60 MBq/200pmol [111In]In-DTPA-
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octreotide) on day 1, 3, 7, 14, 28 or 56 after induction of OA. At day 3 after 
OA induction 3 mice were injected with 40 nmol block, DOTA-Tyr3-TATE, 1 
minute prior to an injection with 60 MBq/200pmol [111In]In-DTPA-octreotide. 
Single-photon emission computed tomography (SPECT) was performed on a 
MILabs VECTor+/CT system (Utrecht, the Netherlands) (34) with an ultra-high 
sensitivity mouse collimator with fifty-four 2.0 mm pinholes. A 55-minutes 
SPECT was acquired in list mode along a spiral trajectory, scan mode fine 
and 10 positions. SPECT was followed by CT (55 keV, 615 mA). SPECT data 
were reconstructed using the pixel-based ordered subsets expectation 
maximization (POSEM) developed by MILabs (35) algorithm with 30 iterations, 
4 subsets and a voxel size of 0.4 mm. Photopeaks 171 and 245 keV were used, 
scatter and background were corrected for with the triple-energy-window 
method (for 171 keV peak % width of 7 and for 245 keV peak % width of 10) 
(36). CT was reconstructed using filtered back-projection. SPECT and CT were 
registered; SPECT data were corrected for attenuation using the CT data (34). 
A post-reconstruction 3-dimensional Gaussian filter was applied. The resulting 
data was analyzed using inviCRO VivoQuant software (Boston, MA, USA) by 
quantification of manually drawn regions of interests (ROIs) based on CT. All 
data were represented as percentage of the injected dose per tissue volume 
%IA/cm3).
Statistical analysis
For the in vitro experiments, a mixed linear model after log transform was used 
followed by a Bonferroni’s post hoc comparisons test using PASW Statistics 22.0 
(SPSS Inc. Chicago, USA). For the histological staining experiment, differences 
in CD64 ranks for the time points were determined by a Kruskal-Wallis test. In 
the uptake experiment and autoradiography the mean values between the 
different groups (± stimulation, ± block) were compared and analyzed with 
a Two-way ANOVA. To compare values for DMM and sham surgery (in vivo 
imaging) the paired t-test was applied. Differences were considered statistically 
significant when p<0.05. 
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Results
Somatostatin receptor subtype 2 mRNA expression 
To establish the effect of inflammatory stimuli on SSTR2 mRNA expression 
of macrophages, SSTR2 mRNA levels were determined in unstimulated and 
IFNγ+TNFα-stimulated macrophages by qPCR. Following stimulation with 
IFNγ+TNFα, expression of SSTR2 mRNA significantly increased by a factor 
of 3.6 (p<0.005) relative to unstimulated macrophages (Fig. 1A). Similar to 
macrophages, stimulation of synovial tissue of OA patients with IFNγ+TNFα, 
also resulted in increased expression levels of SSTR2 mRNA (10-fold, p<0.001) 
relative to unstimulated tissue (Fig. 1B). 
Figure 1 Gene expression levels of somatostatin receptor subtype 2 (SSTR2) in human primary 
macrophages and osteoarthritic synovial tissue. SSTR2 gene expression relative to the expression 
of GAPDH in A unstimulated human monocyte-derived macrophages and IFNγ+TNFα-stimulated 
macrophages. B osteoarthritic synovial tissue, cultured in vitro, with and without IFNγ+TNFα stimulation. 
Data is presented from min to max including the median. 
Binding of SSTR2 tracer 
Stimulation of primary monocyte-derived macrophages with IFNγ+TNFα 
in vitro resulted in a significant increase of [111In]In-DOTA-TATE uptake (Fig. 
2). Relative to unstimulated macrophages the uptake of [111In]In-DOTA-
TATE increased (1.6-fold, p<0.05). For both stimulated and unstimulated 
macrophages uptake of [111In]In-DOTA-TATE was largely blocked following 
addition of excess unlabeled DOTA-TATE (p<0.001).
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Figure 2 Binding of [111In]In-DOTA-TATE to SSTR2 on human monocyte-derived macrophages. 
Binding of [111In]In-DOTA-TATE (as a measure of SSTR2 presence) to M(IFNγ+TNFα) in kBq/1e5 cells. 
Blocking of the specific binding to SSTR2 was performed with excess of unlabeled DOTA-TATE. Data is 
presented as mean + SD.
Autoradiography analysis of binding of the radiolabeled tracer [111In]In-DOTA-
JR11 showed regions with higher signal intensities corresponding to cell 
dense areas on H&E-stained sections (Fig. 3A and 3B). The intensity of the 
autoradiography signal was significantly increased up to 3.1 times (average 
1.6; range 0.5-3.1; p<0.05) in IFNγ+TNFα-stimulated synovial tissue relative to 
unstimulated synovial tissue (Fig. 3C).
Presence of macrophages during experimental OA
To establish the relevance of SSTR2 tracer as a marker for pro-inflammatory 
macrophages in vivo, presence of macrophages and uptake of SSTR2 tracer 
was studied in a mouse DMM model for OA over time.
From knees, which were harvested eight weeks after induction of OA by 
DMM, three consecutive thionin-stained sections of the medial femoral 
condyle and medial tibial plateau were evaluated. The summed OARSI scores 
for three DMM knees were: 2.5, 4.0, and 10.5. Osteophytes were present in all 
DMM knees. Control knees did not have any signs of cartilage degradation 
(OARSI score 0 for all knees) and did not present any indications of osteophyte 
formation (Fig. 4). 
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Figure 3 Binding of [111In]In-DOTA-JR11 to human synovial tissue. (A) Autoradiography of a 
section of an OA synovial explant. Dark spots indicate uptake of [111In]In-DOTA-JR11. (B) H&E staining 
of IFNγ+TNFα-stimulated synovial tissue of the same sample shown in A with 2 40X magnifications. 
Segmentation lines indicate relevant areas used for analysis. (C) Binding of [111In]In-DOTA-JR11 to 
human synovial tissue is shown as NET DLU/mm2 + SD. Samples of synovium derived from 3 different 
OA patients undergoing total knee resection were incubated with (two right bars) and without IFNɣ/
TNFα (two left bars). To determine specific binding a 1000-times excess of unlabeled DOTA-TATE was 
added to some samples (solid black bars).
CD64 positive cells, indicating pro-inflammatory macrophages, were present 
from day 1 onward. The sections were ranked to distinguish low-positivity and 
high-positivity. The number of CD64-positive macrophages were elevated at 
day 1 and 3, and slowly diminished during the following weeks. There were 
statistically differences seen between the ranks at the different time points 
(p<0.0001). No statistically significant differences were seen in the pattern of 
CD64+ macrophages presence over time between the sham-operated and 
DMM knees (Fig. 5).
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Figure 4 Cartilage damage and osteophyte formation after induction of experimental 
osteoarthritis (OA) by DMM. Thionin staining of a mouse knee 8 weeks after OA induction by 
destabilization of the medial meniscus (DMM). The femur condyle and tibia plateau are shown in the 
enlargements. The sham-operated knee had a summed OARSI score of 0 and the knee with DMM 
had a summed OARSI score of 10.5 (maximum possible score 72). Cartilage damage (at asterisk) and 
osteophytes (indicated by the arrows) were seen in all DMM knees. 
 
Figure 5 Presence of CD64+ macrophages during development of experimental osteoarthritis 
after DMM. The continuous line represents the DMM knees. The dotted line represents the sham knees. 
Each group contains 7-9 knees. Data is presented as mean ± SD, p<0.0001 between different time points.
63563-Sandra van Tiel-proefschrift.indd   154 04-09-20   08:46
7
SPECT imaging of pro-inflammatory macrophages 
155
In figure 6A a representative SPECT/CT image is shown of a DMM knee 3 
days after destabilization of the medial meniscus in which accumulation of 
the radioactive tracer was observed. Percentage injected activity per volume 
(%IA/cm3) was calculated over time after DMM. During the first 7 days after 
DMM surgery, increased amounts of radioactivity were found in the knees, 
which gradually decreased over time (Fig. 6B). Herein we saw a similar pattern 
for both the knees in which OA was induced by DMM and for the knees that 
underwent sham surgery. 
To determine the specificity of the radioactive signal a blocking experiment 
was executed. After the SPECT/CT scans the knees and thymus were removed 
and placed in a gammacounter. Both SPECT/CT scans and gammacounter 
data showed that the binding was receptor-specific (Supplementary Digital 
Material 1: Supplementary Figure 1). Co-injection of excess unlabeled DOTA-
Tyr3-TATE reduced uptake of [111In]In-DTPA-octreotide in the knees and thymus.
Figure 6 SPECT/CT imaging of in vivo uptake of [111In]In-DTPA-octreotide in osteoarthritic (OA) 
mice knees. A Sagittal view of a knee 3 days after OA induction through destabilization of the medial 
meniscus (DMM). Scan was made 2 h post injection with [111In]In-DTPA-octreotide. B Percentage 
injected activity ([111In]In-DTPA-octreotide) per volume (knee) (%IA/cm3) was calculated over time after 
induction of OA. The continuous line represents the DMM knees. The dotted line represents the sham 
knees. Each group contains 6 animals. Data is presented as mean ± SD, p= 0.099.
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Discussion
Pro-inflammatory macrophages have been identified as crucial mediators in 
various disease processes. Non-invasive monitoring of their presence during 
disease progression is therefore very desirable. In this report, we showed that 
pro-inflammatory macrophages (IFNγ+TNFα stimulated) had elevated SSTR2 
expression and showed concomitant increased uptake of SSTR2-targeting 
radiolabeled peptides, which are suitable as SPECT tracers. Using such a SSTR2 
SPECT tracer in a translational setting, we also demonstrated that under pro-
inflammatory conditions there was increased binding of the tracer in human 
OA synovium. Moreover, in an in vivo model we showed that macrophage-
associated inflammation resulted in concomitant uptake of [111In]In-DTPA-
octreotide in mouse knees, indicating that an SSTR2-targeting SPECT tracer 
can be used to monitor the course of a pro-inflammatory response over time 
in vivo. 
Destabilization of the medial meniscus in mice was used as a model for OA 
with anticipated involvement of pro-inflammatory macrophages. In many 
other studies this model has been used for studying processes during the 
onset of OA and in studies evaluating novel intervention strategies for OA 
(37-39). This animal model has a low variability (31) and represents posttraumatic 
human injury which leads to joint degeneration (40). During human OA 
development a macrophage influx was seen (41) and macrophage-associated 
inflammation was related with structural damage and disease progression.
As shown in this study, it appeared that the influx of macrophages was 
time dependent and associated with the development path of OA, but 
the macrophage influx in the knee was not exclusively associated with 
development of OA. An influx of macrophages was also observed in the sham-
operated knee, most likely due to the inflammatory reaction to tissue damage 
caused by surgical manipulation. It should be noted that the sham knees had 
no structural cartilage damage or osteophyte formation, features that are 
associated with OA. Since the SSTR2 tracer specifically targets inflammatory 
cells, and not damaged cartilage, SSTR2 receptor uptake occured in both DMM 
and sham-operated knees due to the presence of inflammatory macrophages 
in both situations. The pattern seen with uptake of SSTR2 targeting tracer 
63563-Sandra van Tiel-proefschrift.indd   156 04-09-20   08:46
7
SPECT imaging of pro-inflammatory macrophages 
157
in the knee, and the pattern seen with the presence of pro-inflammatory 
macrophages (histological aCD64 staining) of the knee, proceeded in the same 
way; starting with an high influx of macrophages which decreased during the 
course of time.
For potential clinical relevance we evaluated SSTR2 tracer uptake in synovial 
tissue samples derived from OA patients. OA synovium showed specific 
uptake of [111In]In-DOTA-JR11, which could be further enhanced under acutely 
induced inflammatory conditions (stimulation with IFNγ+TNFα). There was 
considerable variation in uptake of the SSTR2 tracer between patient samples 
which was most likely due to the large heterogeneity in disease state between 
OA patients and whether or not a given patient had a flare of inflammation at 
time of surgery. It is also known that synovium consists of a heterogeneous 
cell population including synoviocytes, macrophages and fibroblasts. 
Although it cannot fully be excluded that SSTR2-binding tracer is taken up 
by cells other than macrophages, we consider this option highly unlikely to 
substantially contribute to the measured activity. It is known that the number 
of macrophages dramatically increases in inflammatory arthritis relative to 
healthy synovia (41, 42), also seen in this study using histological evaluation. 
It is therefore most likely that the signal in inflamed knees is caused by the 
presence of pro-inflammatory macrophages.
In this research high resolution scans are of utmost importance, because the 
target is very small. That is why we used an indium-111 labeled tracer. When 
this tracer is going to be used in the clinic we will be using a radioactive 
isotope compatible with PET. PET has in the clinic a higher resolution, half-life 
of radioactive isotopes is shorter so patients can leave the hospital sooner and 
images are less noisy therefor accurate quantification can be performed.
We made use of a mouse model where we introduced OA through 
destabilization of the medial meniscus. Mice knees are very small and DMM 
results in a mild inflammation. Altough we had these restrictions we were 
able to successfully visualize, quantify and monitor the inflammation process 
by SPECT/CT imaging. Perhaps with the use of a larger animal model and/or a 
disease model with more macrophage involvement, like rheumatoid arthritis 
(43, 44), will facilitate further research. Our findings are promising for the use 
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of SSTR2 targeting tracers in studying macrophage involvement in disease 
processes. Macrophages are crucial in the development and progression 
of various diseases and that is why accurate imaging of pro-inflammatory 
macrophages, beside the already established anti-inflammatory macrophage 
tracers (11, 45), might be an important step forward in understanding disease 
development. This is also indicated by recent publications on studies in which 
macrophages are being imaged in atherosclerotic plaques using the folate, 
mannose and somatostatine type 2 receptor (18, 46, 47). 
Conclusion
Our research showed that pro-inflammatory macrophages (IFNγ+TNFα 
stimulated) had elevated SSTR2 expression and show concomitant elevated 
binding of SSTR2-targeting radiolabeled peptides suitable as SPECT tracers. 
Under pro-inflammatory conditions there was an increase in presence of CD64+ 
cells especially at day 1 and 3 after OA induction. In vivo SSTR2 SPECT imaging 
showed an increase of radioactivity in the knee at day 1-7 after OA induction. 
So, SSTR2 can be a marker to longitudinally monitor pro-inflammatory 
macrophages in vivo.
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Supplemental Data
Figure S1 SPECT/CT imaging of in vivo blocking of 60 MBq/200pmol [111In]In-DTPA-octreotide 
with (B,D,F) or without (A,C,E) 40 nmol DOTA-Tyr3-TATE in mice 3 days after osteoarthritis (OA) 
induction. A Whole body maximum intensity projection. Kidneys and bladder are clearly visible B 
Whole body maximum intensity projection. Tracer is rapidly excreted via urinary tract C Saggital view of 
the thorax. Somatostatin subtype 2 cells in the thymus are visible D Saggital view of the thorax. Signal of 
the thymus is blocked E Saggital view of the OA knee. Radioactive signal is clearly visible F Saggital view 
of the OA knee. Radioactive signal is blocked. H=Head, F=Feet, A=Anterior, P=Posterior, Green asterisk 
= mouse identification chip.
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Figure S2 Relative change in %ID/g after in vivo blocking of 60 MBq/200pmol [111In]In-DTPA-octreotide 
with 40 nmol DOTA-Tyr3-TATE in mice 3 days after osteoarthritis (OA) induction. 
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Summary, Discussion, Concluding remarks
For this thesis we have performed preclinical studies in different models and 
at different levels of complexity with the ultimate aim to optimize cellular 
imaging in regenerative medicine, cancer and osteoarthritis. Single and multi-
modal imaging was performed using MRI, SPECT and CT. 
In Chapter 1 a general introduction to molecular imaging is given. We describe 
the imaging devices used in molecular imaging and cell labelling strategies 
that can be employed. 
Cellular imaging in regenerative medicine
Regenerative medicine focuses on repair, replacement or regeneration of 
damaged tissue to restore functions. Impaired functions can be caused by 
congenital defects, by disease, trauma, and ageing. A variety of technologies 
and approaches such as gene therapy, stem cell therapy and progenitor cell 
therapy, as well as tissue engineering can be used for function repair (1). 
In case of cell therapy it is essential to know if accurate delivery of the cell 
graft occurs (2). Monitoring the fate of the transplanted cells and measuring 
their therapeutic effect (e.g. improved cardiac output) is crucial to establish 
efficacy of cell therapy. Various methods have been studied for cell labelling 
and imaging. One method that has been considered as highly efficient and 
translatable is labelling of the cells with iron oxide nanoparticles. Such particles 
result in a local change in MRI signal and offer the possibility of highly sensitive 
detection of labelled cells at high spatial resolution within anatomical and/or 
functional context as imaged by MRI. As described in Chapters 2, 3 and 4 various 
types of iron oxide particles can be used. In these studies two types of particles 
were applied; 1) Ferumoxide which are super paramagnetic iron oxide particles 
(SPIO) having a particle diameter between 80 and 150nm and an iron oxide core 
(3-5) and 2) the larger micron-sized paramagnetic iron oxide particles (MPIO) 
composed of polystyrene–divinyl benzene polymer micro spheres containing 
a magnetite core and tagged with the fluorescent dye Dragon green (480/520 
nm). MPIO particles have an average size of 1630 nm and have been shown 
to be functionally inert (6, 7). The iron oxide core of both SPIO and MPIO has a 
strong magnetic moment, causing a disturbance of the local magnetic field in 
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MRI resulting in local signal loss in MR images. The efficacy of these particles for 
cell labelling and imaging studies was investigated by variations in iron particle 
labelling protocols, and the influence thereof on incorporation, distribution 
and retention of iron oxide nanoparticles as described in Chapter 2. Cultured 
human umbilical cord cells (HUVECs) were labelled with iron particles. The 
average iron load of SPIO increased when incubation time was extended 
from 4h to 24h. The optimal labelling protocol in this study resulted in 12.0 
pg iron/per cell. For MPIO labelling, incubation time was of less importance, 
since most of the particles were already incorporated in the cell within 4 h, 
with a 100% labeling efficiency and an intracellular iron load of up to 626 pg 
iron/cell. MPIO were taken up more efficiently, were better tolerated without 
causing significant cell death and had a much more pronounced effect on cell 
appearance in an MR image than SPIO. A drawback of the use of the bigger 
MPIO particles is that there are fewer particles per cell. When cells divide, not 
every daughter cell will contain a MPIO particle. This results in the inability to 
track these cells. Optimal label incorporation required different protocols for 
SPIO and MPIO. No standard labelling protocol could be used for different cell 
types growing in vitro. Cell lines differ from each other for example in ease of 
spontaneous particle uptake. They also can differ in particle uptake rate and 
in tolerated load of iron particles in the cell. Other studies showed that iron 
labelled cells can be followed for several weeks in vivo (8, 9). The iron particles 
inside the cells can be visualized with MRI and the iron particles have an effect 
on different MRI parameters (eg. R2' (R2*-R2) = relaxivity). So, cell labelling with 
iron particles offers a promising method for in vivo human and animal model 
cell tracking by MRI. Different processes can occur when iron labelled cells are 
injected in vivo, like cell death, cell migration and cell division, all influencing 
signal intensity (10, 11). Mimicking these biologically relevant processes was 
executed by labelling cells with small (SPIO) and larger (MPIO) iron particles; 
the performed experiments and the results are described in Chapter 3. For the 
MR measurements phantoms were prepared. As a model system for dividing 
cells in vivo, Brown Norway 175 sarcoma cells were labelled with SPIO and 
injected subcutaneously in the flank of a rat. The effects of spatial distribution 
and compartmentalization of paramagnetic iron-oxide particles on relaxivity 
were analyzed. We demonstrated that relaxometry does not allow labelled cell 
quantification when multiple physiological processes such as cell division and 
cell migration coexist. Not only we, but also other groups (12-14), concluded 
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that if there are different physiological processes occurring at the same time 
(which will for sure happen in vivo) which all influence MRI parameters, 
it is very difficult to determine the fate of transplanted iron labelled cells in 
vivo. Using paramagnetic iron oxide particles for cell labelling also has other 
drawbacks. The nanoparticles can have subtle immunological effects (15), 
affect cellular proliferation (16, 17), and nanoparticles can be toxic to certain 
cells at high concentrations (18). The relaxivity changes of iron oxides particles 
are dependent on the environment. The intensity of the iron labelled cells 
becomes degraded as iron oxide becomes diluted by proliferation (19) or by 
lysosomal action (20, 21). To distinguish viable labelled cells with iron deposits 
released from dead or dying cells or macrophages might be provided by MR 
reporter gene technology. Here a gene encoding for expression of proteins 
involved in iron metabolism, e.g. ferritin and transferrin receptors is introduced 
into the cell. (Over) expressing these proteins results in accumulation of iron in 
the cell leading to altered signals on MRI (22, 23). Most MRI images are derived 
from proton (1H) spins, but other half-integer spin nuclei can also be used for 
cell imaging with MRI. New developments have occurred, like fluor-19 imaging, 
which can be used for quantitative magnetic resonance imaging. Fluor-19 has 
several properties to be suitable for MRI: It possesses comparable MR sensitivity 
to proton imaging, Fluor-19 does not naturally occur in the human body, its 
resonance differs by only 6% from that of 1H, potentially allowing 19F MRI to be 
conducted on existing 1H imaging hardware, and it is not naturally present in 
biological tissues so it exhibits no tissue background signal, allowing specific 
and selective assessment of the administrated  19F-containing compounds  in 
cells in vivo (24-26).
For MR imaging of resident cell types, such as for instance in tumor vasculature 
and tissue engineered vasculature structures, it could be advantageous 
to label cells in vivo instead of, as described previously, in vitro with iron 
particles. Changes in vascularization and vascular dysfunction could reveal 
disease development, like in cardiovascular and kidney disease and in tumor 
development and is therefore of interest to image these processes. The aim 
of our in vitro study described in Chapter 4 was to find optimal parameters 
for non-invasive, CD31-targeted (a biomarker constitutively expressed on 
endothelial cell membranes (14)), microbubble-mediated SPIO-labelling of 
endothelial cells. When ultrasound was applied, the microbubbles oscillated 
63563-Sandra van Tiel-proefschrift.indd   168 04-09-20   08:46
8
Summary, Discussion, Concluding remarks
169
due to sequential compression and expansion caused by pressure variations. 
Cell membrane permeability is increased this way, because the microbubbles 
cause shear stress on the cell membrane. They create transient, non-lethal 
holes in the plasma membrane, through which a drug/gene/label is able to 
diffuse into the cell (27-29). Acoustical pressure, sonication time, and SPIO 
incubation time play a role in safe and optimal endothelial cell labelling. The 
next step following the in vitro experiments should be in vivo experiments 
for real time targeted microbubble sonoporation. These can, for example, be 
performed with chicken embryos. Their chorioallantoic membrane (CAM) is a 
simple, highly vascularized extraembryonic membrane and is used to study 
angiogenesis and vascular biology (30). The CAM has great accessibility and 
is easy to handle for both intervention and imaging of the vasculature. SPIO 
labelling of the cells of the vessel wall can be monitored with a high speed 
camera. The microbubble behavior can be recorded and the cellular and 
tissue response might allow a better understanding of microbubble-drug-cell 
interaction. 
Cancer cell imaging for diagnosis and therapy
Targeting of overexpressed receptors on the cell membrane of certain cells 
is applied in peptide radionuclide receptor therapy (PRRT) and imaging. A 
radioactive tracer is composed to target the receptor upon injection in the 
bloodstream, which can be visualised with a PET or SPECT scan. Availability 
of a tracer to target cells can be compromised for example by presence of 
enzymes that degrade the tracer. Too fast excretion of the tracer from blood is 
also problematic, because the time window for the tracer to reach the cell of 
interest is very short. 
In Chapter 5 we describe our research aiming to increase in vivo stability of 
an Indium-111 labelled radiopeptide targeting the gastrin-releasing peptide 
receptor (GRPR). This is a G-protein coupled receptor expressed at high 
density in a number of cancer types such as prostate cancer, breast cancer, 
and gastrointestinal cancer, which makes it an attractive target for peptide 
radionuclide receptor therapy (31, 32). Multiple GRPR radioligands have been 
synthesized during the past decade, mainly for the purpose of receptor-
mediated nuclear imaging and therapy (33, 34). Our GRPR antagonist, 
Sarabesin-3, labelled with the positron-emitting radionuclide Gallium-68 
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has shown excellent receptor affinity and good in vivo stability. Preclinical as 
well as clinical PET imaging studies using [68Ga]Ga-SB3 have been performed 
with success (35, 36); lesions in patients were visualized in about 50 % of the 
cases. For radio-guided tumour detection of malignant lesions, after injection 
of a radiopharmaceutical a handheld detection probe is used during surgery. 
Combining this intra-operative method with information from pre-operative 
imaging will allow accurate surgical guidance, ultimately improving surgical 
outcome while minimizing surgical invasiveness. We wanted SB-3 to be 
useful for both pre-operative imaging and intra-operative radio-guided 
tumour detection and therefore we labelled it with Indium-111. However, 
after labelling with Indium-111 the molecule shows poor in vivo stability (37). 
Radiopeptide integrity is challenged when injected into the circulation, by 
omnipresent proteolytic enzymes in the bloodstream. Enzymes also reside in 
organs, like liver, lungs, kidneys, and gastrointestinal tract, where radiopeptides 
are also exposed to. A neutral endopeptidase (NEP) inhibitor, such as 
phosphoramidon, can inhibit the enzymatic degradation of radiopeptides 
(38, 39). Phosphoramidon (PA) can be injected as a bolus together with a 
radiopeptide (40). The in vivo stability of [111In]In-SB3 +/- PA was analysed in 
blood samples from mice. Radiotracer co-injected with PA showed twice as 
much circulating radioactivity consisting of intact radiotracer compared to 
that in control animals (no co-injection of PA), leading to 100% more intact 
tracer reaching the tumor at 1h post injection. At all-time points studied, there 
was significantly higher tumor uptake when PA was co-administered with 
[111In]In-SB3. The radiotracer uptake in the tumour was receptor-specific 
as concluded from the significantly decreased uptake when an excess of 
unlabelled SB3 was co-administered. Injection with 25 MBq/200 pmol [111In]In-
SB3 +/- PA resulted in clearly improved tumour visualization with SPECT at all 
imaging time points when the radiotracer was combined with PA. After analysis 
of the images to determine the uptake of radioactivity (by drawing region 
of interest) an increase of 1.7 in signal intensity was shown when mice were 
injected with [111In]In-SB3 + PA versus control animals. So, in vivo stabilization of 
[111In]In-SB3 by inhibition of NEP resulted in higher tumour uptake. The 
radiopeptide uptake in the pancreas also increased when [111In]In-SB3 was co-
administered with PA, so the tumour to pancreas ratio remained unaffected. 
Nevertheless, high uptake in the pancreas should be kept in mind when the 
radiotracer would be used for radio-guided surgery of tumor lesions close 
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to the pancreas. The radioactivity washout from the pancreas was relatively 
fast, while tumour radioactivity uptake declined at a lower rate. So, the 
optimal time window for the best tumour:pancreas ratio for pre-operative 
and intra-operative tumour detection would be around 24 h post injection. 
For translation to the clinic of the PA/SB3 combination, the stability of 
SB3 +/- PA in humans should first be tested before the concept can be 
introduced in patients. 
The success of PRRT depends on the amount of radioactivity delivered to 
the tumour in relation to the dose delivered to healthy tissues. To improve or 
widen the use of PRRT, there is a wide field of research ongoing (41). Other, 
more powerful, radionuclides (e,g, α-emitters) could be used (42, 43), various 
kinds of combination therapies can be given (43-45), the administration routes 
of the radiopeptide can be adjusted (46, 47), or the DNA damage response can 
be enhanced (48, 49). 
One of the tracers widely used for PRRT is DOTA-Tyr3-octreotate (DOTA-
TATE) (50, 51). In the clinic we and many others apply radiolabelled DOTA-
TATE to image and treat somatostatin receptor subtype 2 (SSTR2) positive, 
neuroendocrine tumours. For therapy [90Y]Y-DOTA-Tyr3-octreotide and [177Lu]
Lu-DOTA-Tyr3-octreotate (51-53) are mostly used and the disease-control rates 
for these therapies are between 68–94% (54). The blood clearance of these 
tracers in humans is rapid (<10%ID in blood at 3 h post injection) (55). As there 
is no 100% response rate there is room to enhance the therapeutic efficacy. 
A higher dose in the tumor with the current tracer is not an option because 
concomitant higher radiation doses to other organs are also given. The organs 
at risk for long-term toxicity are predominantly the kidneys and the bone 
marrow. The renal radiation dose can however be reduced by co-infusion of 
a gelatin-based plasma expander (Gelofusine), leaving the bone marrow the 
main dose-limiting organ for treatment (56, 57). In Chapter 6 we described 
how we aimed to further improve the biodistribution of radiolabelled DOTA-
TATE by prolonging the tracer circulation time by adding an albumin binding 
domain to the radiopeptide. This new tracer is called Albutate-1 and is 
expected to have a longer circulation time in the blood stream according to 
our concept, possibly resulting in more uptake by the SSTR2 positive cells. We 
determined the characteristics of [111In]In-albutate-1 and [177Lu]Lu-albutate-1 
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analogue. Both DOTA-TATE and Albutate-1 showed a comparable high 
binding affinity for SST2 and a similar uptake and internalization rate of the 
tracers. After radiolabelling [111In]In-Albutate-1 was stable for up to 3 days in 
labelling solution and at least for 24h in mouse serum. When tested in vivo, the 
circulation time of [177Lu]Lu-Albutate-1 was T1/2 = 27.5 h. We determined that 
for the dose tested a tumor absorbed dose per administered activity of 1455 
mGy/MBq. This absorbed dose is 5 times higher than with [177Lu]Lu-DOTA-TATE 
(unpublished data) and is the result of an extended exposure time to radiation. 
Normal organs however also encountered a higher absorbed dose, especially 
bone marrow. We calculated that the spine, which has a cellular fraction 
of 52%, received a total absorbed dose of 765 mGy/MBq. We conclude that 
addition of an albumin binding domain to [177Lu]Lu-DOTA-TATE extended the 
blood circulation time and raised the tumor uptake. However, bone marrow, 
kidneys and all other organs received a high radiation dose, reducing the 
therapeutic index. Other groups also searched for the best balance between 
high tumor dose and limited organ dose using an albumin binding domain 
or Evans blue as albumin binder. In search for the best biodistribution profiles 
the structure of the tracer can be modified by varying the binding strength to 
albumin, and the spacer length. Preferred are a weaker binding strength and 
a shorter spacer length which both result in a shorter dissociation constant 
with a sub sequentially shorter circulation time (58-61). According to our 
results and other studies by other groups, attachment of albumin-binding 
domains to tracers can improve circulation time and increase tumor uptake. 
However, if the plasma protein-binding results in long dissociation times, the 
blood circulation time becomes extended to a level where all other organs 
also receive a high radiation dose, reducing the therapeutic index dramatically. 
Future perspectives are to create a tracer with more optimal pharmacokinetics, 
applying adaptations in albumin binding strength and spacer length. 
Macrophage imaging during osteoarthritis development
As described in Chapters 5 and 6 tumor cells can be visualised using 
peptide radionuclide receptor imaging, but other cell populations that over-
express receptors can be visualised the same way. Inflammatory cells, like 
macrophages, are of high interest, because they play a prominent role in the 
pathogenesis and progression of many different diseases and therefore form 
an interesting therapeutic target (62, 63).
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Macrophages constitute an important cellular component of inflammatory 
diseases. Upon activation macrophages can differentiate, oversimplified 
stated, into pro- or anti- inflammatory macrophages (64). Macrophages can 
change their functional phenotype during their existence; these specific 
functional and phenotypic properties are affected by the micro-environment 
(65). Their varied roles can exacerbate and/or resolve diseases. The phagocytic 
nature, abundance and disease homing properties of macrophages can be 
targeted for imaging and therapeutic purposes. The ability to image specific 
phenotypes (pro- and anti-inflammatory macrophages) could help to predict 
disease progression or assess the stage of disease and considerably contribute 
to current disease treatment regimens (66). 
Osteoarthritis (OA) has traditionally been thought to be a purely biomechanical 
disease, but in recent years there has been a shift in understanding how 
OA originates. Now it is seen as an inflammatory disease with macrophage 
involvement, however it is still unclear to what extent inflammation is an 
initiator versus an outcome of the joint destructive process. The contributions 
of different phenotypes of macrophages to OA pathogenesis are currently 
not well understood (67). It would be favourable to non-invasively trace 
the presence of different phenotypes of macrophages in vivo during OA 
development. A way to achieve this is by SPECT imaging. In Chapter 7 we 
investigated the value of the somatostatin receptor subtype 2 as a novel 
imaging marker for pro-inflammatory macrophages also using the DMM 
osteoarthritic mouse model. First we evaluated gene expression levels of SST2 
in unstimulated as well as in IFNγ+TNFα stimulated human macrophages 
by qPCR. The expression of SST2 mRNA significantly increased by a factor of 
3.6 relative to that in unstimulated macrophages. A similar effect was also 
observed synovial tissue of OA patients. From patients with OA who got a knee 
resection synovial tissue was removed and stimulated in vitro with IFNγ+TNFα, 
resulting in a 10-fold increased expression level of SST2 mRNA relative to that 
in unstimulated tissue. Moreover, stimulation of primary monocyte-derived 
macrophages with IFNγ+TNFα in vitro resulted in a significant increase of [111In]
In-DOTA-TATE uptake. To establish the relevance of SST2 tracer as a marker for 
pro-inflammatory macrophages in vivo, presence of macrophages and uptake 
of SST2 tracer was studied in a mouse DMM model for OA over time. 
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DMM and sham knees were histologically stained for CD64. The number of 
CD64 positive cells, indicating pro-inflammatory macrophages, was elevated 
at day 1 and 3, and slowly diminished during the following weeks. With SPECT, 
increased amounts of radioactivity were found in the knees, during the first 7 
days after DMM surgery followed by a gradual decrease over time. Herein we 
saw a similar pattern for both the knees in which OA was induced by DMM and 
for the knees that underwent sham surgery. As shown in this study, the influx 
of macrophages was time dependent and associated with the development 
path of OA. Influx of macrophages was also observed in the sham-operated 
knee, most likely due to the inflammatory reaction to tissue damage caused 
by surgical manipulation. It should be noted that the sham knees had no 
structural cartilage damage or osteophyte formation. Synovium consists of 
a heterogeneous cell population including synoviocytes, macrophages and 
fibroblasts. Although it cannot fully be excluded that SST2 tracer is taken up 
by cells other than macrophages, we consider this option highly unlikely to 
substantially contribute to the measured activity. 
As said before, macrophages play a role in many different diseases, like also in 
inflammation of an atherosclerotic plaque. In the clinic different pilot studies 
have been performed with an SST2 tracer to image atherosclerotic inflammation 
(68-70). These studies found that 68Ga-DOTA-TATE PET enables measurement 
of generalized atherosclerotic disease activity and offers detailed information 
about local plaque functional phenotype. Imaging with 68Ga-DOTA-TATE has 
therefore the potential to improve cardiovascular disease risk prediction. 
Despite we used an animal model resulting in only mild inflammation, we were 
already able to successfully visualize, quantify and monitor the inflammation 
process by SPECT/CT imaging. These findings are promising for the use of 
SST2 targeting tracers in studying macrophage involvement in several disease 
processes. Macrophages are crucial in the development and progression of 
various diseases, so accurate imaging of pro-inflammatory macrophages, 
beside anti-inflammatory macrophages, might be an important step forward 
in understanding disease development. 
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Figure 1 Cellular imaging in A regenerative medicine using iron labelled cells for MRI; B cancer 
cell imaging for PET or SPECT or therapy using radiolabelled cells; C macrophage imaging during 
osteoarthritis development using radiolabelled cells for PET or SPECT. Inner ring represents the cell 
used in research. Second ring shows the label. Third ring displays the labelled cells. Outer ring exhibits 
the model used with an example of an image obtained with the imaging modality applied. 
Concluding remarks
In this thesis we showed diff erent methods to label cells for cellular imaging to 
determine their role in diagnosis and therapy of various diseases (Fig. 1):
•	  In vitro cell labelling with iron nanoparticles appeared well feasible. 
We executed this method via non-specifi c targeting of the cells using 
a transfection agent or via specifi c targeting with the use of targeted 
ultrasound bubbles. Our labelling procedures did not harm the cells, but 
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in vivo tracking of superparamagnetic iron labelled cells showed some 
drawbacks especially when cell death, cell migration, cell division and 
extracellular SPIO accumulation occur simultaneously. 
•	  Besides labelling of cells with iron nanoparticles, cells can also be 
labelled with a radioactive peptide tracer targeting e.g. a receptor. In 
this thesis work, we aimed for and achieved a longer circulation time of a 
radiopeptide by increasing in vivo stability (SB3) or by adding an albumin 
binding domain to the peptide molecule (Albutate-1). With either 
concepts one must realise that undesired tracer uptake in healthy organs 
may increase as well. Therefore this should always also be adequately 
determined. 
•	  For inflammatory cell imaging we repurposed the currently widely 
available radiotracer for neuroendocrine tumor imaging ([111In]In-DOTA-
TATE, targeting the somatostatin receptor subtype 2) to distinguish 
between different inflammatory cell subtypes. This marker was elevated 
on an inflammatory cell subtypes as determined in vitro and in in vivo. 
Radioactive signal representative of tracer uptake could be measured 
in vivo in an inflammatory disease model, making this tracer useful for 
inflammatory cell imaging. 
•	  The challenge for cellular imaging lies in the development/application 
of the ideal technique. No available imaging technique can currently 
address all research questions. Therefore, depending on the question(s) 
addressed, the most suitable technique or combination of techniques, i.e. 
using multiple modalities, will have to be selected. This will also include 
the most suitable label for a specific question.
63563-Sandra van Tiel-proefschrift.indd   176 04-09-20   08:46
8
Summary, Discussion, Concluding remarks
177
References
1. Stacy MR, Sinusas AJ. Emerging Imaging Modalities in Regenerative Medicine. Current Pathobiology 
Reports. 2015;3(1):27-36.
2. Willadsen M, Chaise M, Yarovoy I, Zhang AQ, Parashurama N. Engineering molecular imaging 
strategies for regenerative medicine. Bioeng Transl Med. 2018;3(3):232-55.
3. Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY, et al. Efficient magnetic cell 
labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood. 2004;104(4):1217-
23.
4. Neri M, Maderna C, Cavazzin C, Deidda-Vigoriti V, Politi LS, Scotti G, et al. Efficient in vitro labeling 
of human neural precursor cells with superparamagnetic iron oxide particles: Relevance for in vivo 
cell tracking. Stem Cells. 2008;26(2):505-16.
5. Zhang Z, van den Bos EJ, Wielopolski PA, de Jong-Popijus M, Bernsen MR, Duncker DJ, et al. In vitro 
imaging of single living human umbilical vein endothelial cells with a clinical 3.0-T MRI scanner. 
Magn Reson Mater Phy. 2005;18(4):175-85.
6. Rodriguez O, Fricke S, Chien C, Dettin L, Vanmeter J, Shapiro E, et al. Contrast-Enhanced In Vivo 
Imaging of Breast and Prostate Cancer Cells by MRI. 2006;5(1):113-9.
7. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP. MRI detection of single particles for 
cellular imaging. 2004;101(30):10901-6.
8. De Vries IJM, Lesterhuis WJ, Barentsz JO, Verdijk P, Van Krieken JH, Boerman OC, et al. Magnetic 
resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. 
Nature Biotechnology. 2005;23(11):1407-13.
9. Himes N, Min J-Y, Lee R, Brown C, Shea J, Huang X, et al. In vivo MRI of embryonic stem cells in a 
mouse model of myocardial infarction. 2004;52(5):1214-9.
10. Terrovitis J, Stuber M, Youssef A, Preece S, Leppo M, Kizana E, et al. Magnetic Resonance Imaging 
Overestimates Ferumoxide-Labeled Stem Cell Survival After Transplantation in the Heart. 
2008;117(12):1555-62.
11. Pawelczyk E, Arbab AS, Chaudhry A, Balakumaran A, Robey PG, Frank JA. In Vitro Model of 
Bromodeoxyuridine or Iron Oxide Nanoparticle Uptake by Activated Macrophages from Labeled 
Stem Cells: Implications for Cellular Therapy. 2008;26(5):1366-75.
12. Walczak P, Kedziorek DA, Gilad AA, Barnett BP, Bulte JWM. Applicability and limitations of MR 
tracking of neural stem cells with asymmetric cell division and rapid turnover: The case of the 
Shiverer dysmyelinated mouse brain. 2007;58(2):261-9.
13. Winter EM, Hogers B, Van Der Graaf LM, Gittenberger-De Groot AC, Poelmann RE, Van Der Weerd L. 
Cell tracking using iron oxide fails to distinguish dead from living transplanted cells in the infarcted 
heart. 2010;63(3):817-21.
14. Küstermann E, Roell W, Breitbach M, Wecker S, Wiedermann D, Buehrle C, et al. Stem cell 
implantation in ischemic mouse heart: a high-resolution magnetic resonance imaging 
investigation. 2005;18(6):362-70.
15. Easo SL, Mohanan PV. In vitro hematological and in vivo immunotoxicity assessment of dextran 
stabilized iron oxide nanoparticles. 2015;134:122-30.
16. Wang Y-XJ, Zhu, Leung, Lee, Zhao, Wang, et al. Enhanced cellular uptake of aminosilane-coated 
superparamagnetic iron oxide nanoparticles in mammalian cell lines. 2012:953.
17. Huang D-M, Hsiao J-K, Chen Y-C, Chien L-Y, Yao M, Chen Y-K, et al. The promotion of human 
mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. 
2009;30(22):3645-51.
18. Singh N, Jenkins GJS, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide 
nanoparticles (SPION). Nano Reviews. 2010;1(1):5358.
19. Danhier P, Magat J, Levêque P, De Preter G, Porporato PE, Bouzin C, et al. In vivo visualization and 
ex vivo quantification of murine breast cancer cells in the mouse brain using MRI cell tracking and 
electron paramagnetic resonance. 2015;28(3):367-75.
63563-Sandra van Tiel-proefschrift.indd   177 04-09-20   08:46
Chapter 8
178
20. Roose D, Leroux F, De Vocht N, Guglielmetti C, Pintelon I, Adriaensen D, et al. Multimodal imaging 
of micron-sized iron oxide particles following in vitro and in vivo uptake by stem cells: down to the 
nanometer scale. 2014;9(6):400-8.
21. Shapiro EM, Skrtic S, Koretsky AP. Sizing it up: Cellular MRI using micron-sized iron oxide particles. 
2005;53(2):329-38.
22. Gilad AA, Winnard PT, Van Zijl PCM, Bulte JWM. Developing MR reporter genes: promises and 
pitfalls. 2007;20(3):275-90.
23. Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. A new transgene reporter for in vivo magnetic 
resonance imaging. Nat Med. 2005;11(4):450-4.
24. Chapelin F, Capitini CM, Ahrens ET. Fluorine-19 MRI for detection and quantification of immune cell 
therapy for cancer. Journal for ImmunoTherapy of Cancer. 2018;6(1).
25. Srinivas M, Heerschap A, Ahrens ET, Figdor CG, Vries IJMD. 19F MRI for quantitative in vivo cell 
tracking. 2010;28(7):363-70.
26. Fox M, Gaudet J, Foster P. Fluorine-19 MRI Contrast Agents for Cell Tracking and Lung Imaging. 
2016:53.
27. Ferrara K, Pollard R, Borden M. Ultrasound Microbubble Contrast Agents: Fundamentals and 
Application to Gene and Drug Delivery. Annual Review of Biomedical Engineering. 2007;9(1):415-
47.
28. Lentacker I, De Cock I, Deckers R, De Smedt SC, Moonen CTW. Understanding ultrasound induced 
sonoporation: Definitions and underlying mechanisms. Advanced Drug Delivery Reviews. 
2014;72:49-64.
29. Kooiman K, Vos HJ, Versluis M, De Jong N. Acoustic behavior of microbubbles and implications for 
drug delivery. 2014;72:28-48.
30. Nowak-Sliwinska P, Segura T, Iruela-Arispe ML. The chicken chorioallantoic membrane model in 
biology, medicine and bioengineering. 2014;17(4):779-804.
31. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian 
bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in 
normal and disease states. Pharmacol Rev. 2008;60(1):1-42.
32. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in 
human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), 
NLE(14)] bombesin(6-14). Clin Cancer Res. 2002;8(4):1139-1146.
33. Sancho V, Di Florio A, Moody TW, Jensen RT. Bombesin receptor-mediated imaging and cytotoxicity: 
review and current status. Current drug delivery. 2011;8(1):79-134.
34. Moreno P, Ramos-Álvarez I, Moody TW, Jensen RT. Bombesin related peptides/receptors and their 
promising therapeutic roles in cancer imaging, targeting and treatment. 2016;20(9):1055-73.
35. Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, et al. Preclinical and first 
clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. 
2015.
36. Bakker I FA, Busstra MB et al PET imaging of prostate cancer using the GRPr-targeting ligand 
Sarabesin-3 prior to radical prostatectomy [abstract]. Eur J Nucl Med Mol Imaging. 2016;43:S1-
S734.
37. Lymperis E M-NT, Kaloudi A et al. Transient in vivo NEP inhibition enhances the theranostic 
potential of the new GRPR antagonist [111In/177Lu]SB3 [abstract]. Eur J Nucl Med. 2014;41(s319).
38. Nock BA, Maina T, Krenning EP, De Jong M. “To Serve and Protect”: Enzyme Inhibitors as 
Radiopeptide Escorts Promote Tumor Targeting. 2014;55(1):121-7.
39. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: 
structure, inhibition, and experimental and clinical pharmacology. Pharmacological Reviews. 
1993;45(1):87-146.
40. Kaloudi A, Nock BA, Lymperis E, Krenning EP, De Jong M, Maina T. Improving the In Vivo Profile 
of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor 
Phosphoramidon. 2016;31(1):20-8.
63563-Sandra van Tiel-proefschrift.indd   178 04-09-20   08:46
8
Summary, Discussion, Concluding remarks
179
41. Adant S, Shah GM, Beauregard J-M. Combination treatments to enhance peptide receptor radionu-
clide therapy of neuroendocrine tumours. Eur J Nucl Med Mol I. 2019.
42. Chan HS, de Blois E, Morgenstern A, Bruchertseifer F, de Jong M, Breeman W, et al. In Vitro 
comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. PLoS One. 
2017;12(7):e0181473.
43. Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJM, et al. Peptide receptor 
radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. 
Clinical and Translational Imaging. 2014;2(1):55-66.
44. Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, et al. Effects of 
chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl 
Med. 2001;42(12):1856-62.
45. Basu S, Ostwal V. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-
DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is 
redifferentiation akin phenomenon a reality in neuroendocrine tumors? Nucl Med Commun. 
2016;37(6):669-71.
46. Chatalic KL, Kwekkeboom DJ, de Jong M. Radiopeptides for Imaging and Therapy: A Radiant 
Future. J Nucl Med. 2015;56(12):1809-12.
47. Pool SE, Kam BL, Koning GA, Konijnenberg M, Ten Hagen TL, Breeman WA, et al. [(111)In-DTPA]
octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview 
of preclinical and clinical observations and implications for tumor radiation dose after peptide 
radionuclide therapy. Cancer Biother Radiopharm. 2014;29(4):179-87.
48. Nonnekens J, van Kranenburg M, Beerens CE, Suker M, Doukas M, van Eijck CH, et al. Potentiation 
of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. Theranostics. 
2016;6(11):1821-32.
49. Mark. Targeting the DNA Damage Response in Cancer. Molecular Cell. 2015;60(4):547-60.
50. Pencharz D, Gnanasegaran G, Navalkissoor S. Theranostics in neuroendocrine tumours: 
somatostatin receptor imaging and therapy. Br J Radiol. 2018;91(1091):20180108.
51. Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for 
Peptide Receptor Radionuclide Therapy. Pharmaceuticals. 2019;12(3):114.
52. Kolasinska Ć, Pęczkowska, Ćwikła, Michałowska, Pałucki, Bodei, et al. A Clinical Efficacy of PRRT 
in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx 
Gene Mutation. Journal of Clinical Medicine. 2019;8(7):952.
53. Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide 
therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, 
and quality of life. Onco Targets Ther. 2017;10:551-7.
54. Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled Somatostatin Analogue 
Therapy Of Gastroenteropancreatic Cancer. 2016;46(3):225-38.
55. Esser JP, Krenning EP, Teunissen JJM, Kooij PPM, Van Gameren ALH, Bakker WH, et al. Comparison of 
[177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for 
PRRT? 2006;33(11):1346-51.
56. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, De Jong M. Kidney protection during 
peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol I. 
2010;37(5):1018-31.
57. Melis M, Bijster M, De Visser M, Konijnenberg MW, De Swart J, Rolleman EJ, et al. Dose-response 
effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 
tumours. 2009;36(12):1968-76.
58. Siwowska K, Haller S, Bortoli F, Benesova M, Groehn V, Bernhardt P, et al. Preclinical Comparison of 
Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties. Mol 
Pharm. 2017;14(2):523-32.
59. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled 
peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for 
prevention. J Nucl Med. 2010;51(7):1049-58.
63563-Sandra van Tiel-proefschrift.indd   179 04-09-20   08:46
Chapter 8
180
60. Benesova M, Umbricht CA, Schibli R, Muller C. Albumin-Binding PSMA Ligands: Optimization of the 
Tissue Distribution Profile. Mol Pharm. 2018;15(3):934-46.
61. Umbricht CA, Benesova M, Schibli R, Muller C. Preclinical Development of Novel PSMA-Targeting 
Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Mol 
Pharm. 2018;15(6):2297-306.
62. Taghizadeh E, Taheri F, Renani PG, Reiner Z, Navashenaq JG, Sahebkar A. Macrophage: A Key 
Therapeutic Target in Atherosclerosis? Curr Pharm Des. 2019;25(29):3165-74.
63. Gordon S. The Macrophage as Therapeutic Target: Springer; 2003.
64. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 
2008;8(12):958-69.
65. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages Sequentially Change Their 
Functional Phenotype in Response to Changes in Microenvironmental Influences. The Journal of 
Immunology. 2005;175(1):342-9.
66. Patel SK, Janjic JM. Macrophage targeted theranostics as personalized nanomedicine strategies for 
inflammatory diseases. Theranostics. 2015;5(2):150-72.
67. Orlowsky EW, Kraus VB. The role of innate immunity in osteoarthritis: when our first line of defense 
goes on the offensive. J Rheumatol. 2015;42(3):363-71.
68. Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, et al. Detection of Atherosclerotic 
Inflammation by 68 Ga-DOTATATE PET Compared to [ 18 F]FDG PET Imaging. Journal of the 
American College of Cardiology. 2017;69(14):1774-91.
69. Mojtahedi A, Alavi A, Thamake S, Amerinia R, Ranganathan D, Tworowska I, et al. Assessment of 
vulnerable atherosclerotic and fibrotic plaques in coronary arteries using (68)Ga-DOTATATE PET/
CT. Am J Nucl Med Mol Imaging. 2015;5(1):65-71.
70. Rominger A, Saam T, Vogl E, Ubleis C, La Fougere C, Forster S, et al. In Vivo Imaging of Macrophage 
Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium 
Burden and Risk Factors. 2010;51(2):193-7.
63563-Sandra van Tiel-proefschrift.indd   180 04-09-20   08:46
63563-Sandra van Tiel-proefschrift.indd   181 04-09-20   08:46
63563-Sandra van Tiel-proefschrift.indd   182 04-09-20   08:46
9
Nederlandse samenvatting
63563-Sandra van Tiel-proefschrift.indd   183 04-09-20   08:46
Chapter 9
184
Nederlandse samenvatting
Voor dit proefschrift hebben we preklinische studies uitgevoerd in 
verschillende ziektemodellen met verschillende niveaus van complexiteit. 
Het uiteindelijk doel was het optimaliseren van beeldvorming van cellen in 
regeneratieve geneeskunde, kanker en artrose. Beeldvorming werd uitge- 
voerd met magnetic resonance imaging (MRI), single photon emission 
computed tomography (SPECT) en computed tomography (CT). In Hoofdstuk 1 
wordt een algemene inleiding gegeven over moleculaire beeldvorming. 
We beschrijven beeldvormende apparaten die worden gebruikt en strategieën 
die kunnen worden toegepast voor cellabeling.
Cellulaire beeldvorming in regeneratieve geneeskunde
Regeneratieve geneeskunde richt zich op herstel, vervanging of regeneratie 
van beschadigt weefsel om functies te herstellen. Verminderde functies 
kunnen worden veroorzaakt door aangeboren afwijkingen, maar ook door 
ziekte, trauma en veroudering. Bij gebruik van celtherapie is kennis van de 
juiste lokalisatie van getransplanteerde cellen essentieel. Het volgen van 
het lot van getransplanteerde cellen en het meten van hun therapeutisch 
effecten (bijv. verbeterde hartfunctie) is cruciaal om de werkzaamheid van 
celtherapie vast te stellen. We hebben verschillende methoden onderzocht 
voor cellabeling en beeldvorming. Eén methode die als zeer efficiënt wordt 
beschouwd, en mogelijk in de kliniek te gebruiken is, is het labelen van de 
cellen met ijzeroxide-partikels. Dergelijke ijzeroxide-partikels resulteren 
in een lokale verandering van het MRI-signaal en maken zeer gevoelige 
driedimensionale detectie van gelabelde cellen mogelijk. Zoals beschreven 
in de hoofdstukken 2, 3 en 4 kunnen verschillende soorten ijzeroxide-
partikels worden gebruikt. In ons onderzoek zijn twee soorten partikels 
toegepast; Ferumoxide, super paramagnetische ijzeroxide-partikels (SPIO) en 
de grotere paramagnetische ijzeroxide-partikels (MPIO). De ijzeroxidekernen 
van zowel SPIO als MPIO hebben een sterk magnetisch moment, waardoor 
het lokale magnetische veld in MRI wordt verstoord, hetgeen resulteert in 
lokaal signaalverlies in MR-beelden. De doeltreffendheid van deze deeltjes 
voor cellabel- en beeldvormingsstudies werd onderzocht door variaties in 
de labelingprotocollen voor ijzeroxide-partikels en de invloed daarvan op 
opname, distributie en retentie, zoals beschreven in Hoofdstuk 2. Gekweekte 
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menselijke navelstrengcellen (HUVECs) werden gelabeld met ijzerpartikels. 
De gemiddelde SPIO-opname nam toe wanneer de incubatietijd werd 
verlengd van 4 uur tot 24 uur. Het optimale labelingprotocol in deze studie 
resulteerde in 12,0 pg ijzer/per cel. Voor MPIO-labeling was de incubatietijd 
van minder belang, aangezien de meeste deeltjes al binnen 4 uur in de cel 
waren opgenomen, met een labelefficiëntie van 100% en een intracellulaire 
ijzeropname tot 626 pg ijzer/cel. MPIO werden efficiënter opgenomen, werden 
beter verdragen (geen significante celdood) en hadden een veel sterker effect 
op het uiterlijk van de cel dan SPIO. Een nadeel van het gebruik van de grotere 
MPIO-partikels is dat er minder partikels per cel opgenomen worden. Wanneer 
cellen delen, zal niet elke dochtercel MPIO-partikels bevatten. Dit resulteert 
in het niet verder kunnen volgen van deze cellen. Optimale cellabeling 
vereiste verschillende protocollen voor SPIO en MPIO. Er kon geen standaard 
labelingprotocol worden gebruikt voor verschillende celtypen in vitro. Het 
gemak waarmee ijzeroxidepartikels spontaan werden opgenomen verschilde 
per cellijn, ook verschilde de snelheid van de opname van ijzeroxidepartikels en 
de getolereerde hoeveelheid ijzeroxidepartikels in de cel. De ijzeroxidepartikels 
in de cellen kunnen worden gevisualiseerd met MRI; de ijzeroxide partikels 
hebben een effect op verschillende MRI-parameters (bijv. R2' (R2 * -R2) = 
relaxiviteit). Cellabeling met ijzeroxidepartikels biedt dus een veelbelovende 
methode voor het in vivo volgen van cellen in mens en dier door middel van 
MRI. Verschillende processen kunnen optreden wanneer met ijzer gelabelde 
cellen in vivo worden geïnjecteerd, zoals celdood, celmigratie en celdeling, die 
allemaal de signaalintensiteit beïnvloeden. Het nabootsen van deze biologisch 
relevante processen werd uitgevoerd door cellen te labelen met kleine (SPIO) 
en grotere (MPIO) ijzeroxidepartikels; de uitgevoerde experimenten en de 
resultaten worden beschreven in Hoofdstuk 3. Voor de MR-metingen werden 
fantomen gemaakt. Als model voor het in vivo delen van cellen werden Brown 
Norway 175 sarcoomcellen gelabeld met SPIO en subcutaan geïnjecteerd in de 
flank van een rat. De effecten van ruimtelijke distributie en compartimentering 
van de ijzeroxidepartikels op de relaxiviteit werden geanalyseerd. We hebben 
aangetoond dat relaxometrie geen kwantificering van gelabelde cellen toelaat 
wanneer meerdere fysiologische processen, zoals celdeling en celmigratie, 
tegelijk plaats vinden. De veranderingen in relaxiviteit van ijzeroxidepartikels 
bleken afhankelijk van de omgeving. De intensiteit van de met ijzer gelabelde 
cellen nam af naarmate ijzeroxide werd verdund door proliferatie. Voor 
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MR-beeldvorming van bijvoorbeeld tumorvasculatuur en weefsel-
gemanipuleerde vaatstructuren, zou het gunstig zijn om cellen in vivo 
te labelen in plaats van, zoals eerder beschreven, in vitro met ijzeroxide 
partikels. Veranderingen in vascularisatie en vasculaire disfunctie zouden 
ziekteontwikkeling kunnen onthullen en het is daarom van belang om deze 
processen in beeld te brengen. Ons doel van het in vitro onderzoek beschreven 
in Hoofdstuk 4 was om optimale parameters te vinden voor niet-invasieve, 
CD31-gerichte (CD31 is een biomarker op endotheelcelmembranen), door 
microbellen uitgevoerde SPIO-labeling van endotheelcellen. Bij toepassing 
van ultrageluid oscilleerden de microbellen door opeenvolgende compressie 
en uitzetting veroorzaakt door drukvariaties. Op deze manier werd de 
permeabiliteit van het celmembraan vergroot, omdat de microbellen 
zogenaamde shear stress (afschuifspanning) op het celmembraan veroorzaken. 
Ze creëren kortstondige, niet-dodelijke gaten in het plasmamembraan, 
waardoor een medicijn/gen/label in de cel kan diffunderen. Labelen 
van endotheelcellen op deze manier is mogelijk, maar akoestische druk, 
sonicatietijd en SPIO-incubatietijd spelen ook een rol bij het veilig en optimaal 
labelen van endotheelcellen. 
Beeldvorming van kankercellen voor diagnose en therapie
Targeting van tot overexpressie gebrachte receptoren op het celmembraan van 
bepaalde cellen wordt toegepast bij peptide-radionuclide-receptor-therapie 
(PRRT) en bij beeldvorming. Een radioactieve tracer is zo samengesteld dat het 
kan binden aan een receptor op een cel na injectie in de bloedbaan, hetgeen 
daarna kan worden gevisualiseerd met een PET of SPECT scan. De mogelijkheid 
van een tracer om aan een receptor te binden kan worden verhinderd, 
bijvoorbeeld door de aanwezigheid van enzymen die de tracer afbreken. 
Te snelle uitscheiding van de tracer uit bloed is ook problematisch, omdat 
dan de tijd waarin de tracer de cel kan bereiken te kort is. In Hoofdstuk 5 
beschrijven we ons onderzoek dat gericht is op het verhogen van de in vivo 
stabiliteit van een met Indium-111 gelabeld radiopeptide gericht tegen de 
gastrine-releasing peptidereceptor (GRPR). Dit is een receptor die met hoge 
dichtheid tot expressie wordt gebracht in een aantal kankertypes, zoals 
prostaatkanker, borstkanker en gastro-intestinale kanker, wat het tot een 
aantrekkelijk doelwit maakt voor therapie met radiopeptiden. Onze GRPR-
antagonist, Sarabesin-3, gelabeld met het positron-emitterende radionuclide 
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Gallium-68, heeft een uitstekende receptoraffiniteit en goede in vivo stabiliteit 
getoond. Zowel preklinische als klinische PET studies met [68Ga]Ga-SB3 zijn 
met succes uitgevoerd. Laesies bij patiënten in vergevorderde staat van 
ziekte werden in ongeveer 50% van de gevallen zichtbaar gemaakt. Voor 
radiogestuurde tumordetectie van kwaadaardige laesies wordt na injectie van 
een radiofarmacon tijdens chirurgie een draagbare detectiesonde gebruikt. 
Door deze intra-operatieve methode te combineren met informatie van 
preoperatieve beeldvorming, kan nauwkeurige chirurgische begeleiding 
worden verkregen, waardoor uiteindelijk de chirurgische uitkomst wordt 
verbeterd en de chirurgische invasiviteit wordt geminimaliseerd. Ons 
doel was SB-3 geschikt te maken voor zowel preoperatieve beeldvorming 
als intra-operatieve radio-gestuurde tumordetectie, daarom hebben we 
het peptide gelabeld met Indium-111. Na het labelen met Indium-111 
vertoonde het molecuul helaas een slechte in vivo stabiliteit. De integriteit 
van het radiopeptide wordt bij injectie in de bloedsomloop op de proef 
gesteld door alom aanwezige proteolytische enzymen. Enzymen bevinden 
zich ook in organen, zoals lever, longen, nieren en maagdarmkanaal. Een 
neutrale endopeptidase (NEP) remmer, zoals phosphoramidon (PA), kan 
de enzymatische afbraak van radiopeptiden remmen. De in vivo stabiliteit 
van [111In] In-SB3 +/- PA werd geanalyseerd in bloedmonsters van muizen. 
De radiotracer die gelijktijdig met PA werd geïnjecteerd, bleef 100% meer 
intact dan in controle dieren (geen co-injectie van PA). Dit leidde vervolgens 
tot 100% meer intacte tracer die de tumor bereikte 1 uur na injectie. Op alle 
onderzochte tijdspunten zagen we een significant hogere tumoropname 
wanneer PA gelijktijdig werd toegediend met [111In]In-SB3. De opname van 
radiotracer in de tumor was receptor-specifiek, zoals werd geconcludeerd uit 
de significant verminderde opname wanneer een overmaat aan niet-gelabeld 
SB3 gelijktijdig werd toegediend. Injectie met 25 MBq/200 pmol [111In]In-SB3 
+/- PA resulteerde in duidelijk verbeterde tumorvisualisatie op alle tijdstippen 
na injectie wanneer de radiotracer werd gecombineerd met PA. De opname 
van het radiopeptide in de alvleesklier nam ook toe, zodat de verhouding 
tussen tumor en alvleesklier onaangetast bleef. Toch moet een hoge opname 
in de alvleesklier in gedachten worden gehouden wanneer de radiotracer zou 
worden gebruikt voor radiogestuurde chirurgie van tumorlaesies in de buurt 
van de alvleesklier. Het uitwassen van radioactiviteit uit de alvleesklier was 
echter relatief snel, terwijl de tumorradioactiviteit in een lager tempo afnam. 
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Het optimale tijdvenster voor de beste verhouding tumor: pancreas voor 
preoperatieve en intra-operatieve tumordetectie zou waarschijnlijk ongeveer 
24 uur na injectie zijn. 
Het succes van PRRT hangt af van de hoeveelheid radioactiviteit die aan de 
tumor wordt afgegeven in verhouding tot de dosis die aan relevante gezonde 
weefsels wordt afgegeven. Om het gebruik van PRRT te verbeteren of breder 
in te kunnen zetten, is nog veel onderzoek nodig. Eén van de tracers die veel 
voor PRRT wordt gebruikt is DOTA-Tyr3-octreotaat (DOTA-TATE). In de kliniek 
passen wij, en vele anderen, radioactief gelabelde DOTA-TATE toe om neuro-
endocriene somatostatine receptor-subtype 2 (SSTR2)-positieve tumoren 
in beeld te brengen en te behandelen. De tumorrespons voor deze therapie 
ligt tussen 68 en 94%. De bloedklaring van deze tracer, bij de mens, is snel 
(<10% geïnjecteerde dosis in het bloed na 3 uur). Aangezien er geen 100% 
volledige tumorrespons is, is er ruimte om de therapeutische werkzaamheid 
te verbeteren met bijvoorbeeld hogere doses van het radiofarmacon, maar 
dit wordt beperkt door gelijktijdige hogere stralingsdoses op andere organen. 
De organen die op lange termijn risico lopen op toxiciteit zijn voornamelijk 
de nieren en het beenmerg. De nierdosis kan echter worden verlaagd 
door bijv. co-infusie van een op gelatine gebaseerde plasma-expander 
(Gelofusine). Het beenmerg blijft dan het belangrijkste dosis beperkende 
orgaan gedurende de behandeling. In Hoofdstuk 6 beschrijven we hoe 
we de biologische distributie van radioactief gelabelde DOTA-TATE verder 
wilden verbeteren door de circulatietijd van de tracer te verlengen door een 
albumine-bindend domein aan het radiopeptide te koppelen. De resulterende 
tracer is Albutate-1 en zal volgens ons concept naar verwachting een langere 
circulatietijd in de bloedbaan hebben, mogelijk resulterend in meer opname 
door de tumorcellen. We bepaalden de kenmerken van [111In]In-DOTA-Tyr3-
albutate-1 en [177Lu]Lu-DOTA-Tyr3-albutate-1. Zowel DOTA-TATE als Albutate-1 
vertoonde een vergelijkbare hoge bindingsaffiniteit voor SSTR2 en een 
vergelijkbare opname- en internalisatie snelheid van de tracers. Na radioactief 
labelen was [111In]In-Albutate-1 tot 3 dagen stabiel in labeling-oplossing en 
tenminste 24 uur in muizenserum. Bij in vivo testen was de circulatietijd van 
[177Lu]Lu-Albutate-1 T1/2 = 27,5 uur. We berekenden dat de tumor 
geabsorbeerde dosis per toegediende activiteit 1455 mGy/MBq was, sterk 
verhoogd t.o.v. de tracer zonder albumine bindend domein. Normale organen 
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ontvingen echter ook een hogere geabsorbeerde dosis, vooral het beenmerg. 
We berekenden dat de wervelkolom een totale geabsorbeerde dosis van 765 
mGy/MBq ontving, een forse dosis. We concludeerden dat toevoeging van 
een albumine-bindend domein aan [177Lu]Lu-DOTA-TATE de bloedcirculatietijd 
sterk verlengde en de tumoropname verhoogde. Beenmerg, nieren en alle 
andere organen kregen echter ook een hogere stralingsdosis, waardoor de 
therapeutische index helaas daalde. 
Macrofaagbeeldvorming tijdens de ontwikkeling van artrose
Zoals beschreven in hoofdstukken 5 en 6 kunnen tumorcellen worden 
gevisualiseerd met behulp van peptide-radionuclide receptorbeeldvorming, 
maar ook andere celpopulaties die receptoren tot overexpressie brengen 
kunnen op deze manier worden gevisualiseerd. Ontstekingscellen, zoals 
macrofagen, zijn van groot belang omdat ze een prominente rol spelen in het 
ontstaan, ontwikkelen en verloop van veel verschillende ziekten, ze vormen 
daarom een interessant therapeutisch doelwit. Macrofagen vormen een 
belangrijk cellulair onderdeel van ontstekingsziekten. Bij activering kunnen 
macrofagen differentiëren, zoals vereenvoudigd wordt aangegeven, in pro- 
of anti-ontstekingsremmende macrofagen. Macrofagen kunnen tijdens hun 
bestaan hun functionele fenotype veranderen. Deze specifieke functionele 
en fenotypische eigenschappen worden beïnvloed door de micro-omgeving 
en deze uiteenlopende rollen kunnen ziekten verergeren en/of oplossen. Hun 
fagocytotische aard, overvloedige aanwezigheid en migratie naar plaatsen 
met disbalans kunnen worden gebruikt voor beeldvorming en therapeutische 
doeleinden. Het vermogen om specifieke fenotypen af te beelden (pro- en anti- 
ontstekingsremmende macrofagen) zou kunnen helpen de ziektevoortgang 
te voorspellen of het ziektestadium te beoordelen en zou aanzienlijk kunnen 
bijdragen aan de huidige behandelingsregimes van de ziekte. Van artrose (OA) 
werd traditioneel gedacht dat het een puur biomechanische ziekte is, maar de 
laatste jaren is er een verschuiving ontstaan in het begrijpen hoe OA ontstaat. 
Nu wordt het gezien als een ontstekingsziekte waarbij macrofagen betrokken 
zijn, maar het is nog steeds onduidelijk in hoeverre ontsteking een initiator is 
versus een resultaat van het gezamenlijke destructieve proces. De bijdragen 
van verschillende fenotypen van macrofagen aan het ontstaan, ontwikkeling 
en verloop van OA zijn momenteel niet goed bekend. Het zou gunstig zijn om 
de aanwezigheid van macrofagen in vivo tijdens OA ontwikkeling niet-invasief 
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te kunnen traceren. Een manier om dit te bereiken is door SPECT beeldvorming. 
In Hoofdstuk 7 hebben we de waarde van de SSTR2 onderzocht als een 
nieuwe beeldvormingsmarker voor pro-inflammatoire macrofagen, opnieuw 
met behulp van het DMM artrose muismodel. Eerst evalueerden we de 
genexpressie niveaus van SSTR2, in zowel niet-gestimuleerde als in interferon 
gamma (IFNγ) en tumor necrose factor alfa (TNFα) gestimuleerde menselijke 
macrofagen, door middel van een kwantitatieve polymerasekettingreactie. De 
expressie van SSTR2 mRNA nam significant toe met een factor 3,6 ten opzichte 
van die in niet-gestimuleerde macrofagen. Een soortgelijk effect werd ook 
waargenomen bij synoviaal weefsel van OA patiënten. Bovendien resulteerde 
stimulatie van primaire monocyten afgeleide macrofagen met IFNγ + TNFα 
in vitro in een significante toename van [111In]In-DOTA-TATE opname. Om de 
relevantie van SSTR2 tracer als een marker voor pro-inflammatoire macrofagen 
in vivo vast te stellen, werd de aanwezigheid van macrofagen en opname van 
SSTR2 tracer in de tijd bestudeerd in een DMM muismodel voor OA. DMM 
en sham geopereerde knieën werden histologisch gekleurd voor CD64. Het 
aantal CD64-positieve cellen, wat wijst op pro-inflammatoire macrofagen, was 
op dag 1 en 3 verhoogd en nam de daarop volgende weken langzaam af. Voor 
ons in vivo beeldvormend onderzoek zijn scans met hoge resolutie van het 
grootste belang, omdat het doelwit erg klein is (knie van een muis). Daarom 
hebben we een met indium-111 gelabelde tracer gebruikt. Indium-111 is een 
radionuclide dat gebruikt wordt met SPECT, een techniek die in de prekliniek 
een hogere spatiele resolutie heeft dan preklinische PET. Met SPECT werden 
verhoogde hoeveelheden radioactiviteit gevonden in de knieën gedurende 
de eerste 7 dagen na DMM chirurgie, gevolgd door een geleidelijke afname in 
de tijd. Hierin zagen we een soortgelijk patroon voor zowel de knieën waarin 
artrose werd veroorzaakt door DMM als voor de knieën die een sham-operatie 
ondergingen. Zoals in deze studie werd aangetoond, was de instroom van 
macrofagen tijdsafhankelijk en geassocieerd met de ontwikkeling van 
artrose. Instroom van macrofagen werd ook waargenomen in de sham-
knie, waarschijnlijk als gevolg van de ontstekingsreactie op weefselschade 
veroorzaakt door chirurgische manipulatie. Opgemerkt moet worden dat 
de sham knieën geen structurele kraakbeenschade of osteofyt vorming 
vertoonden.
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De uitdaging voor cellulaire beeldvorming ligt in de ontwikkeling / toepassing 
van de ideale techniek. Geen enkele beschikbare beeldvormende techniek 
kan op dit moment alle beeldvorming-gerelateerde onderzoeksvragen 
beantwoorden. Daarom zal, afhankelijk van de vraag, de meest geschikte 
techniek of combinatie van technieken, d.w.z. met gebruikmaking van 
meerdere modaliteiten, moeten worden gekozen. Dit includeert ook het 
meest geschikte label en het beste model voor een specifieke vraag.
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Workshop Year ECTs
NKRV, Eindhoven 2019 0,3
NKRV, Rotterdam 2019 0,3
NKRV, Delft 2016 0,3
Immuno-imaging and Molecular Therapy 2016 1,5
NKRV, Amsterdam 2015 0,3
Molecular Medicine day  2014 0,3
Departmental research meeting 2013 0,15
Conferences  Year ECTs
EANM, Barcelona, Spain 2019 1,2
MI Labs user meeting, De Bilt 2019 0,3
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EMIM, Glasgow, Great Brittan 2019 1
EANM, Dusseldorf, Germany 2018 1,2
EANM, Vienna, Austria 2017 1,2
MI Labs user meeting, Utrecht 2017 0,3
MI Labs user meeting, Utrecht 2016 0,3
EMIM, Utrecht 2016 1
EANM, Hamburg, Germany 2015 1,2
MI Labs user meeting, Utrecht 2014 0,3
EMIM, Torino, Italy 2013 1
Teaching and other activities  Year ECTs
Molecular Imaging for clinical physicist 2019 0,1
Supervising trainees 2014-2019 10
Reviewing articles for journals 2013-2019 1
Departmental research meetings 2013-2019 1
Departmental journal clubs 2014-2018 1
 Total 35,45
Orals and posters 
 SPECT imaging of pro-inflammatory macrophages using radiolabeled 
somatostatin analog (oral), MoMaDc meeting, 2019
 Profiles of monocyte and macrophage subsets during the course of 
osteoarthritis in the destabilization of the medial meniscus mouse model 
(oral), Molecular Medicine Day, 2019
 Analysis of peripheral blood monocyte and synovial macrophage subsets 
during osteoarthritis progression in the destabilization of the medial meniscus 
mouse model, poster, OARSI, 2019 
111In/177Lu-DOTA-[Tyr3]-albutate-1, a novel long circulating radiotracer for the 
somatostatin receptor subtype 2 (oral), EANM, 2018
Challenges of low count in vivo imaging (poster), EANM, 2017
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Somatostatin receptor type 2 as a marker for pro-inflammatory macrophages: 
monitoring osteoarthritis (poster), Imaging research on the move, 2017
Somatostatin receptor type 2 as a marker for pro-inflammatory macrophages 
(poster), EMIM, 2017
Macrophage phenotypes are associated with processes of osteoarthritis in the 
collagenase induced osteoarthritis (CIOA) and destabilization of the medial 
meniscus (DMM) mouse models (poster), OARSI, 2017
Somatostatin receptor type 2 as a marker for pro-inflammatory macrophages 
(oral), MI Labs user meeting, 2017
Imaging joint inflammation with 111In-Octreoscan (poster), EANM, 2016
Imaging joint inflammation with 111In-Octreoscan (poster), EMIM, 2016
Macrophage imaging: can we show both sides of the medal? (oral), Research 
meeting Orthopaedics Department, 2016
Imaging joint inflammation with 111In-Octreoscan (oral), MI Labs User Meeting, 
2015
Macrophage imaging: can we show both sides of the medal? (oral), NKRV, 2015
Imaging somatostatin receptor expression on macrophages in osteoarthritis 
models (poster), EANM, 2015
Macrophage imaging: Can we show both sides of the medal? (oral), 
Departmental research meeting, 2013
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List of Publications
Sandra van Tiel, Thea Maina, Berthold Nock, Mark Konijnenberg, Erik de 
Blois, Yann Seimbille, Monique Bernsen, Marion de Jong [111In]In/[177Lu]Lu-
DOTA-[Tyr3]-albutate-1, a novel long-circulating radiotracer targeting the 
somatostatin receptor subtype 2. Under revision, Pharmaceuticals
Sandra T. van Tiel#, Lizette Utomo#, Jan de Swart, Erik de Blois, Marion de 
Jong, Yvonne M. Bastiaansen-Jenniskens, Monique R. Bernsen. Evaluation of 
a radiolabeled somatostatin analog for SPECT imaging of pro-inflammatory 
macrophages. Manuscript accepted by Biomedical research and reviews
L. Utomo1, N. Fahy1, N. Kops1, S.T. van Tiel, J.H. Waarsing, J.A.N. Verhaar, 
P.J.M.8 Leenen, G.J.V.M. van Osch, Y.M. Bastiaansen-Jenniskens. Macrophage 
phenotypes and monocyte subsets after destabilization of the medical 
meniscus in mice. Manuscript submitted to Journal of Orthopaedic research
Ilya  Skachkov, Ying  Luan, Sandra  T. van  Tiel, Antonius F. W.  van  der  Steen, 
Nico  de  Jong, Monique R.  Bernsen, Klazina  Kooiman. SPIO labeling of 
endothelial cells using ultrasound and targeted microbubbles at low 
mechanical index. PLoS One. 2018 Sep 20;13(9):e0204354
Ingrid L. Bakker, Sandra van Tiel, Joost Haeck, Gabriela N. Doeswijk, Erik de 
Blois, Marcel Segbers, Theodosia Maina, Berthold A. Nock, Marion de Jong, 
and Simone U. Dalm. In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for 
Pre- and Intra-Operative Imaging for Prostate Cancer. Mol Imaging Biol. 2018 
Mar 19
Bernsen MR, Guenoun J, van Tiel ST, Krestin GP. Nanoparticles and clinically 
applicable cell tracking. Br J Radiol. 2015 Oct; 88(1054):20150375
Duinhouwer LE, van Rossum BJ, van Tiel ST, van der Werf RM, Doeswijk GN, 
Haeck JC, Rombouts EW, Ter Borg MN, Kotek G, Braakman E, Cornelissen JJ, 
Bernsen MR. Magnetic Resonance Detection of CD34+ Cells from Umbilical 
Cord Blood Using a 19F Label. PLoS One. 2015 Sep 22;10(9): e0138572
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Joost Haeck, Karin Bol, Sander Bison, Sandra van Tiel, Stuart Koelewijn, Marion 
de Jong, Jifke Veenland and Monique Bernsen. Optimized time-resolved 
imaging of contrast kinetics (TRICKS) in dynamic contrast-enhanced MRI after 
peptide receptor radionuclide therapy in small animal tumor models. Contrast 
Media Mol Imaging. 2015 May 21
Ten Hagen TL, Seynhaeve AL, de Wiel-Ambagtsheer Ga, de Bruijn EA, van Tiel 
ST, Ruegg C, Meyring M, Grell M, Goodman SL, Eggermont AM. The αVβ3/αVβ5 
integrin inhibitor cilengitide augments tumor response to melphalan isolated 
limb perfusion in a sarcoma model. Int J Cancer. 2013 Jun 1;132(11):2694-704
Kotek G, van Tiel ST, Wielopolski PA, Houston GC, Krestin GP, Bernsen MR. 
Cell quantification: evolution of compartmentalization and distribution of 
iron-oxide particles and labeled cells. Contrast Media Mol Imaging. 2012 Mar-
Apr;7(2):195-203 
Alic L, Haeck JC, Bol K, Klein S, van Tiel ST, Wielopolski PA, de Jong M, Niessen 
WJ, Bernsen M, Veenland JF. Facilitating tumor functional assessment by 
spatially relating 3D tumor histology and in vivo MRI: image registration 
approach. PLoS One. 2011; 6(8):e22835
van Tiel ST, Wielopolski PA, Houston GC, Krestin GP, Bernsen MR. Variations 
in labeling protocol influence incorporation, distribution and retention of 
iron oxide nanoparticles into human umbilical vein endothelial cells. Contrast 
Media Mol Imaging. 2010 Sep-Oct;5(5):247-57.
van Buul GM, Farrell E, Kops N, van Tiel ST, Bos PK, Weinans H, Krestin GP, 
van Osch GJ, Bernsen MR. Ferumoxides-protamine sulfate is more effective 
than ferucarbotran for cell labeling: implications for clinically applicable cell 
tracking using MRI. Contrast Media Mol Imaging. 2009 Sep; 4(5):230-6.
Bernsen MR, Moelker AD, Wielopolski PA, van Tiel ST, Krestin GP. Labelling of 
mammalian cells for visualisation by MRI. Eur Radiol. 2009 Aug 12. 
Farrell E, Wielopolski P, Pavljasevic P, van Tiel S, Jahr H, Verhaar J, Weinans H, 
Krestin G, O’Brien FJ, van Osch G, Bernsen M. Effects of iron oxide incorporation 
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for long term cell tracking on MSC differentiation in vitro and in vivo. Biochem 
Biophys Res Commun. 2008 May 16;369(4):1076-81
Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtsheer 
G, van Tiel ST, Eggermont AM, Ten Hagen TL. Tumor necrosis factor alpha 
mediates homogeneous distribution of liposomes in murine melanoma that 
contributes to a better tumor response. Cancer Res. 2007 Oct 1;67(19):9455-62. 
Brunstein F, Rens J, van Tiel ST, Eggermont AM, ten Hagen TL. Histamine, a 
vasoactive agent with vascular disrupting potential, improves tumour response 
by enhancing local drug delivery. Br J Cancer. 2006 Dec 18;95(12):1663-9
Brunstein F, Eggermont AM, de Wiel-Ambagtsheer G, van Tiel ST, Rens J, ten 
Hagen TL. Synergistic antitumor effects of histamine plus melphalan in isolated 
hepatic perfusion for liver metastases. Ann Surg Oncol. 2007 Feb;14(2):795-801
Hoving S, Seynhaeve AL, van Tiel ST, aan de Wiel-Ambagtsheer G, de Bruijn 
EA, Eggermont AM, ten Hagen TL. Early destruction of tumor vasculature in 
tumor necrosis factor-alpha-based isolated limb perfusion is responsible for 
tumor response. Anticancer Drugs. 2006 Sep;17(8):949-59. 
Brunstein F, Santos ID, Ferreira LM, van Tiel ST, Eggermont AM, Ten Hagen 
TL. Histamine combined with melphalan in isolated limb perfusion for the 
treatment of locally advanced soft tissue sarcomas: preclinical studies in rats. 
Acta Cir Bras. 2005 Jul-Aug;20(4):275-9
Hoving S, Seynhaeve AL, van Tiel ST, Eggermont AM, ten Hagen TL. Addition 
of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH 
liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-
bearing rats. Anticancer Drugs. 2005 Jul;16(6):667-74. 
Hoving S, Brunstein F, Aan de Wiel-Ambagtsheer G, van Tiel ST, de Boeck G, 
de Bruijn EA, Eggermont AM, Ten Hagen TL. Synergistic antitumor response of 
interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-
bearing rats. Cancer Res. 2005 May 15; 65(10):4300-8. 
63563-Sandra van Tiel-proefschrift.indd   205 04-09-20   08:46
Chapter 11
206
Hoving S, van Tiel ST, Eggermont AM, ten Hagen TL. Effect of low-dose tumor 
necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-
077) on soft-tissue- and osteosarcoma-bearing rats. Anticancer Res. 2005 Mar-
Apr;25(2A):743-50. 
van Etten B, Eggermont AM, van Tiel ST, Ambagtsheer G, de Wilt JH, ten 
Hagen TL. Gene therapy in in vivo isolated perfusion models. Curr Gene Ther. 
2005 Apr;5(2):195-202. 
Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, 
Eggermont AM, ten Hagen TL. Synergistic antitumor activity of histamine plus 
melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst. 
2004 Nov 3;96(21):1603-10. 
Preda A, Wielopolski PA, Ten Hagen TL, van Vliet M, Veenland JF, Ambagtsheer 
G, van Tiel ST, Vogel MW, Eggermont AM, Krestin GP, van Dijke CF. Dynamic 
contrast-enhanced MRI using macromolecular contrast media for monitoring 
the response to isolated limb perfusion in experimental soft-tissue sarcomas. 
MAGMA. 2004 Dec;17(3-6):296-302
van Etten B, Eggermont AM, Ambagtsheer G, van Tiel ST, ten Hagen TL. 
Impaired neutralising antibody formation and high transduction efficacy 
after isolated hepatic perfusion with adenoviral vectors. Br J Cancer. 2004 Oct 
18;91(8):1610-3. 
Van Etten B, Van Tiel ST, Ambagtsheer G, Eggermont AM, Ten Hagen TL. Isolated 
limb perfusion based anti-p21ras gene therapy in a rat rhabdomyosarcoma. 
Anticancer Res. 2004 Jul-Aug;24(4):2295-301. 
ten Hagen TL, Hoving S, Ambagtsheer G, van Tiel ST, Eggermont AM. Lack 
of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-
bearing rats. Br J Cancer. 2004 May 4;90(9):1830-2. 
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Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, Seynhaeve 
AL, Fiers W, ten Hagen TL. Tumor necrosis factor-alpha augmented tumor 
response in B16BL6 melanoma-bearing mice treated with stealth liposomal 
doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer. 
2004 Apr 10;109(3):442-8. 
van Etten B, de Vries MR, van IJken MG, Lans TE, Guetens G, Ambagtsheer G, 
van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL. Degree of 
tumour vascularity correlates with drug accumulation and tumour response 
upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer. 2003 Jan 
27;88(2):314-9. 
Lans TE, ten Hagen TL, van Horssen R, Wu PC, van Tiel ST, Libutti SK, Alexander 
HR, Eggermont AM. Improved antitumor response to isolated limb perfusion 
with tumor necrosis factor after up regulation of endothelial monocyte-
activating polypeptide II in soft tissue sarcoma. Ann Surg Oncol. 2002 
Oct;9(8):812-9. 
Seynhaeve AL, de Wilt JH, van Tiel ST, Eggermont AM, ten Hagen TL. Isolated 
limb perfusion with actinomycin D and TNF-alpha results in improved tumour 
response in soft-tissue sarcoma-bearing rats but is accompanied by severe 
local toxicity. Br J Cancer. 2002 Apr 8;86(7):1174-9. 
ten Hagen TL, Seynhaeve AL, van Tiel ST, Ruiter DJ, Eggermont AM. Pegylated 
liposomal tumor necrosis factor-alpha results in reduced toxicity and 
synergistic antitumor activity after systemic administration in combination 
with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J 
Cancer. 2002 Jan 1;97(1):115-20. 
de Wilt JH, Bout A, Eggermont AM, van Tiel ST, de Vries MW, ten Hagen TL, 
de Roos WK, Valerio D, van der Kaaden ME. Adenovirus-mediated interleukin 3 
beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma 
in rats. Hum Gene Ther. 2001 Mar 20;12(5):489-502. 
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de Wilt JH, Manusama ER, van Etten B, van Tiel ST, Jorna AS, Seynhaeve AL, ten 
Hagen TL, Eggermont AM. Nitric oxide synthase inhibition results in synergistic 
anti-tumour activity with melphalan and tumour necrosis factor alpha-based 
isolated limb perfusions. Br J Cancer. 2000 Nov;83(9):1176-82. 
Ten Hagen TL, Van Der Veen AH, Nooijen PT, Van Tiel ST, Seynhaeve AL, 
Eggermont AM. Low-dose tumor necrosis factor-alpha augments antitumor 
activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing 
rats. Int J Cancer. 2000 Sep 15;87(6):829-37. 
van IJken MG, van Etten B, de Wilt JH, van Tiel ST, ten Hagen TL, Eggermont 
AM. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic 
perfusion with melphalan in a rat sarcoma model. J Immunother. 2000 Jul-
Aug;23(4):449-55. 
de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. 
Tumour necrosis factor alpha increases melphalan concentration in tumour 
tissue after isolated limb perfusion. Br J Cancer. 2000 Mar;82(5):1000-3. 
van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten 
Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in 
TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances 
anti-tumour effects. Br J Cancer. 2000 Feb;82(4):973-80. 
de Wilt JH, Manusama ER, van Tiel ST, van IJken MG, ten Hagen TL, Eggermont 
AM. Prerequisites for effective isolated limb perfusion using tumour necrosis 
factor alpha and melphalan in rats. Br J Cancer. 1999 Apr;80(1-2):161-6. 
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Curriculum Vitae
Sandra Theresia van Tiel was born on October 10th 1971 in Rotterdam, The 
Netherlands. After finishing her secondary education at the Christelijke 
Scholengemeenschap Henegouwerplein in Rotterdam, she continued with her 
study Life Sciences at Hoger Laboratorium Onderwijs in Delft. Her internship 
was at the department of Medical Pharmacology of the University of Leiden. 
In 1996 she started working as a research technician at the Department of 
Surgical Oncology of the Erasmus MC under supervision of Dr. Timo ten Hagen 
and Prof. Dr. Lex Eggermont. In 2005 she started to work at the Department 
of Radiology under supervision of Dr. Monique Bernsen. Under supervision of 
Prof. Dr. Marion de Jong, of the Radiology & Nuclear Medicine Department, she 
started her PhD work in 2013, resulting in her thesis entitled: “Cellular imaging 
in regenerative medicine, cancer and osteoarthritis”. Her studies focused on 
labelling cells involved in disease, with the aim to non-invasively detect cells 
for staging of disease and interference in disease development. Currently 
she is employed at the AMIE Core facility as Application Specialist for nuclear 
imaging and MRI.
Sandra married Mark van Ramshorst in 2008 and in that same year they got 
their son Steyn.
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